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Abstract 
 
The poorer cancer survival in England in comparison to countries of comparable wealth may 
be explained by variations in diagnostic and treatment practices, and in disease stage. This 
highlights the importance of General Practitioners (GPs) in facilitating earlier diagnosis and 
access to secondary care. Poor access to secondary care has been associated with poorer cancer 
outcomes. As GPs are the first point of contact with health services for most patients, it is 
possible that some problems associated with access in secondary care originate from poor GP 
access. Despite this, there is little evidence describing the relationship between access to GPs 
and cancer outcomes. This research examines the association between geographical 
accessibility and cancer outcomes along the cancer care pathway, with a focus on access to the 
GP. 
The research begins by reviewing policies on improving access to cancer services, and finds 
some trade-offs that result when meeting contrasting policy goals. For example, centralisation 
may improve efficiencies, but may increase inequities in access. One study found that cancer 
services in England may not be located according to need, but are more likely to be 
concentrated in urban areas where incidence rates are lower. The other studies examine how 
geographical access associates with outcomes related to primary care, secondary care and the 
interface between these two. These studies found that longer travel to primary care has an 
opposite association on outcomes in rural compared to urban areas, and, has important 
implications on the mode of cancer diagnosis in secondary care. Additionally, longer travel to 
both primary and secondary care, and living in an urban area is associated with worse survival, 
furthermore, times delays and disease stage may be important mediators for these associations. 
This research generates original evidence showing that geographical access to primary care for 
diagnosis may have important consequences for cancer outcomes. The findings suggests that 
rural areas may not necessarily experience poorer outcomes, warranting future research on 
access issues amongst patients living in urban areas. 
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1.1  Introduction 
Cancer is the leading cause of death in the UK (Independent Cancer Taskforce 2015; National 
Records for Scotland 2013), resulting in over 160,000 deaths per year (Cancer Research UK 
2016a). It is estimated that half of those born post 1960 will be diagnosed with cancer at some 
point in their lifetime (Ahmad et al. 2015). The UK also has poorer cancer survival rates in 
comparison to other countries of equal wealth (Coleman et al. 2010; De Angelis et al. 2013).   
 
These differences in survival may be explained by differences in factors operating at the 
patient, health practitioner, or health system level. For instance, disease stage may be an 
explanatory factor and it has been suggested that patients in the UK present with more advanced 
disease stage at diagnosis than their European counterparts (Coleman et al. 2010; Walters et al. 
2013). Another suggestion is that the survival differences may be as a result of differences in 
how cancer is diagnosed and treated (Coleman et al. 2010). The latter is particularly important 
because survival rates in the UK are similar to Denmark, another European country that shares 
a similar primary care system to the UK, whereby GPs (General Practitioners) control access 
to secondary care services for diagnosis and treatment. There are suggestions that the system 
of GP gatekeeping may determine cancer outcomes; one study has reported lower survival rates 
in healthcare systems with a primary care gate keeper (Vedsted & Olesen 2011). Identifying 
the mechanisms that may explain how primary care influences the cancer outcomes that are 
reported farther up the cancer care continuum is an area that warrants further investigation. 
Access issues are felt most acutely by patients with a long standing illness because of their 
need to access services more frequently (Haynes & Bentham 1982). Most cancer patients 
would have sought both primary and secondary care a number of times in the course of the 
disease, which emphasises the need to investigate issues related to accessing cancer services.  
 
1.2  Access to cancer services and cancer outcomes 
Examining variations in access to diagnosis and treatment may contribute to understanding the 
variations in cancer survival. Access has been a central tenet in the NHS since its inception 
with the goal of providing free access on the basis of clinical need and not ability to pay (NHS 
2015). The NHS is considered as one of the most equitable service in the western world due to 
its provision of universal access (The Commonwealth Fund 2010). Despite this, the NHS has 
had some shortcomings in terms of its overall performance, and some of these shortcomings 
are related to accessibility issues that will be explored in more detail in this research. 
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Although the goal of universal access has alleviated some barriers in access such as those 
associated with affordability, patients are still required to pay for some social and economic 
costs of use. Some social costs may be associated with accessing GPs, whereby opening hours 
may not be convenient for those unable to obtain appointments during working hours (Carr-
Hill et al. 1997), and this may particularly affect those in employment. Some economic costs 
include costs associated with travel, and the opportunity costs of time that is spent on travelling 
or waiting for an appointment (Carr-Hill et al. 1997). These costs are important in the context 
of understanding barriers in access to services because greater access costs act to lower the 
utilisation of the health services. Geographical inaccessibility my further amplify the effect of 
these social and economic costs, and this may have implications for cancer outcomes.  
 
Previous studies have reported associations between poor access to secondary care services 
and cancer outcomes. One study based in England showed that longer travel to the hospital of 
treatment was associated with lower odds of obtaining optimal treatment in patients with lung 
and rectal cancers (Jones et al. 2008). Other studies based in northern Scotland showed that 
greater distances to a specialist cancer centre were associated with more advanced disease stage 
and with poorer survival from lung, prostate and colorectal cancers (Campbell et al. 2001; 
Campbell et al. 2000) . Poorer access to hospital services has also been associated with worse 
outcomes in other parts of the world (Dejardin et al. 2008; Dejardin et al. 2014; Wan et al. 
2012; Silva et al. 2011). 
 
There is less evidence on the association between access to early diagnosis services and cancer 
outcomes. One study that looked at access from the perspective of the ease of obtaining a GP 
appointment found practices that provided more timely access to primary care had fewer self-
referred visits to the emergency departments (Cowling et al. 2013). Another study based in the 
USA found that poor geographical access to primary care significantly increased the risk of 
late breast cancer diagnosis (Wang et al. 2008). There is limited evidence on the association 
between access to the GP and cancer survival in the UK. 
 
Investigating the influence of access to primary services on cancer outcomes is important; 
firstly, with the exception of emergency services, access to secondary care services for 
diagnosis and treatment can only be obtained by referral from primary care services. Thus, 
restricted access to primary care may in turn reduce access to secondary care (Carr-Hill et al. 
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1997). Furthermore, the likelihood of GPs to make referrals may be influenced by accessibility 
to services, and by consideration of the journeys that their patients may make (Carr-Hill et al. 
1997; Sladden & Thomson 1998; Haynes & Bentham 1982). Thereby, when the opportunity 
cost of access is high (such as longer journey time), GPs may refer fewer patients into 
secondary care (Carr-Hill et al. 1997), making it plausible that some of the poor outcomes 
associated with access to secondary care may have originated from decisions made in primary 
care. Additionally, inaccessibility to primary care services may influence patient decisions to 
consult their GPs with symptoms. For example, one previous study found GP consultation rates 
to decline with increasing distance (Haynes & Bentham 1982). Poor access may have a greater 
deterrent effect when the perceived risk or benefit of treatment is lower (Carr-Hill et al. 1997), 
and may be more apparent when symptoms are deemed low risk. The combination of GPs’ and 
patients’ perceptions of accessibility may therefore determine treatment options, and ultimately 
clinical outcomes. 
 
 
1.3  Defining and measuring access 
Healthcare utilisation is the most commonly applied proxy of  access to services and assumes 
that use of health services is evidence of access to those services (Allin et al. 2007). Use of 
utilisation to estimate access raises conceptual and methodological concerns. This is because 
service utilisation does not account for variations in the use of health care, such as those related 
to differences in preferences, cultural or financial barriers, or other factors such as differences 
in levels of risk aversion (Oliver & Mossialos 2004; Allin et al. 2007). Utilisation rates may 
therefore not fully reflect need which is a useful measure in investigating health inequalities 
(Allin et al. 2007).  
 
A more comprehensive definition of access has been suggested as ‘opportunity to access’ and 
has been be articulated as ‘the ability to secure a specified range of services, at a specified level 
of quality, subject to a specified maximum level of personal inconvenience and cost, while in 
possession of a specified amount of information’ (Allin et al. 2007) (pg.4). This definition 
recognises the distinction between the possibility of using a service if required (potential 
access) and actually using a service (utilisation) (Allin et al. 2007).   
 
Access to healthcare can thereby be classified into two dichotomous groups at the broadest 
level; potential vs. revealed (actual) access. These broad groups can be further categorised into 
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geographical/spatial and non-geographical/aspatial access (Wang 2006; Khan 1992), whereby 
the former is moderated by space or distance to services, and the latter is normally conditioned 
by social barriers. Table 1.1 shows these high-levels dimensions of access. 
 
 
Table 1.1 Dimensions of access to healthcare 
 Geographical Non-geographical 
Potential 
 
Potential 
Geographical access 
Potential non-
geographical access 
Realized 
 
Revealed 
Geographical access 
 
Revealed non-
geographical access 
Source: Khan, 1992 
 
 
Although this research will focus on revealed geographical access, it will also examine how 
geographical access relates to other dimensions of access. This is because there are 
considerable overlaps in the dimensions; as an example, it is likely that individual and system 
level factors such as socio-cultural (acceptability), cost (affordability) and waiting times 
(availability) may interact with geographical location or distance to influence health seeking 
decisions (Thiede & Akweongo 2007). 
 
1.3.1 Measuring geographical accessibility 
There are three commonly applied measures of geographical accessibility. The simplest one is 
the use of supply-demand ratios to calculate the ratio of population vs. providers within a 
common geographical or administrative boundary (McGrail & Humphreys 2009a). This 
method is popular with policy makers because is it intuitive. However, it is overly simplistic 
as it does account for movement across administrative boundaries (McGrail & Humphreys 
2009a). A more appropriate measure of accessibility is one that does not assumes that 
individuals are static and tied to a geographic unit, and recognises that people and places are 
dynamic and interacting entities (Vallée & Chauvin 2012). 
 
Another commonly used and widely acceptable in measuring accessibility to health services is 
travel impedance, which computes accessibility as either travel time or distance from the point 
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of interest to a health service (McGrail & Humphreys 2009b). The limitation of this method is 
that it doesn’t account for capacity of the service provider, or the size of the population i.e. 
availability (Wang 2006; McGrail & Humphreys 2009a). Use of travel impedance is therefore 
advocated for when demand of services is less of a concern (Wang 2006) such as in rural and 
remote areas where demand for services is reduced.  
 
The most robust but also most challenging measure of spatial access uses variations of gravity 
models that employ a ‘distance decay’ function, which assumes that service use diminishes 
with longer distance. These models can be further enhanced by also factoring in both the supply 
and demand of services (Luo 2004; Luo & Qi 2009; Wang 2006). However, gravity models 
have been criticised for their difficulty in determining the distance decay function, which is 
estimated from actual physician-patient interaction, and varies by service type and population 
under study (Guagliardo 2004; McGrail & Humphreys 2009a). 
 
1.3.2 Rurality 
The terms rurality and geographical accessibility have been used interchangeably when 
examining the association between access to health services and health outcomes. This is in 
recognition of the lower service accessibility and higher geographical isolation that exists in 
rural areas.  For example, the average estimated journey time to the nearest hospital in rural 
areas is nearly twice as much as that in urban areas; this rural urban difference is greatest when 
using public transport (22 vs. 40 minutes) and when cycling (14 vs. 40 minutes), but less 
marked when driving (7 vs. 12 minutes) (Department for Transport 2014a). 
 
There is a widely held view that people who reside in rural areas have better health outcomes 
such as mortality (Jones & Lake 2013; Haynes 1987), but other views suggest that poor health 
amongst the rural poor is hidden by the by favourable averages of health and deprivation 
measures (Haynes & Gale 2000). Poor health is less associated with deprivation in rural than 
in urban areas, but this may be a statistical artefact produced by inconsistent scale of analysis 
and the distribution of rich and poor in rural and urban areas (Haynes & Gale 2000). For 
instance, large areas of inner city neighbourhoods tend to concentrate people with similar 
socio-economic status, while small rural areas have less homogenous populations (Haynes & 
Gale 2000). Rural disadvantage may also manifest as having higher levels of chronic conditions 
(Douthit et al. 2015) as a result of a more elderly population; who may be further disadvantaged 
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by residing in more remote areas that experience the greatest loss of health services (Haynes 
1987; Haynes & Bentham 1982; Bentham & Haynes 1985). 
 
Studies looking at rural and urban differences in cancer outcomes have also had contrasting 
findings. Research conducted in France and Australia has shown lower odds of presenting 
symptoms to the GP amongst patients living in rural areas (Launoy et al. 1992; Emery et al. 
2013). Another Australian study showed increased time delays from presentation to obtaining 
a diagnosis amongst the most remote female patients with ovarian cancer (Jordan et al. 2010). 
In contrast, research from the USA reveals a rural reversal, whereby risk of later stage 
colorectal cancer was found in urbanised areas, negating previous assumptions of rural-
disadvantage on the basis of poor access (McLafferty & Wang 2009). Similarly, a study 
looking at primary care access and visits to the emergency departments in England found that 
rural practices had significantly lower visits than those located in urban areas (Cowling et al. 
2013).  
 
So far, there is inconclusive evidence on the rural and urban differences in cancer outcomes. 
This research will consider rurality as a dimension of geographical access, in a similar manner 
to other measures of access such as distance or travel times. It will use the Department for 
Environment Food and Rural Affairs (DEFRA) definition of rurality which classifies 
settlements with populations of less than 10,000 as rural (DEFRA 2013b). 
 
1.4  Structure of thesis 
The objective of this research is to investigate the potential influence of geographical access 
on cancer outcomes along the cancer care continuum. The implicit assumption is that of a 
vertical progression of disease from symptom/s presentation to diagnosis, treatment and 
survival or death. This progression correlates with patients’ care along the care pathway that 
begins from early detection, to primary care, proceeding to secondary care, and ending with 
palliative care; although the latter is beyond the scope of this study. Although a linear processes 
is assumed, the research also recognises that the complex nature of how health services are 
organised means that receipt of cancer care is anything but linear. There is also a recognition 
that geographical access may be intertwined with the other dimensions such as cost or financial 
factors and socio-cultural acceptability of utilising health services.  
 
 23 
 
The research is presented in seven chapters which includes this introduction (Chapter One) and 
a conclusion chapter (Chapter Seven). The relationship between these chapters is represented 
in Figure 1.1. The dashed line shows that the findings from the literature review feed into the 
analytical chapters by helping formulate relevant research questions. The bold lines show the 
connection between the chapters, whereby the analysis begins by taking an area level 
perspective in Chapter Three, and thereafter, drilling down onto specific aspects of the cancer 
pathway in the subsequent chapters. 
 
 
Figure 1.1- Flowchart showing the connection between the thesis chapters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Two is a narrative review that traces the development of national cancer policy in 
England with a specific focus on policies on improving access. This Chapter is an in-depth 
review of five policy documents: A Policy Framework of Commissioning Cancer Services, 
hereafter referred to as the ‘Calman and Hine report’ (Calman & Hine 1995), the NHS Cancer 
Plan (Department of Health 2000), the Cancer Reform Strategy (Department of Health 2007), 
Improving Outcomes Cancer Strategy (Department of Health 2011a) and Achieving World 
Class Cancer Outcomes (Independent Cancer Taskforce 2015).  
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Three of the five policy documents, NHS Cancer Plan, Cancer Reform Strategy and Improving 
Outcomes were led by the respective Governments of the time, whereas the other two 
strategies, Calman and Hine report and Achieving World Class Outcomes, were developed by 
senior physicians and an Independent Taskforce, respectively. This difference in authorship 
makes an interesting comparison when examining the recommendations and implementation 
of the proposed policies. The strategies will be examined in order to assess their position on 
how to achieve the four broad objectives of healthcare policies that are commonly applied when 
judging health system performance; improving access, narrowing inequalities, improving 
quality and reducing inefficiencies (Le Grand 1993; Palfrey 2000; The Commonwealth Fund 
2010). Any progress in meeting the policy objectives will be assessed, as well as any interaction 
and/or trade-offs between the objectives. Other sources of evidence will also be reviewed to 
support the findings. 
 
Chapter Three will build on the findings of the narrative review. The chapter will assess any 
intrinsic overlaps between the four policy objectives and examine whether any trade-offs that 
may exist in meeting policy objectives have any measurable impact on outcomes. To do this, 
the chapter will use publicly available area level data, to examine geographical equity in cancer 
services, by investigating the extent to which cancer management and treatment services in 
England are located according to need. Equity in access to healthcare is an important policy 
objective in England. Indeed, the NHS was founded on the principle that services would meet 
everyone’s needs, and would be based on clinical need and not ability to pay (NHS 2015). It is 
important to investigate the progress of this principle nearly seven decades since the inception 
of the NHS. This analysis conducted at an area level will generate hypotheses that can be 
explored in depth using more granular datasets in subsequent chapters. 
 
The rest of the chapters (Four, Five and Six) use individual level datasets to investigate the 
relationship between access to GPs and cancer outcomes. Primary care is the first point of 
contact with the health services for most patients in the UK. Furthermore, GPs in the UK 
facilitate access to secondary care services which makes it plausible that some of the poor 
outcomes observed in secondary care may actually originate from poor access in primary care 
(Carr-Hill et al. 1997; Haynes & Bentham 1982); an example would be the use of emergency 
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services which may be a marker of inaccessibility of GP services. Access will be studied from 
the perspective of travelling time to services and as rural or urban residency. 
 
Chapter Four uses a Scottish cancer registry dataset linked with primary care records to assess 
whether geographical access to GPs affects how patients present to their GP with symptoms 
that may be related to cancer. Symptoms related to cancer can be broadly categorised based on 
their ease of diagnosis; thus symptoms such as rectal bleeding may be considered alarming, 
whereas others such as constipation are considered vague due to their atypical nature. The 
prospect of longer journeys may make patients less inclined to attribute these symptoms to 
cancer. Therefore, it is likely that inaccessibility may reduce the odds of obtaining a diagnosis 
following presentation with atypical symptoms. The considerable rurality in northern Scotland 
makes this area a good case study for investigating any geographical and socio-cultural 
variations in symptoms presentation. 
 
Chapters Five and Six employ a record level dataset from the English cancer registries that has 
been linked with hospital records, with information on screening and with cancer waiting times. 
This linkage has enabled the ascertainment of the route that patients took to obtain a cancer 
diagnosis. Routes such as emergency presentations have previously been associated with 
poorer outcomes. However, it is not clear the extent to which this is because of poor access. 
Chapter Five investigates whether access to the GP determines the routes to diagnosis and will 
compare the associations between access and desirable routes (screening and urgent referrals), 
with the association between access and less desirable routes (emergency presentations and 
death certificate only diagnoses). 
 
Chapter Six examines how access to the GP, and to the hospital of treatment is associated with 
cancer waiting times, disease stage and cancer survival. This Chapter also investigates potential 
mechanisms that may explain these associations using cancer waiting times and disease stage 
as two potential mediators. 
 
This research benefits from the high-quality data information collected by the UK Cancer 
Registries; the data has an estimated case ascertainment completeness of up to 99% (Moller 
2011) and contains socio-economic, demographic and clinical variables that are important for 
research purposes. The quality of the registry data has been improved by linkage with 
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complementary datasets such as Hospital Episode Statistics (HES), which has improved the 
accuracy of common variables such as disease stage, and has enabled the use of information 
on comorbidities. Further linkage with other routine datasets such as screening and Cancer 
Waiting Times (CWTs) datasets makes it possible to perform analysis that integrates different 
processes and outcomes on the care continuum. Additionally, the registry dataset spans a period 
of several decades, offering a wide window of opportunity for studying the development and 
impact of health policies that normally take lengthy periods to implement, and for their impact 
to manifest.  
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Chapter 2                              
A review of the development 
of cancer policies in 
England; evaluating the 
progress of policy objectives 
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2.1  Background 
The five strategies on cancer published between 1995 and 2015 describe comprehensive 
policies of improving cancer care and outcomes (Calman & Hine 1995; Department of Health 
2000; Department of Health 2007; Department of Health 2011a; Independent Cancer Taskforce 
2015). Their content and approach has been influenced by a myriad of social, economic and 
political changes that have spanned the last two decades. These include but are not limited to 
five governments, significant NHS (National Health Service) re-organisation, advances in 
information technology, and economic fluctuations. The various polices may therefore have 
had varying levels of achievements in meeting their intended objectives. 
 
Service re-organisation in the delivery of cancer services have at times been coordinated with 
wider reforms related to changes in government. At other times though, changes have occurred 
in isolation of government involvement. The earliest and perhaps most significant restructuring 
of cancer services that was instigated by the Calman and Hine report (Calman & Hine 1995) 
was not related to any wider reforms, and was entirely independent of government. The report 
had policy recommendations that had far reaching consequences in the configuration of cancer 
services in England and Wales. Some of the policies such as the creation of specialised cancer 
centres to cater for rare cancers and specialised treatment, and cancer units to manage the more 
common cancers continue to be enacted two decades since they were proposed.  
 
Although the majority of Calman and Hine recommendations had the full support of health 
professionals, they were only fully realised after the first national Government strategy on 
cancer, the NHS Cancer Plan (Department of Health 2000), provided the necessary resources 
and leadership needed to fully implement the policies (Haward 2006). Since the NHS Cancer 
Plan, there have been two further Government strategies on cancer; the Cancer Reform Strategy 
(Department of Health 2007) and Improving Outcomes Strategy on Cancer (Department of 
Health 2011a). The most recent cancer strategy, Achieving World Class Cancer Outcomes, was 
however independent of government, and was developed by an Independent Taskforce on 
behalf of NHS England and five other national arm’s length bodies (Independent Cancer 
Taskforce 2015). 
 
Decisions to reform health services are often met with resistance because they are not only 
associated with significant expenses and service disruption, but are also perceived as a threat 
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to the existing workforce or to the institutional culture. However, the pressure to reform may 
at times be necessary, in cancer care; the increase in cancer incidence and cost of treatment 
necessitates adoption of cost-effective approaches that do not compromise quality of care, or 
exacerbate inequalities. Reforms may thereby be considered necessary in order to introduce 
changes in the system. 
 
All the five cancer strategies endeavour to make improvements in the delivery of services in 
order to improve cancer outcomes. In so doing, they all propose numerous changes in the 
commissioning and provision of cancer care. At the heart of these changes are overarching 
policy objectives that can be broadly categorised into four goals; reducing inefficiencies, 
improving quality and access and narrowing inequalities. These goals are consistent with the 
benchmark applied in judging the performance of health systems (Le Grand 1993; Palfrey 
2000; The Commonwealth Fund 2010). These four policy objectives however do not operate 
in isolation as demonstrated in Figure 2.1. Equity and efficiency are normally considered to 
lie at the opposing end of each other. For example, a trade-off ultimately ensues in the attempt 
of equitably distributing a scarce resource like healthcare. Both equity and efficiency are 
additionally interlinked with goals to improve quality and access. The inter-relatedness 
between the different policy objectives will be explored in more detail in subsequent sections 
of this chapter. 
 
Figure 2.1 – Conceptual framework of the interplay between the four health policy 
objectives 
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Another important consideration in the process of reviewing policy statements is that the NHS 
is a highly politicised organisation that different political parties have use as leverage for 
swinging the electorate in their favour (Baggott 2007). For example, the Labour administration 
won the 1997 elections on the back of a commitment to address the under-funding crisis in the 
NHS (Crinson 2009). Despite the political and societal importance of health policies, their 
effectiveness and impact on health outcomes is seldom evaluated (World Health Organization 
2010; Buse et al. 2012; Walt et al. 2008; Embrett & Randall 2014).  
 
This lack of evaluation of policy impact can be attributed to a number of challenges such as 
the failure to set up systems of monitoring and evaluation alongside policy initiation (Le Grand 
1993). There are also methodological challenges in unpicking the multifaceted causal chains 
required in identifying and quantifying cause and effect relationships (Buse et al. 2012; World 
Health Organization 2010). Other challenges include the long time-lags between policy 
implementation and observation of outcomes, which create difficulties in demonstrating policy 
effect on outcomes, and may be a disincentive for evaluation (World Health Organization 
2010). The mismatch in time frames is yet another challenge; the relatively slow pace of 
research vs. the rapidity of political decision-making is a barrier to collaboration between 
policy makers and researchers (World Health Organization 2010). Time conflicts may also 
exist between the long term nature of policy development and implementation, and the short 
term nature of some research (Walt et al. 2008). Further, there are conceptual challenges in 
objectively quantifying abstract factors such as power, values and ideologies that are central to 
the policy process (Walt et al. 2008; Douglas 1984). Lastly, findings from policy analysis are 
not always transferable; the analytical process takes into account political, social and economic 
contexts which might be area specific but my not be generalizable to other areas (World Health 
Organization 2010). 
 
Despite the difficulties, understanding the impact of government policies in health and 
assessing whether they achieve their intended goals should be prioritized. This knowledge 
would aid in informing policy making by linking political ideology with the desired social and 
health outcomes, it would also inform the debate on the most efficient and effective use of 
scarce resources (World Health Organization 2010). Some suggested methodologies for 
evaluating the effect of health policy involve retrospective analyses, which involves piecing 
fragments of facts together methodically (World Health Organization 2010). Other 
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recommended methodologies that are frequently employed in humanities and social sciences 
involve summarising complex processes by use of conceptual frameworks and logic models 
(World Health Organization 2010; Kelly et al. 2010). 
 
2.1.1  Chapter Objective 
This chapter is a retrospective narrative review whereby existing evidence is assessed in order 
to map the development of policy objectives proposed on improving cancer care in England. 
Specific focus is given on the policy objective to improve access to cancer services. Alongside 
access, policy objectives on quality, efficiency and quality are also considered, in recognition 
of the considerable overlap between access and these other policy objectives. Findings from 
this review have been used to shape the research questions, and to provide the policy context 
in the analytical Chapters Three to Six. 
 
The chapter is divided into three sections; the first section describes the methodology used in 
reviewing the evidence. The second section summarises the progress on the aforementioned 
objectives during the period of study, this section also provides some narrative of how progress 
may have been influenced by the policy making process, and offers some reflection on the 
interrelationship between access and the other three objectives. The last section gives a 
summary of the key findings, and offers some thoughts on the direction on future policies on 
access to drive better cancer outcomes.  
 
2.2  Methodology  
Key policy documents on cancer have been reviewed in order to identify the overarching 
objectives of cancer policy, and the approach to policy implementation. Other sources of 
evidence have also been reviewed to assess the progress to date of the identified objectives. 
These sources of evidence include peer reviewed publications, books, policy opinions, expert 
analyses and reports from leading health policy charities and Think Tanks such as the King’s 
Fund, Cancer Research UK and Macmillan Cancer Support. In addition, the findings are 
supplemented by quantitative analysis of existing datasets where the data is available (Buse et 
al. 2012).  
 
The review of literature begins by identifying the outcome of interest and works backwards to 
trace potential influencers along the way. This approach has been suggested as a useful means 
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of yielding insights into the outcomes associated with policies implemented at population level 
(World Health Organization 2010). The approach is also recommended in analysis of policy 
where true experiments cannot be carried out, and where there are no control groups (World 
Health Organization 2010). One major limitation to this methodology is that it is susceptible to 
observation bias which may lead to contradictory findings, and may make the findings 
unattractive to decision makers (World Health Organization 2010). An example of observation 
bias is when personal values influence the analysis, the research question and/or the findings. 
Use of multiple sources may help improve the validity of the findings and minimise such bias 
(Buse et al. 2012). In this narrative review, qualitative findings from secondary sources have 
been supplemented with the quantitative analysis of trend data, where possible. 
 
The study period covered in the review coincides with the period covered by the national 
policies on cancer in England; beginning with the Calman and Hine report written in 1995, to 
the most recent strategy on cancer developed by the Independent Taskforce that was published 
in 2015. Table 2.1 provides a brief summary of the policy documents reviewed in relation their 
approach on improving access, narrowing inequalities, reducing inefficiencies and improving 
quality. This summary (Table 2.1) gives a glimpse of how these objectives have been translated 
into policy and some direction on implementation. The content in Table 2.1 has been explored 
in more depth in the rest of this Chapter where policy statements are reviewed alongside 
secondary sources to help identify any levels of success of failure.  
 
Some understanding of the policy making process is important in order to help with 
understanding why some national policies meet their objectives and others do not. Policies are 
akin to a ‘web of decisions’ (Crinson 2009) in recognition of the challenges encountered in the 
process of making these decisions. This process of decision making takes place in a complex 
environment (context) of competing goals (content) and involves multiple influencers (actors) 
(Buse et al. 2012). The interaction between these different factors determines the success or 
failure of policy implementation and of achieving the intended objectives. These relationships 
are conceptualised in Figure 2.2. 
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Figure 2.2 - Conceptualising the influence of the policy process on health policy 
objectives 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Adapted from Buse et al, 2012. 
 
 
In this conceptual framework, context indicates the prevailing systematic factors such as social, 
political and economic local factors that may have an impact on the making or implementation 
of health policy. Contextual factors may be in the form of ‘situational’ factors, such as an 
increasingly elderly population. They may also be structural factors such as the prevailing 
political or judicial system, or may come in the form of cultural factors such as attitudes that 
may influence the acceptance, access or delivery of health interventions (Buse et al. 2012). 
 
Actors, as shown in  Figure 2.2, are individuals or groups, who participate in the policy 
process, and have a varying influence based on their power and interest (Alford 1975). Actors 
in healthcare have in the past been broadly categorised into three groups; ‘professional 
monopolisers’ who control medical knowledge, ‘corporate rationalisers’, who plan and finance 
health care and ‘equal-health advocates’ who represent an alternative viewpoint and/or demand 
improvements in health services (Alford 1975). Decisions in the making of health policy are 
based on ongoing negotiations amongst actors (Alford 1975). Over the years, there have been 
changes in terms of the number of actors and the roles they represent that has introduced 
important paradigm shifts in terms of the assertiveness and the competition amongst actors. 
One notable change is in the loss of the medical profession’s economic and political autonomy, 
and the corresponding rise in a patient-driven service where patients play an increasingly active 
role in their healthcare (Crinson 2009; Klein 2006; Borras et al. 2014). In cancer care, this 
paradigm change can be broadly summed up as a shift from a disease-focused management to 
a patient-centred approach, where more attention is given to psychosocial aspects, quality of 
life, patients’ rights and empowerment (Borras et al. 2014). 
Actors 
Context (social, political, economic) 
Policy 
content 
Progress on 
health policy 
objectives 
 
PROCESS PROCESS 
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Process (Figure 2.2) refers to the way in which policies are initiated, developed, negotiated, 
communicated, implemented and evaluated (Buse et al. 2012). The policy making process is 
an iterative one that involves several stages, with the key ones being; problem identification, 
policy formulation, option analysis, policy implementation and evaluation (Buse et al. 2012). 
These processes react to contextual changes and influences from the actors. The example below 
demonstrates how this framework might have worked in the context of the recommendations 
proposed by the Calman and Hine report 
 
Context: - Changes in delivery of cancer services in the UK were driven by the social, 
political and economic climate of the 1990s. There was increasing public and political 
interest in improving the worse cancer outcomes in England in comparison to other 
wealthy countries. Poor outcomes were thought to be driven by funding cuts in the NHS 
and by the ‘postcode lottery’ in access to services (Haward 2006). 
 
Actors: - The recommendations were drafted by the ‘Expert Advisory Group on 
Cancer’ that was chaired by the most senior advisors on health (Chief Medical Officers 
(CMO) in England and Wales) and supported by a selected group of 12 health 
professionals. The group also sought input from a national consultation exercise which 
contributed to over 300 responses (Calman & Hine 1995; Haward 2006).  
 
Content: - The report set out principles for cancer care in England and Wales. The key 
recommendation was a new structure of cancer services to ensure that the benefits of 
specialised care were available to all patients. The authors purposely kept the report 
broad in scope and refrained from specifying costs; references to cost might have posed 
serious risks to the publication of the report in view of the political climate of the day 
(Haward 2006). 
 
Process: - There was general professional consensus of the recommendations proposed 
by the Calman and Hine report. But despite this, full implementation of the policies was 
difficult to achieve. The key setbacks to implementation were a shortage of manpower 
and resources, the loosely defined objectives, and a lack of national monitoring and 
accountability (Haward 2006; Rachet et al. 2009). Full implementation was only 
achieved after a change in the political climate. The new government incorporated the 
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Calman and Hine recommendations in its cancer strategy and allocated resources to 
deal with the shortfalls in manpower and facilities. To oversee the full implementation 
of the policies, a national cancer director was appointed and progress was to be 
monitored against clearly laid out objectives and process targets (Haward 2006) .
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Table 2.1- Summary of key objectives of cancer policies in England 
 
Strategy’s 
Timeline 
Policy document Approach to efficiency, quality, equity and access 
1995 -2000 
 
John Major’s 
Conservative 
Administration 
A Policy Framework 
for Commissioning 
Cancer Services  
(1995) 
 
Also known as the 
Calman - Hine 
Report  
This policy framework was initiated in response to the increase in cancer incidence, the variations in outcomes 
and treatment, and the huge economic consequences resulting from cancer. The Chief Medical Officers for 
England and Wales put forward the following main recommendations that are relevant to this review; 
- To minimise inequalities in access to diagnosis and treatment 
- To ensure the highest quality of care that would be achieved by increased specialisation 
- A change in the commissioning of cancer services whereby cancer units and cancer centres would provide an 
integrated network of care. Cancer units would manage common cancers while the management of rare 
cancers and provision of specialist treatment such as radiotherapy would be provided by Cancer Centres 
 
2000 – 2006 
 
Tony Blair’s 
Labour 
Administration 
NHS Cancer Plan; A 
plan for action, a 
plan for investment 
(2000)  
This strategy incorporated the Calman and Hine recommendations on developing a national plan that would 
deliver improvements in all aspects of cancer care. The strategy’s main commitments that are relevant to this 
review were as follows; 
- A funding commitment of an extra £570 million a year to modernise cancer services and offset years of 
underfunding. This would pay for additional services in order to end postcode lottery in service provision 
- A move from the ‘internal market’ model to a new model where power was devolved to Primary Care 
Trusts. Central Government will still have a role of setting standards, monitoring performance and system 
inspection. 
- The introduction of performance monitoring in order to improve quality. Targets would also help monitor 
progress; for example, the national inequalities targets would monitor areas such stop smoking services that 
were set up to reduce social-economic inequalities by targeting manual workers.  
- Improved access would be achieved by introducing targets on waiting times for diagnosis and treatment; 
these include a maximum one month of waiting time from urgent referral for suspected cancer to treatment 
 
2007 – 2010  
 
Gordon Brown’s 
Labour 
Administration 
Cancer Reform 
Strategy (2007)  
The Cancer Reform Strategy built on the momentum of the Cancer Plan to enhance the proposals developed by 
the Cancer Plan. In this respect, these two strategies are not radically different. The main proposal set out by the 
Cancer Reform Strategy are; 
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- In order to improve outcomes and reduce inequalities as set out in the previous strategy, the Cancer Reform 
Strategy needed access to good quality information and intelligence. This marked the establishment of the 
National Cancer Intelligence Network (NCIN) 
- Cancer Networks were established so as to help deliver more value for money by strengthening 
commissioning, the networks would do so by coordinating services and fostering collaborations across 
organisational boundaries 
- The National Cancer Equality Initiative (NCEI) was established to help reduce inequalities in treatment and 
outcomes by helping to develop research proposals on cancer inequalities, to test interventions and to advise 
on policy development  
- The National Awareness and Early Diagnosis Initiative (NAEDI) was launched in recognition that late 
diagnosis is a major contributing factor to poor cancer survival rates in the UK. NAEDI would help 
coordinate activities to help increase symptoms awareness and encourage earlier presentation.  
 
2011 – 2015 
 
David 
Cameron’s and  
Nick Clegg’s  
 
Conservative 
and Liberal 
Democrats 
Coalition 
Improving 
Outcomes, a Strategy 
for Cancer (2011)  
The strategy was preceded by an economic recession and was enacted alongside a major reform of the English 
health services. Some of the policy content and approach to implementation were ideologically different from the 
Cancer Plan and Cancer Reform Strategy in the following ways; 
- The strategy had a significant emphasis on efficiency savings; the 2011/12 NHS Operating Framework 
aimed to achieve up to £20bn efficiency savings within a period of four years 
- The government challenged the NHS to meet efficiency goals without compromising on quality, this was to 
be delivered under the Quality Innovation, Productivity and Prevention (QIPP) programme. The resources 
saved would be invested back into services to improve quality.  
- It was expected that information transparency would help scrutinise quality of care and reduce inequalities.  
Focusing activity on the most vulnerable was also deemed to have the greatest scope for improving 
outcomes. 
- Initiation of a bottom-up-approach’ where individuals, groups and communities were encouraged to play a 
greater role in participation, raising awareness and in creating partnerships, a concept referred to as ‘big-
society’ 
- There was a big push to focus on outcomes and abolish performance measures and targets such as waiting 
times. However waiting times were retained following a review that showed an overwhelming public and 
professional support 
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2015 – 2020 
 
David Cameron 
Conservative 
Administration 
(up to 2016) 
  
And  
Theresa May’s  
Conservative 
Administration 
(present) 
 
Achieving World 
Class Cancer 
Outcomes. A 
Strategy for England 
2015 - 2020 
This strategy is unique as it was developed by an Independent Taskforce on behalf of arm length bodies. This 
independence from government strikes similarities with the Calman and Hine report. The following are its key 
proposals; 
- Similar to the Calman and Hine report, the strategy re-emphasises the importance of striking a balance 
between improving quality through specialisation and ensuring equitable access to services  
- The importance of general practitioners in improving survival was re-emphasised. This would be achieved 
by reducing late diagnosis and improving optimal access to services. The roll-out of Multidisciplinary 
Diagnostic Centres (MDCs) that offer same day testing on relevant symptoms is proposed.  
- Emphasis on improving patient experience with the objective of establishing patient experience to be on par 
with clinical effectiveness and safety.  
- A recognition of the shortfall in the investment that is required to offset current workforce and equipment 
deficits.  
- An overhaul of the current commissioning to develop services that are better co-ordinated along the care 
pathway. This would improve earlier diagnosis, reduce costly emergency admissions, and deliver efficiency 
savings. 
- A recognition that changes in commissioning and improving patient experience in the most marginalised 
would reduce inequalities in access and variations by sub-groups (socio-economics, ethnicity, age). 
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2.3  Access to services 
All the four strategies recognise that optimal access to cancer services is crucial to improving 
cancer outcomes and reducing inequalities. Access is intrinsically linked with the other three 
healthcare objectives assessed in this review. As an example, timely access is advocated as a 
means of improving quality, and which was a key driver to the introduction of cancer waiting 
time standards (waiting times will be covered in more detail subsequent sections). Access is 
also a key ingredient in measuring health equity; a common definition of equity in health is 
‘equal access for equal need’ (Allin et al. 2007; Oliver & Mossialos 2004). Similarly, 
healthcare utilisation is a commonly applied metric in estimating productivity in health (Office 
of National Statistics 2015b). The extent of the overlap between access and these other policy 
objectives is explored in more detail in sections 2.4, 2.5 and 2.6 of this chapter. 
 
The multi-dimensional nature of access makes it challenging to define, to measure and to 
monitor. Access can take three interconnected dimensions; affordability (ability to pay), 
acceptability (social-cultural) and availability (physical/locational or appointments) (Thiede & 
Akweongo 2007). In the UK, the introduction of the NHS ensured universal access to 
healthcare for all, hence removing barriers in access related to affordability. This universal 
access to healthcare has been accorded support by the public, professionals and even 
politicians; despite differences in political ideologies in the latter. This support has had the 
advantage of safeguarding free accessibility. However, one dis-benefit of the popularity of the 
NHS is that is has become a ‘political party football’ and is often a major issue for political 
debate often with the goal of achieving election victory (Baggott 2007). Nevertheless, the NHS 
has generally been spared from the extensive privatisations that took place in other nationalised 
industries during the 1980s (Baggott 2007), and this can be credited to the support accorded to 
a national health service that offers free and universal access (Baggott 2007). 
 
The acceptability dimension of access refers to how services are perceived by individuals and 
communities, and how services accommodate patients’ beliefs and attitudes (Thiede & 
Akweongo 2007). These attitudes may be influenced by differences in demographic 
characteristics such as age, sex, ethnicity, language, cultural beliefs and socio-economic status 
or by geographical location. The availability dimension of access encompasses both spatial 
‘geographical’ or aspatial ‘non-geographical’ perspectives summarised in Table 1.1. The 
monitoring of access to health care in the English NHS is dominated by the ‘non-geographical’ 
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dimension of accessibility with a specific emphasis on waiting lists and waiting times (Godden 
& Pollock 2009). Cancer waiting times were introduced by the Cancer Plan (Department of 
Health 2000) as a means of promoting more rapid access which was thought to improve cancer 
survival. Table 2.2 summarises the cancer waiting time that were initially proposed in 2000 by 
the Cancer Plan and which later on evolved following the proposals developed by the Cancer 
Reform Strategy. Interestingly, the subsequent cancer policy published in 2011, Improving 
Outcomes (Department of Health 2011a), advocated for a disbandment of all process measures, 
including cancer waiting time targets, and in their place proposed a greater focus on outcomes 
measures (Department of Health 2011b). 
 
Table 2.2 - Summary of cancer waiting times targets 
 
 Maximum two-week wait for first outpatient appointment for patients referred urgently with 
suspected cancer by a GP 
 Maximum one month wait from urgent GP referral to treatment for acute leukaemia and 
children’s and testicular cancers 
 Maximum one month wait from date of decision to treat to first treatment for breast cancer 
 Maximum two month wait from urgent GP referral to first treatment breast cancer 
 Maximum one month wait from date of decision to treat to first treatment for all cancers; 
 Maximum two month wait from urgent GP referral to first treatment for cancer 
 Maximum 31-day wait for subsequent treatment where the treatment is surgery 
 Maximum 31-day wait for subsequent treatment where the treatment is an anticancer drug 
regimen 
 Maximum 62-day wait from a consultant’s decision to upgrade a patient’s priority to first 
treatment for all cancers 
 Maximum 62-day wait from a referral from an NHS screening service to first treatment for all 
cancers 
 Maximum two-week wait for first outpatient appointment for patients referred with breast 
symptoms, where cancer was not initially suspected 
 
Source: Department of Health Review of Cancer Waiting Time Standards, 2011 
 
 
2.3.1 Access to early diagnosis services 
All the five strategies reviewed recognise the importance of access to services for the earlier 
detection and earlier diagnosis of cancer. The Cancer Plan extended the age range of access to 
breast cancer screening to include women aged 65 to 70, with availability for request for those 
over 70 years of age.  Access to early diagnosis was also prioritised in the Cancer Reform 
Strategy and culminated to the establishment of the National Awareness and Early Diagnosis 
Initiative (NAEDI). NAEDI’s advocacy work has pushed for an increased recognition in the 
role of GPs in improving cancer outcomes. The two most recent cancer strategies, Improving 
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Outcomes Strategy and Achieving World Class Outcomes, indicate a significant shift from the 
focus on cancer treatment to giving more attention to early diagnosis. This shift has been driven 
by the recognition that later diagnosis in England is a major determinant for poor survival rates, 
and that between 10,000 and 11,000 deaths could be avoided every year by earlier diagnosis 
(Department of Health, 2011a; Independent Cancer Taskforce, 2015). The current early 
diagnosis initiatives are piloting the efficacy of alternative diagnostic pathways to be prioritised 
in areas where GP access is poor; these will include self-referrals and referral pathways from 
other primary health professionals besides GPs (Independent Cancer Taskforce 2015). Another 
proposed development in the referral pathways is the introduction of multi-disciplinary 
diagnostic centres (MDC) which are single testing locations offering multiple tests on 
symptoms on the same day. In addition to offering diagnostics for more typical symptoms, 
MDCs would also offer diagnostics for atypical symptoms; thereby resolving some of the 
challenges associated in determining appropriate referral pathways for non-specific symptoms 
that maybe related to cancer (Independent Cancer Taskforce 2015). 
 
2.3.2 Policies on geographical access 
The geographical accessibility of cancer services was a central theme in the Calman and Hine 
report. The authors recommended that, ‘all patients should have access to a uniformly high 
quality of care wherever they may live, and that this care should be provided as close to the 
patient's home as is compatible with high quality, safe and effective treatment’ (Calman & Hine 
1995) (pg. 6). The authors also recommended service reconfiguration whereby cancer units 
would focus on the management of common cancers, and specialised cancer centres would 
provide management for both common and rare cancers as well as offer specialised diagnostics 
and treatment (Calman & Hine 1995). A positive outcome of increased specialisation of cancer 
services in England has been the improvement in cancer survival (Oliphant et al. 2013). 
However, this may have inadvertently exacerbated inequalities in access and subsequently in 
outcomes. In particular, specialist hospitals tend to be concentrated in large cities which means 
some patients have had to travel further to access cancer care (Gatrell & Elliott 2015).   
 
Despite the trade-off that results in attempting to meet somewhat competing policy objectives 
such as the simultaneous improvements in quality and access, three of the five cancer strategies 
do not address the obvious but inadvertent consequences of increased specialisation on 
geographical accessibility to services. These three strategies also coincidentally happen to be 
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the Government led strategies that were proposed between 2000 and 2011; the Cancer Plan, 
Cancer Reform Strategy, and Improving Outcomes Strategy on cancer (Department of Health 
2000; Department of Health 2007; Department of Health 2011a). This shortcoming has been 
rectified in the most recent strategy, Achieving World-Class Cancer Outcomes (Independent 
Cancer Taskforce 2015). This recent strategy shares similarity with the Calman and Hine report 
in recognising the importance of geographical accessibility in achieving optimal utilisation of 
diagnosis and treatment services. The strategy also reiterates the importance of balancing 
service specialisation, against creating variations in access that may disadvantage patients who 
travel the farthest (Independent Cancer Taskforce 2015). Table 2.3 lists the four 
recommendations set out in this most recent strategy in relation to reviewing, updating and 
implementing the evidence on geographical access to cancer services. Thus far, the recent 
strategy has been the most comprehensive in describing issues pertaining to poor geographical 
accessibility of cancer services and in suggesting a course of action. 
 
 
Table 2.3 - Cancer strategy recommendations related to geographical access to services 
Recommendation 26: CRGs should regularly evaluate emerging evidence to determine whether 
service configuration for surgery merits further centralisation and to advise NHS England 
accordingly. 
 
Recommendation 27: NCIN should undertake an up-to-date evaluation of the impact on cancer 
outcomes of patients living different distances from a cancer Centre. Historical data suggested 
that longer distance from a Centre results in lower probability of curative treatment.  
 
Recommendation 29: From autumn 2015, NHS England should commence a rolling 
programme of replacements for LINACs as they reach 10-year life, as well as technology 
upgrades to all LINACs in their 5th year. All LINACs that are already ten years old should be 
replaced by the end of 2016 at the latest. This should be driven through a national capital fund, 
overseen in the first 2-3 years by a small implementation team, who will also need to ensure that 
equipment is geographically distributed to serve local populations optimally. 
 
Recommendation 43: NHS England, working through the CTYA Clinical Reference Group 
should: 
• Consider whether paediatric treatment centres should be reconfigured to provide a better 
integrated network of care for patients and families. 
• Establish clear criteria for designation and de-designation of treatment centres for TYA 
patients. 
• Ensure that any transition gap between children’s’ and adult services is addressed. 
• Assess impact of proposals on travel times for families. 
Source: Achieving world-class cancer outcomes, 2015 
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2.3.3 Progress on the objective to improve access 
Monitoring timely access to cancer services in England has been by measured by how rapidly 
patients referred with suspected cancer receive a consultant appointment (see Table 2.2). The 
national operational standard for this target is for 93% of the referred cancer patients to have 
their first outpatient attendance within two weeks of referral (NHS England 2015). These 
standards take into account that some local variations at provider level will exist based on 
provider’s case mix or patients’ choice (NHS England 2015). Figure 2.3 shows that at a 
national level this target has been consistently met. The proportion of patients seen within two 
weeks of a GP referral rose between 2009 and 2012, but has been in decline since (Figure 2.3). 
This decline may be explained by the increase in referrals through the two-week wait route 
(Figure 2.3, dashed line). Two things may be happening concurrently, firstly, it is possible that 
waiting time targets have increased utilisation of treatment as GPs increase the number of 
referrals into secondary care. Secondly, this increase in referrals may make it more difficult to 
meet the waiting time target as staff and other resources such as workforce and equipment may 
have remained static. 
 
 
Figure 2.3- Two week wait from GP urgent referral to first consultant appointment 
 
 
Source: NHS Cancer Waiting Time Statistics. Data collected before December 2008 is not comparable 
due to changes in how the data is collected 
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The evidence on the effectiveness of waiting times reductions on cancer mortality is so far 
inconclusive (Neal 2009). One study has shown that decreasing waiting times from diagnosis 
to surgery has little impact on breast cancer survival (Redaniel et al. 2013), whereas other 
studies have reported a ‘waiting time paradox’ whereby patients with short diagnostic intervals 
have higher mortality than patients with long diagnostic intervals (Ramos et al. 2007; 
Rupassara et al. 2006). This paradox may be explained by the fact that patients with poor 
prognosis are given medical priority (Tørring et al. 2011) or it could also be due to differences 
in tumour progression; symptoms in a fast growing tumour are likely to progress rapidly 
leading to faster diagnosis but poorer outcomes (Neal 2009). Despite the lack of consensus on 
their clinical effectiveness on cancer survival, waiting times policies were retained in the 2010 
health reforms because of the perceived psychological benefits they have on patients. There 
was a unanimous view from patient groups, cancer charities, and health professionals that the 
cancer waiting time standards have helped to drive service improvement and have reduced 
patients’ anxiety related to delays with diagnosis and treatment (Department of Health 2011b).  
 
When access to healthcare is viewed from the perspective of ‘utilisation’, notable variations 
that may be related to different attitudes towards health and illness, or to differences in clinical 
practice have been reported. As an example, there is increasing evidence to suggest that older 
patients are less likely to receive the most clinically effective treatment for their cancer, this 
may be linked to the poorer outcomes reported in older people (Royal College of Surgeons of 
England 2012; Macmillan Cancer Support 2012). Figure 2.4 shows a consistent decline in the 
rate of colorectal excision procedures after the age of 69 years. This decline in treatment rates 
does not correlate with the increased incidence of colorectal cancers and diverticular disease in 
older patients (Royal College of Surgeons of England 2012). Rather, the differences may be 
explained by a combination of factors such as presence of comorbidities, patient choice or 
clinical attitudes towards treating older patients; which include misunderstanding of the 
toxicities and side effects of treatments, or even challenges in providing appropriate community 
support for older cancer patients (Department of Health 2010). 
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             Figure 2.4 - Rate of elective colorectal excision procedures by age 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Source: The Royal College of Surgeons and Age UK, 2012 ©. Reproduced with permission 
 
 
With regards to achieving geographical accessibility, there is ample evidence demonstrating 
the association between geographical accessibility to secondary services and poorer outcomes 
(Campbell et al. 2001; Campbell et al. 2000; Jones et al. 2008; Crawford et al. 2009; Sauerzapf 
et al. 2008). There is also some evidence on the influence of rurality on health seeking 
behaviour such as consultation with the GP, or reporting symptoms (Haynes & Bentham 1982; 
Emery et al. 2013). Despite this, there is presently no national indicator to measure or monitor 
progress on geographical access to health services and so it is not known to whether there has 
been any improvements in achieving equality in access to all regardless of location, or whether 
the implications of not achieving equitable access remain a concerning issue.  
 
2.4  Efficiency of cancer services in England 
An efficient healthcare system is one that maximizes the quality of care and outcomes with the 
given resources, and at the same time ensures that investments yield net value over time (The 
Commonwealth Fund 2010). The simplest measure of healthcare efficiency is productivity, 
which uses multiple information such as inputs (labour, goods and services), outputs (hospital, 
GP services), and computes productivity at the desired scale i.e. national, hospital or disease 
level (Langabeer  II & Ozcan 2009; Office of National Statistics 2015b). Measuring efficiency 
of cancer services at a national level presents several challenges as it is dependent of the 
availability of reliable data at the disease level, the information required to do this for cancer 
care in England is not yet readily available. 
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2.4.1 Commissioning of cancer services 
The commissioning process can be described as a process of developing, planning, purchasing 
and coordinating the delivery of health services in order to improve population health (Crinson 
2009). Commissioning therefore determines whether efficiencies or productivity will be 
accrued; as health commissioners aim to make the most optimal use of health resources to 
achieve the intended outcomes (National Audit Office 2010b). 
 
The period covered in this review has seen major changes in healthcare commissioning. To 
begin with, the authors of the Calman and Hine report recognised the importance of informed 
commissioning, thus aptly referring to this report as ‘A Framework for Commissioning Cancer 
Services’ (Calman & Hine 1995). Despite this explicit reference to commissioning, this report 
steered clear of any explicit references to money, due to the risk in publication posed by the 
political climate of the day (Haward 2006).  During the 1990s, and at around the time of 
publishing the Calman and Hine report, the Conservative Government had introduced a 
significant change in how NHS funds were utilised. The new system was referred to as ‘internal 
market’ and it divided the NHS into ‘purchasers’ such as GP fundholders and health authorities 
and ‘providers’ such as hospitals. Purchasers were given a budget which they could use to 
secure services for their population, and ‘providers’ were to compete for these services 
(Baggott 2007). This system was expected to generate efficiencies as providers competed for 
business, there are some accounts of increased productivity measured by changes in activity 
relative to resources, which increased by around 7 per cent between 1991 and 1996. On the 
other hand, there is also evidence of inequities that stemmed from variation in access to hospital 
services between patients of fund-holders and non-fundholding GPs (Baggott 2007). 
 
GP fundholders were replaced by Primary Care Trusts (PCTs) when the Labour Party came 
into power in 1997. The Government sought to increase efficiencies by developing a system of 
incentive payment to the more efficient providers, this system was referred to as a ‘supplier 
market’ (Crinson 2009). PCTs were responsible for commissioning cancer services, via a lead 
clinician on cancer, whose role was to contribute to developing cancer networks that would 
enable better coordinated care along the care pathway (Department of Health 2000). PCTs were 
also to provide logistical support to GPs to enable them to effectively plan the needs of their 
population (Crinson 2009). Cancer Networks in turn were to support PCTs in their 
commissioning role by helping maintain dialogue with clinical teams and users (Department 
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of Health 2007). The incoming Labour Government supported the Calman and Hine proposals 
fully, however, the full implementation of major recommendations such as increasing specialist 
cancer care required a balance between the critical mass required to achieve optimal care 
(Department of Health 2007), equity in access (Munro 2001), and efficient collaboration across 
care pathways (Department of Health 2007). This was to be achieved by commissioning 
services across a network based on care pathways as opposed to organisational boundaries; 
Cancer Networks were best placed to do this because they provided the required critical mass 
of approximately one to two million people (Department of Health 2007). 
 
The commissioning landscape changed once more in 2010 when the coalition Government 
transferred the function of PCTs to the GP commissioners under the newly formed Clinical 
Commissioning Groups (CCGs). At a national level, NHS England was also established to 
oversee the commissioning of specialised services such as diagnostics and treatment of rare 
cancers. Public Health England was also established to oversee services that require national 
level coordination such as cancer screening. Efficiency savings were to be realised under the 
Quality Innovation Productivity and Prevention (QIPP) challenge (Department of Health 
2011a). Although QIPP had been established by the Labour administration under the umbrella 
of NHS Institute for Innovation and Improvement, its role was strengthened by the Coalition 
administration, and the programme was rebranded as the NHS Improving Quality. Under QIPP, 
NHS organisations were encouraged to demonstrate efficiency savings that had been re-
invested back into services in order to improve quality (Department of Health 2011a). 
 
The Improving Outcomes Cancer Strategy also recognised the role of Cancer Networks as 
specialist advisers to commissioners, however, it also hinted at changes to the networks, 
ranging from their complete eradication, to a reduction of their remit to early diagnosis only 
(Department of Health 2011a). The intention to bring changes to the networks was apparent 
when  GP commissioners were given freedom to obtain commissioning advice from elsewhere 
(Department of Health 2011a). This move was opposed by many who recognised the 
contribution of Cancer Networks in improving outcomes, in maintaining an integrated service 
across the entire pathway, and in ensuring service users are meaningfully involved in the whole 
commissioning cycle (All Party Parliamentary Group on Cancer 2011; MacMillann Cancer 
Support 2011). The landscape of the Cancer Networks has been in constant evolution, their 
role was largely retained in 2013 but under the umbrella of newly formed Strategic Clinical 
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Networks (SCN) (NHS 2012). SCN would build on the strength of the Cancer Networks but 
would cover a wider remit of disease areas, thus ensuring commissioners would have a broad 
range clinical expertise (NHS 2012). The most recent cancer strategy published in 2015 has 
proposed the establishment of Cancer Alliances that are in many ways reminiscent of the 
abolished Cancer Networks. These Alliances will bring together key partners at a sub-regional 
level in order to drive improvements and support integrated care pathways (Independent 
Cancer Taskforce 2015), as well as provide strategic support and leadership (MacMillan 
Cancer Support 2015). 
 
2.4.2 Funding in cancer services 
Labour and Conservative Governments have had different approaches towards investing in 
health services. The Cancer Plan, produced under the Labour administration, had an 
unparalleled commitment to investment in comparison to the subsequent government strategies 
on cancer. The Labour administration was responding to concerns of poorer survival in 
England in comparison to other European countries. There were also concerns about large 
inequalities in cancer mortality, and on less funding for cancer care in comparison to other 
European countries (Department of Health 2000). The Labour Government responded by 
scaling up England’s spending by an estimated £570 million a year, it was expected that this 
extra funding would correct decades of neglect and under-investment by the previous 
administration (Department of Health 2000). The funding was aimed at tackling the deficit in 
the cancer workforce, investing in cutting edge diagnostic equipment, and strengthening 
research (Department of Health 2000). 
 
Subsequent cancer strategies have been much more conservative on their approach towards 
spending. For instance, the Cancer Reform Strategy, whilst re-affirming continuity in vital 
investments, also emphasised the monitoring of variations in spending in order to improve 
efficiencies, and reiterated the importance of cancer networks as advisors to cancer 
commissioners (Department of Health 2007). Efficiency savings was once again emphasised 
in the Improving Outcomes Strategy on Cancer. The concern over inefficiencies coincided with 
a period of low economic growth that followed a major financial recession, but it was also 
informed by ideological differences; as an example, the incoming Coalition Government was 
driven by a belief that the Labour Government had been prolifically wasteful (Conservative 
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Party, 2010)*. These differences in ideology are exemplified by the Improving Outcomes 
Strategy’s challenge to the NHS to deliver efficiency savings of £20billion within four years 
(Department of Health 2011a). These savings were deemed necessary in the face of rising 
cancer incidence and increasing demand for expensive treatments. However, implementing 
such enormous cost savings measures without compromising quality presents a considerable 
challenge to a health service that is already overstretched.  
 
The gross NHS expenditure on cancer over the past decade is shown on Figure 2.5, which 
reveals a steady increase in spending between 2003/04 and 2009/10. Spending however 
plateaued between 2010 and 2012 before continuing to increase slightly in 2012/13. Figure 2.5 
suggests that the Cancer Reform Strategy’s (Department of Health 2007) pledge to cut 
unnecessary spending from 2007 onwards may not have had any impact on the total spend, 
however, the spending cuts announced in the 2010 NHS reforms may have had some impact 
on cancer expenditure. Analysis of the NHS expenditure statistics shows that real expenditure 
on cancer rose by 2.9% in the 2008/09 financial years, and by 11.2% in 2009/10 (Cancer 
Research UK 2012). However, there was a 2.6% real terms decrease in cancer spend in 2010/11 
(averaging an estimated 3.4 per cent per population head) (Cancer Research UK 2012). This 
decline was as a result of low nominal growth in the total NHS expenditure, a reduction in the 
proportion of the NHS budget allocated to cancer, and high inflation (Cancer Research UK 
2012).  These patterns observed in cancer spend are observed across the entire NHS 
expenditure; healthcare expenditure grew strongly between 1997 and 2009 with an annual 
average growth rate of 8.1% but growth slowed after 2009 with an annual average growth rate 
of 1.4% between 2009 and 2011 (Office of National Statistics 2013a). 
 
Healthcare spending on cancer is associated with better health outcomes, even after controlling 
for need (to factor in that areas with higher need have more expenditure) (Centre for Health 
Economics 2007). Perhaps in recognition of this association, the most recent strategy on cancer 
observes that offsetting the current spending deficit will be required in order to deliver a 
modern high quality service (Independent Cancer Taskforce 2015). The strategy proposes 
necessary investments such as; an increase in workforce, updating radiotherapy equipment, 
improving access to new cancer treatment and allocating more funds for cancer research 
                                                          
* There are 19 mentions of ‘waste’ in the 2010 Conservative Manifesto 
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(Independent Cancer Taskforce 2015). The total cost of meeting the recommendations set out 
in the this strategy is estimated as £400m per annum (Independent Cancer Taskforce 2015). 
 
 
Figure 2.5 - Programme budgeting aggregate PCT expenditure for England for cancers 
and tumours – 2003/04 to 2012/13 
 
 
Source - DH Programme budgeting, 2014 
 
 
2.4.3  Delivering value for money 
There are methodological issues in ascertaining value for money from investments made on 
cancer services. The Office of National Statistics methodology uses productivity estimates 
(Office of National Statistics 2007) which estimate the amount of output which is produced for 
each unit of input. These estimates can be criticised as they do not measure value for money, 
nor wider performance. As an example, productivity estimates cannot determine whether inputs 
were purchased at the lowest possible cost or whether the desired outcomes were achieved 
(Office of National Statistics 2015b). Nevertheless, productivity estimates measure efficiency 
up to a certain point, because increasing productivity is a sign of greater efﬁciency in producing 
outputs from given inputs (Office of National Statistics 2007). ONS productivity statistics are 
not disease specific so it is difficult to relate them specifically to cancer services. Also 
healthcare productivity is measured at UK not England level and so cannot be related to health 
policies implemented in England. Nevertheless, these ONS productivity statistics are the 
closest to determining the value of money in the NHS investments over time. 
 
The estimated trend of healthcare productivity since 2000 is shown in Figure 2.6. The reduced 
volume of inputs from 2010 onwards coincides with the QIPP efficiency challenge, which 
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required the NHS in England to make £20 billion of savings by the end of the spending review 
period (Office of National Statistics 2015b). Productivity increased in most years, with an 
annual average growth rate in quality adjusted productivity of 0.8% (Office of National 
Statistics, 2015).  
 
Figure 2.6 - Growth rates for healthcare output, inputs and productivity, UK 2000-2013 
 
 
 
Source: ONS, 2015 
 
 
There is no definitive evidence to ascertain whether cancer services offer value for money. This 
is despite the fact that efficiency is a key policy objective in cancer care. An evaluation of the 
impact of the Cancer Reform Strategy on efficiency found that there may be some measurable 
improvements in efficiency such as in treating more people as day cases, and in reductions in 
the length of stay (National Audit Office 2010a). Studies looking at individual aspects of care 
have shown an association between proactive case management by Clinical Nurse Specialists 
and increased efficiency savings (Baxter 2011). There is also evidence associating the increase 
in doctors’ specialisation with value for money (Max Bachmann et al. 2003); increases in 
surgical volume is associated with lower costs, but only up to a specific threshold beyond which 
higher volume begins to incur higher costs. So far there is no conclusive evidence on the cost-
effectiveness of the increasing service centralisation of cancer services (Ke et al. 2012). A 
counter argument to centralisation is that any benefits such as cost savings on the NHS may be 
transferred to patients who have to incur the cost of  travelling farther for care, additionally, 
longer journey may reduce the likelihood of compliance with and uptake of treatment (Ke et 
al. 2012).  
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2.5  Improvements in Quality 
High quality care is care that is effective, safe, coordinated and patient-centred (The 
Commonwealth Fund 2010). Effectiveness in healthcare is determined by the appropriateness 
in preventing or in treating a condition, or in controlling chronic illnesses (The Commonwealth 
Fund 2010). Cancer survival rates are used as a marker of quality of services because better 
survival is a reflection of improvements in early diagnosis and in effective treatment (Richards 
2009). Clinical effectiveness and safety has historically received greater prominence than 
patient experience, however, the last two cancer strategies have reinforced the importance of 
using  cancer patient experience is as a marker of service quality (Department of Health 2011a; 
Independent Cancer Taskforce 2015). The most recent strategy goes as far as proposing for 
patient experience to be given equal parity with clinical effectiveness (Independent Cancer 
Taskforce 2015).  
 
Information on cancer patient experience in England is collected by the NHS Cancer Patient 
Experience Survey (CPES) that was established by the Cancer Reform Strategy; earlier cancer 
patient surveys were conducted before the introduction of CPES, in 2000 and in 2004 and were 
the basis of the CPES Programme. Cancer patient surveys are now conducted annually and the 
feedback obtained is expected to help drive quality improvements and thereby improve cancer 
outcomes. However, evidence suggests that the surveys have had minimal impact in terms of 
quality improvements (Department of Health 2012a), which has led to endorsements to 
incorporate the surveys into quality improvements; such as using feedback from patients to 
inform the design and delivery of services (Department of Health 2011a; Independent Cancer 
Taskforce 2015). The increasing importance in monitoring patient experience indicates a 
paradigm shift from a disease focused to a patient-centred approach (Borras et al. 2014; Crinson 
2009), and it may be a demonstration of the increasing power of patients as an interest group.  
 
All the five strategies on cancer acknowledged that cancer survival in England lagged behind 
that of other comparable European countries, thereby identifying improvements in survival as 
a key policy objective. The Cancer Plan had a bold ambition to deliver the fastest improvement 
in cancer services in Europe in five years and to match the survival rates of the best European 
countries by 2010 (Department of Health 2000). The EUROCARE statistics on one year 
relative survival rates for cancers diagnosed between 1995-1999 and 2000-2007 show that 
seven years after the Cancer Plan, England was yet to catch up with Sweden (Europe’s best) 
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(Table 2.4). However, there has been some progress as England has one of the fastest increase 
in relative survival in Europe, and this has been increasing at nearly the same speed as that of 
Sweden (Table 2.4). 
 
Table 2.4 - One year age standardised relative survival (%) for all malignant neoplasms 
in adults patients, diagnosed in the 1995-1997 and 2000-2007 
 
1995 – 1999 2000 - 2007 
Increase in relative 
survival   
Sweden 76.03 Sweden 81.13  5.10 
UK England 63.14 UK England 68.14  5.00 
European Average 69.55 European average 72.53  2.98 
 
Source - EUROCARE 4 and 5 Database 
 
Cancer survival rates in England have been consistently improving for all combined cancer 
types (Figure 2.7). There have also been steady improvements in individual cancer types, 
although there is a clear survival difference between cancers of good prognosis such as breast, 
prostate and colon and rectum cancers and cancers of poor prognosis such as stomach, lung, 
brain and pancreatic sites (Figure 2.8). 
 
Figure 2.7 - One and five year survival index for all cancers combined, by calendar year 
of diagnosis (15-99 years), 2000 – 2014 
 
 
 
Source – Office of National Statistics, 2016 
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Figure 2.8 - Trend in age adjusted one year index of survival (%) for selected cancer 
sites in adults (15-99 years) in England 
 
 
 
Source – Quaresma et al, 2015 
 
 
 
2.5.1 Policy impact on cancer survival 
 
There is some evidence showing that the observed increase in cancer survival may be directly 
attributed to some of the governments’ policies on cancer. A comprehensive assessment of the 
impact of the NHS Cancer Plan on cancer survival rates in England attributed the accelerated 
rate of increase in one year relative survival to this strategy (Rachet et al. 2009). Survival rates 
were generally improving before the Cancer Plan and so there were methodological difficulties 
in ascertaining the contribution of the policy to any improvements in survival. The assessment 
therefore focused on the acceleration in the survival trend between three distinct periods; 1996 
- 2000 (before the cancer plan), 2001 - 2003 (policy initialisation), and 2004 - 2006 (policy 
implementation), and compared the progress in England with that of Wales. The Welsh national 
policy on cancer was published six years after the English Cancer Plan and therefore any impact 
of the Cancer Plan would be determined if survival rates in England accelerated more rapidly 
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in England than in Wales following several years of latency (Rachet et al. 2009). The study 
concluded that although cancer survival was very similar in England and Wales, the gains in 
1-year survival were more marked in Wales during 1996–2000 and 2001–2003, whereas gains 
in England were more marked from 2004 onwards. The improvements in Wales were 
associated with the implementation of recommendations by a report from the Welsh Office 
(Cancer Services Expert Group 1996) post 1997. Whereas England’s survival improvements 
maybe  related to the implementation of the cancer plan (Rachet et al. 2009; Richards 2009).   
 
It is difficult to ascertain which individual policy changes should be attributed to the 
improvements in cancer survival rates. In England, it is most likely that it is the contribution 
of the sum of all; service redesign, increased funding, multidisciplinary working, clinical 
audits, better information being key factors amongst others. There is some evidence to associate 
increased specialisation (as advocated by the Calman-Hine report and endorsed in subsequent 
strategies) with improvement in survival; for instance, surgical specialisation has been shown 
to improve colorectal cancer survival, with survival differences reported in patients treated by 
specialist vs. non-specialist surgeons (Oliphant et al. 2013).  
 
The association between increases specialisation and survival improvements may be as a result 
of greater experience amongst specialist surgeons, making them more likely to perform 
thorough investigations (M Bachmann et al. 2003). Specialist hospitals are also able to offer 
better clinical care on aspects such as nursing, nutrition and palliation (M Bachmann et al. 
2003). Increased specialisation also extends to the use of Clinical Nurse Specialists (CNS) 
whose utilisation has also led to improvements in quality (Gurzick & Kesten 2010; Moore et 
al. 2002). Other studies have shown that the emotional support that CNS offer patients is also 
highly regarded (Liebert & Furber 2004), in addition, the national Cancer Patient Experience 
Survey found that patients with an allocated CNS gave more positive scores on almost all 
questions compared to those without (Department of Health 2012a). However, the reported 
variability in access to specialist treatment and to CNS has important equity implications for 
patients who are unable to access these services (Campbell et al. 2000; Sauerzapf et al. 2008; 
Ream et al. 2009; Department of Health 2012a; Independent Cancer Taskforce 2015).  
 
Use of Multidisciplinary Teams (MDTs) has also been championed as a means of improving 
clinical decision making, although there is lack of consensus on their benefits. Evaluations of 
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the clinical impact and effectiveness of MDTs conclude that the cost of the meetings are very 
high but produce minimal clinical impact (Fleissig et al. 2006; Chinai et al. 2013). This has 
resulted to some recommendations for MDTs to focus on the very complex cases rather than 
on all cancer patients (Fleissig et al. 2006; Chinai et al. 2013).  
 
Another practice recommended by cancer policy that may have led to overall quality 
improvements is the undertaking of clinical audits and ensuring clinical governance. One of 
the earliest audits in cancer care was commissioned to review the progress of Calman and Hine 
recommendations, to provide an assessment of the current state of services and provide a 
baseline for measuring future progress (Department of Health 2000). At present, there are four 
established cancer specific clinic audits; the National Lung Cancer Audit (LUCADA), National 
Bowel Cancer Audit (NBOCAP), National Head and Neck Cancer Audit (DAHNO) and 
Oesophago-gastric Cancer Audit (Department of Health 2011a). These audits have been 
credited to improving service quality (Department of Health 2011a), and there are proposals 
for them to be extended to more cancer sites such a prostate cancer, as well as the establishment 
of a primary care cancer diagnosis audit (Department of Health 2011a). 
 
More improvements in cancer survival are anticipated because of current initiatives in 
improving early detection and diagnosis. The National Awareness and Early Diagnosis 
Initiative (NAEDI) established by the Cancer Reform Strategy has been at the forefront of 
coordinating activities and research in early diagnosis. The importance of early diagnosis in 
improving England’s cancer survival on par with other European countries is iterated in all 
cancer strategies reviewed. The most recent strategy, Achieving World-Class Cancer 
Outcomes, projects that 11,000 deaths annually can be prevented by improvements in early 
diagnosis (Independent Cancer Taskforce 2015). 
 
Alongside recognising the impact of earlier diagnosis on improving cancer survival, there is 
also an acknowledgement of the difficult task that GPs have in suspecting cancer, in making 
appropriate referral when the symptoms are non-specific (Department of Health 2011a). The 
referral guidelines for suspected cancer that were first published in 2000 to support GPs in 
making referral decisions have been updated twice since to incorporate current evidence. The 
most recently revised referral guidelines are noteworthy in their efforts to improve early 
diagnosis by referring patients with non-alarming or vague symptoms. Previous guidelines 
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were inconsistent with regards to the risk threshold for referral, and investigation for referral 
was rarely initiated where positive predictive values (PPV)† were below 5% (NICE 2015). The 
revised guidelines have now included symptoms with a PPV of as low as 3% , and it is 
anticipated that this will is improve earlier diagnosis (NICE 2015) which will consequently 
improve survival. 
 
2.6  The Equity Challenge 
Inequalities in cancer can manifest as differences in the cancer care experience or outcomes in 
relation to an individual’s socio-economic status, cancer type, race, age, gender, disability, 
belief, sexual orientation and geographical location (All Party Parliamentary Group on Cancer 
2009).  
 
Tackling inequalities has been at the forefront of all the cancer strategies reviewed. The Cancer 
Plan recognised the presence of acute inequalities in cancer care and outcomes stating that; 
‘People from deprived backgrounds are more likely to get some types of cancer, and overall 
are more likely to die from it once they have been diagnosed’ (Department of Health 2000) (pg. 
19). This strategy sought to reduce inequalities by targeted efforts in the most deprived such as 
efforts to reduce smoking rates in manual groups (Department of Health 2000).  The Cancer 
Reform Strategy also highlighted inequalities as a priority, declaring that a lack of evidence on 
their nature was a hindrance to addressing the issue. In response, the Government set up the 
National Cancer Equality Initiative (NCEI) which was mandated to optimise data collection in 
order to enable a better understanding of inequalities, to promote research and evidence on 
cancer inequalities, and to spread good practice (Department of Health 2007). More recently, 
the Improving Outcomes Strategy on cancer has attributed England’s poorer outcomes to the 
worse outcomes observed in vulnerable groups and deprived areas; ‘Higher morbidity and 
mortality in disadvantaged groups and areas are a key driver for our poor average outcomes’ 
(Department of Health 2011a) (pg. 3). The most recent strategy, Achieving World-Class 
Outcomes Cancer Strategy, also reiterates the impact of socio-economic variations and 
attributes 15,300 cases and 19,200 deaths per year to the gap between the most and least 
deprived (Independent Cancer Taskforce 2015). 
 
                                                          
†   Positive Predictive Value (PPV) is the risk of having the disease of interest given a specific symptom 
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Cancer inequalities in England manifest as; higher cancer incidence and mortality in deprived 
groups, in older people, in some ethnic minorities and in men. The exception here is breast 
cancer where women who are more affluent have higher incidence, although they also have 
lower mortality than the less affluent women. Cancer incidence is generally lower amongst 
ethnic minority groups, with the exception of prostate cancer where incidence is greater 
amongst Black African and African-Caribbean men. Liver cancer incidence is higher among 
South Asians, and mouth cancer is highest among Bangladeshis (Department of Health 2010). 
Inequalities have also been reported in levels of patient experience, with black and minority 
ethnic groups reporting poorer experience of care (Department of Health 2012a). Some older 
people also experience clinically inappropriate under treatment, which may be attributed to the 
slower rate of improvements in mortality in older people in comparison to younger age groups 
(Department of Health 2010). 
 
There are also known geographical inequalities in cancer diagnosis, treatment and outcomes in 
England that are intrinsically related to how services are organised and how patients access 
them. These geographical inequalities have been reported as the regional differences in survival 
whereby survival rates are generally lower in Northern England than in the South of the country 
(Walters et al. 2010). Trend data shows that the north-south divide has become less pronounced 
over time (Office of National Statistics 2013b); Figure 2.9 demonstrates the narrowing of 
cancer survival rates between Clinical Commissioning Groups located in the north and south 
of England. This reduction in geographical inequality is particularly significant in breast cancer 
survival, which has been attributed to the successful implementation of the NHS Cancer Plan 
recommendations (Walters et al. 2010).  
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Figure 2.9 - Smoothed maps of the one-year survival index (%) for all cancers combined 
in 211 Clinical Commissioning Groups: England, 1996, 2001, 2006 and 2011, patients’ 
ages 15-99 years 
 
Source - ONS, 2013 ©. Re-used with permission. Licence for re-use is available at 
http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/  
 
Analysis of individual level data reveals geographical inequalities that are associated with 
access to cancer services. For instance, poor geographical access has been associated with 
decreased likelihood of histological diagnosis (Crawford et al. 2009) and poorer uptake of 
optimal treatment (Sauerzapf et al. 2008; Jones et al. 2008). Proximity to specialist services 
has been associated with uptake of care, in lung cancer; large variations in resection rates has 
been linked to local provision of specialist thoracic surgeons, whereby, presence of a surgeon 
at a lung MDT, has been associated with higher resection rates (Lau et al. 2013). Another study 
found that specialist thoracic surgical services have higher resection rates for patients referred 
directly to them compared to those patients referred from the wider and much larger catchment 
areas that they serve (Khakwani et al. 2013).   
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2.6.1 Closing the gap 
Despite the consistent policy attention on tackling unjustified inequalities, there has been little 
progress in closing the inequality gap. For example, inequalities by socio-economic groups 
have persisted despite the universal access to health in the UK. The exact origins of these 
inequalities remain unclear, but it is likely that they arise from complex interactions of factors 
that operate at different levels; biological, behavioural or psychosocial and health system levels 
(Munro 2005). Thus, inequalities may be as a result to differences in tumour aggression 
(Woods et al. 2006), disease stage (Møller et al. 2009), or comorbidity (Møller et al. 2012). At 
a behavioural level, inequalities may be as a result to different attitudes towards seeking health 
care (Niksic et al. 2015; Moffat et al. 2017). They may also arise due to factors operating at the 
health system level such as differences in clinical practice (King’s Fund 2011), or as a result 
of environmental factors such as variations geographical and locational access to services 
(Munro 2005). 
 
It is estimated that closing the gap in survival between the most and least affluent would prevent 
anywhere between 7,000 (Ellis et al. 2012) to 19,200 deaths (Independent Cancer Taskforce 
2015) in England only. Whilst understanding healthcare inequalities requires the rigour of 
scientific investigation, addressing them fully requires political will power that involves 
addressing inequalities of the wider determinants of health that operate outside the health 
system (Navarro 2009; Whitehead & Popay 2010; Marmot et al. 2017). It is therefore 
welcoming that most of the cancer strategies reviewed had a political commitment to 
addressing inequalities, by targeted action on determinants of poor survival such as diet, 
smoking, alcohol consumption and physical activity, and focussing initiatives on the most 
disadvantaged groups and areas (Department of Health 2011a; Independent Cancer Taskforce 
2015; Department of Health 2000). 
 
The extent to which cancer strategies have successfully achieved the objective to reduce 
inequalities is not fully known. An assessment on the impact of the Cancer Plan on the equity 
goal found that the strategy was successful in improving cancer survival rates, but was 
unsuccessful in reducing the socio-economic gap in survival (Rachet et al. 2010). Figure 2.10 
shows the consistency of the survival gap in 1 year relative survival rates between the most and 
least deprived groups. Secondly, the assessment found that the socio-economic gap in relative 
survival differed between cancers of good vs. poor prognosis; socio-economic inequalities 
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were wider for cancers of good prognosis‡ (Figure 2.10). Lastly, the assessment reported 
‘persistent and wide socioeconomic inequalities in the excess hazard of death in the period 
immediately after a cancer diagnosis’ (Rachet et al. 2010) (pg. 452), suggesting that more 
attention should be given to earlier diagnosis and prompt access to optimal treatment across all 
socioeconomic groups (Rachet et al. 2010). 
 
Figure 2.10 - Trends in 1-year relative survival for the most deprived (solid line) and 
most affluent (dashed line) groups, by cancer prognosis, England 1996–2006. Lines are 
the regression plots fitted in a single model, which comprises every survival estimate by 
deprivation and calendar year. 
 
Source – Rachet et al, 2010, Re-used with permission. Licence for re-use is available at 
https://creativecommons.org/licenses/by-nc-sa/3.0/ 
 
 
Most of the socioeconomic deficits in survival occur shortly after diagnosis, and they tend to 
attenuate or disappear with time since diagnosis (Rachet et al. 2008; Møller et al. 2012). In 
colorectal cancer for instance, excess mortality (survival deficit) in the most deprived groups 
is a short term phenomenon, that is largely confined to the first year (colon cancer) and two 
years (rectal cancer) after diagnosis (Møller et al. 2012). As described earlier in this section, 
these variations in survival may explained by differences in patient and disease characteristics 
                                                          
‡ Cancers of good prognosis are bladder, breast, cervix, colon, Hodgkin’s disease, kidney, larynx, leukaemia, 
melanoma, myeloma, Non-Hodgkin lymphoma, ovary, prostate, rectum, testis and uterus. Cancer of poor 
prognosis are brain, lung, oesophagus, pancreas and stomach, (Rachet et al, 2010). 
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and a number of studies have demonstrated this. Another suggested explanations is in relation 
to the organisation and quality of cancer care services (Møller et al. 2009), inequalities from 
this may arise as a result to variations in optimal access to early diagnosis and treatment 
services (Richards 2009; Rachet et al. 2010). As described elsewhere in this section, there is 
evidence showing how the structure of treatment services may exacerbate inequalities in cancer 
outcomes (Khakwani et al. 2013; Lau et al. 2013). The extent by which access to early 
diagnosis services may generate or perpetuate any inequalities in cancer outcomes is largely 
unknown, this research will contribute to towards generating evidence for this.  
 
 
2.7  Highlighting the key findings from a policy perspective 
Achieving health policy goals in cancer care presents significant challenges to policymakers 
and healthcare providers. Increase in life expectancy and improvements in early detection has 
led to an increase in cancer incidence, whilst improved treatment has increased survivorship. 
On the other hand, the health resources required to manage and treat the disease are increasingly 
scarce, and this ultimately results in a trade-off when attempting to meet competing policy 
goals such as equity and efficiency. The other challenge lies in measuring and monitoring some 
policy objectives such as access that have no universal definition and have a wide scope that 
encompasses spatial and non-spatial aspects. There are also numerous methodological 
difficulties in evaluating the impact of policy, the shortage of meaningful evaluation means 
policy makers often have limited evidence on the progress of their recommendations.  
 
A review of literature suggests that the NHS productivity has been increasing by an annual 
average of 0.8% (Office of National Statistics 2015b), which may be indicative of greater 
efficiencies in the health system (Office of National Statistics 2007). Productivity estimates are 
not available at disease level and so the efficiencies specific to cancer services remain unclear. 
The goal to improve quality on the other hand has had unquestionable success, as demonstrated 
by improvements in survival rates and in patient experience. The increase in survival rates has 
been attributed to efforts implemented following the publication of the Cancer Plan (Rachet et 
al. 2009). In contrast, the equity goals also outlined in the Cancer Plan have not been met and 
for some cancers the inequality gap in survival has widened (Rachet et al. 2009). Policy 
objectives to improve access to cancer services have focused on monitoring cancer waiting 
times, although their impact on clinical outcomes has been inconclusive (Department of Health 
2011b). Other dimensions of access such as geographical access continue to have significant 
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implications on outcomes, nearly two decades since the Calman and Hine report identified this 
as an issue of concern. Despite this, geographical access has failed to receive policy 
consideration in the three Government strategies, although it has now received attention in the 
most recent strategy (Independent Cancer Taskforce 2015). 
 
2.7.1 Politicking and the development of health policy  
Political ideologies can be traced in the Government policies on health, and this has had an 
impact on policy content, on the approach to policy implementation, and on the achievement 
of policy objectives. Differences in political ideologies have meant that change is inexplicably 
linked with the delivery of healthcare, the following quote articulates the constancy of change 
within the NHS; ‘Change is a permanent feature of the NHS, organisations are revamped, 
funding flows are redirected, and lines of accountability redrawn as the political tide sweeps 
remorselessly backwards and forwards. Acronyms appear and disappear as the fraught politics 
of the NHS demand that a new working group be established or a redundant committee be 
dispatched…if the never-ending public clamour for improved state health services is to be 
assuaged, policies must be produced, lobbies satisfied and still further promises made’ (Salter 
1998) (pg.4).  
 
The narrative review has highlighted some of the key changes as they pertain to cancer services, 
some of which may be deemed necessary, for example, establishing specialist cancer centres 
for the management and treatment of rare cancers. However, the relevance of other changes 
can be questioned due to the disruption they cause to the health system. Political analysts use 
the term ‘path dependency’ to describe the process where incoming governments initiate some 
changes but retain elements of their predecessors’ policies (Baggott 2007). The abolition of 
Cancer Networks to create Strategic Clinical Networks (SCNs) is an example of path-
dependency, whereby the incoming Conservative Government of 2010 had intended to get rid 
of Cancer Networks but instead rebranded them as SCNs. These newly formed SCNs were to 
advise commissioners on a wide range of diseases and not just cancer. Although this sharing 
of knowledge may prove to be useful, it might come at the expense of cancer care if the SCNs 
resources are spread too thinly. Perhaps in the recognition of the shortcomings of the SCN, the 
most recent cancer strategy has proposed the establishment of Cancer Alliances which bear 
striking resemblance to the disbanded Cancer Networks, particularly with regards to driving 
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improvements by promoting service integration along the cancer care pathway (Independent 
Cancer Taskforce 2015; MacMillan Cancer Support 2015). 
 
Despite ideological differences and the political rhetoric, there are numerous similarities 
between the different strategies examined. Such congruence tends to be on areas where there 
is indisputable clinical evidence. For instance, the Labour administration’s Cancer Plan fully 
endorsed the National Screening Programmes that were rolled out by the previous Conservative 
Government. The Cancer Plan went further to provide resources to extend the age range 
covered by breast cancer screening and to enable screening programmes for other cancer types. 
There is also full agreement in terms of the focus on early diagnosis across all the strategies. 
The National Awareness and Early Diagnosis Initiative (NAEDI) that was established by the 
Labour Government gained momentum under the Coalition and Conservative administrations. 
Another area where there has been full consensus is in the role of information and intelligence 
to inform practitioners and commissioners. This culminated to the establishment of National 
Cancer Intelligence Network (NCIN) which has been recently rebranded as the Public Health 
England National Cancer Registration and Analysis Service (PHE NCRAS), although it has 
retained its function of driving improvements in cancer care and outcomes through information 
and intelligence. 
 
One notable paradigm shift that may undoubtedly have an impact on the policy making process 
is the increasing importance of the patient group. Patients have historically possessed the least 
‘power’ in the policy making process as they have been viewed as receivers not co-owners of 
the medical model (Borras et al. 2014). The initiation a Cancer Patient Experience Survey 
(CPES) marked a collective attempt towards a more patient centred care. The initial shortfalls 
in the full utilisation of the cancer patient survey have been overcome, and this may be credited 
to recent policy recognition of the patients’ voice importance in informing commissioning and 
making service improvements (Department of Health 2011a; Independent Cancer Taskforce 
2015) 
 
One persistent challenge that policy makers have is in demonstrating the effectiveness of 
government policies on health (World Health Organization 2010). Overcoming this may 
require the combined effort between research, policy makers and health practitioners (Embrett 
& Randall 2014). The many parallels between evaluating the impact of health policy and 
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evaluating public health interventions may present opportunities for collaborations (Kelly et 
al. 2010). The first parallel is in methodological difficulties, both types of evaluation 
experience long and complex causal chains between intervention or implementation to health 
outcome, which presents challenges in demonstrating cause and effect, and makes it impossible 
to conduct true experimental studies (World Health Organization 2010; Kelly et al. 2010).  
 
The second methodological difficulty arises in the normative aspect of public health and health 
policy concepts such as equity or power that may imply judgement or blame on certain 
individuals, groups or organisations. This may be regarded unattractive by researchers or even 
as threatening to professional and political interests (Embrett & Randall 2014). The challenge 
for public health researchers when investigating clinical factors that influence health and well-
being, is to consider the political environment where decisions are made, where policies are 
implemented, and any socio-political factors that may act as a barrier to policy adoption. This 
is because ‘the way in which an intervention is delivered, the systems infrastructure and the 
nature of the recipient population are at least as important in determining outcome as the 
intervention itself and are an integral part of the causal chain’ (Kelly et al. 2010) (pg. 1060). 
Unfortunately, guidelines for doing this nature of research are currently unavailable which 
makes most public health researchers ill-equipped to attempting such research (Marmot et al. 
2010).  
 
Whilst not proposing to attempt policy analysis at any length, the studies presented in the rest 
of this thesis will make explicit reference to present and past cancer policies that pertain to 
health care accessibility. In so doing, the research will use policy as a lens to identify gaps in 
the evidence and to help with framing the research questions. Having a comprehensive 
understanding of the wider policy perspective will assist in interpreting the findings, by 
highlighting potential implications that are of relevance to police makers and health 
practitioners. 
 
2.7.2 Future policies of geographical access to cancer services 
One finding from the review is that more work is needed to characterise how other dimensions 
of access beyond cancer waiting times determine cancer outcomes. This will involve 
investigating other areas that may have been overlooked, such as issues pertaining to 
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geographical access to primary care, socio-cultural factors that may influence service 
utilisation, and the interactions between these dimensions.  
 
The existing evidence to date demonstrates that issues of geographical accessibility are 
particularly acute with access to specialised services such as radiotherapy and surgery. Some 
of the gaps in the current evidence are highlighted in the most recent cancer strategy (Table 
2.3). Unlike the previous cancer strategies, the recent strategy has tasked various key players 
to lead on implementing its 96 recommendations. PHE NCRAS and Clinical Reference Groups 
(CRGs) have been assigned to lead on the recommendations on the impact of geographical 
accessibility to services by reviewing the evidence on the merits of service configuration and 
further centralisation (Table 2.3). The successful implementation of this task will require 
combined efforts of which academic research will undoubtedly play a role, such as in evidence 
generation. 
 
In this recent cancer strategy, service configuration to create specialist centres has been 
attributed to improving of cancer outcomes, as a result of bigger centres having better 
experience of rescuing the patient if something goes wrong; even though the strategy 
recognises that the rate of complication is the same in both specialist and non-specialist centres 
(Independent Cancer Taskforce 2015). Given the known benefits of creating centres of 
excellence, there is a need to balance the benefits of greater specialisation with the dis-benefits 
of more patients traveling further, and as such, the strategy recommends an assessment of the 
impact on cancer outcomes on patients living farther from a cancer centre (Independent Cancer 
Taskforce 2015). This is particularly crucial amongst patients residing in the most remote areas, 
whereby travelling for treatment has been estimated to account for nearly 13% life post 
diagnosis, in addition to incurring the financial burden on longer travel, as well as social and 
emotional separation from family and friends who may struggle to make visits (Baird et al. 
2000). 
 
The recent cancer strategy also recommends an assessment of the impact of travel times for 
children, young people and families (Independent Cancer Taskforce 2015). These proposals 
are timely and point to the need of going further than what the existing evidence has 
highlighted. This is because the impact of poor access on outcomes disproportionally affects 
the most vulnerable groups; those with chronic conditions, the elderly, young families, the 
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disabled and deprived groups (Bentham & Haynes 1985; Mungall 2005). These groups of 
patients may require more frequent access, may have pre-existing mobility issues (Bentham & 
Haynes 1985; Mungall 2005), or may experience relatively greater cost dis-benefits of paying 
for travel. More research is required to characterise the access issues in these vulnerable groups.  
 
Lastly, a common theme across all the cancer strategies was the recognition of earlier diagnosis 
as a key driver to improving to improving outcomes, however, all strategies failed to 
acknowledge that geographical access to primary care diagnosis is a prerequisite to optimal 
access of earlier diagnosis. For instance, access to the GP may have important implications for 
obtaining planned referrals to secondary care, and for reducing uptake of emergency 
admissions, there is however very little empirical evidence to show this.  
 
Given the important of access in the evolution of cancer policy in the UK, the next chapters 
explore how access continues to be associated with cancer outcomes. These chapters will 
answer pertinent questions related to the geographical accessibility of cancer services that were 
apparent following this review. To do this, the analysis will combine statistical and 
geographical analytical techniques, focussing on the access objective, but also taking into 
consideration how this objective overlaps with the objectives of equity, quality and efficiency. 
To begin with, the next chapter investigates the issue of geographical equity in access that was 
highlighted in the Calman and Hine recommendations over two decades ago. That chapter will 
assess the current state of equity in access to cancer management and treatment services in 
England by investigating whether these services are located according to population need.  
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3.1  Background 
As discussed in Chapter Two, equity in access to healthcare is an important policy objective in 
England. The NHS was founded on the principle that services would be available to everyone 
and would be free at the point of delivery (NHS 2015). Equity is also embedded in the operating 
model for the commissioning of specialised services, where NHS England seeks to provide 
consistent services to all regardless of location (NHS England 2012). The provision of 
equitable cancer services is dependent on how they are organised. In England, service 
configuration since the 1990s has been informed by the Calman and Hine report, which 
recommended high quality and also accessible cancer care (Calman & Hine 1995). The report 
stated that, ‘All patients should have access to a uniformly high quality of care as close to the 
patient's home as possible’ and that ‘services should be planned to minimise travelling times 
whilst maintaining the highest standards of specialist care’ (Calman and Hine, 1995, p.6). 
These recommendations have been endorsed by consecutive Governments with particular 
attention paid to improving quality by establishing specialised cancer centres (Department of 
Health 2000; Haward 2006). Indeed, some improvements in cancer survival in England have 
been attributed to this increase in specialisation (Haward 2006; Oliphant et al. 2013).  
 
The Calman-Hine recommendations also introduced a dilemma with regards to centralisation 
of services that ensures all patients have access to specialist care without having to travel too 
far for it (Munro 2001). Healthcare providers and policymakers are thus faced with the 
substantial challenge of delivering geographically equitable cancer services within the 
constraints of finite healthcare resources and in the face of rising cancer incidence rates. Some 
geographical inequalities in access are inevitable (Gatrell & Wood 2012) because certain 
populations, such as rural residents, will always need to travel farther to access specialist 
services. Inequalities in access are however unacceptable when they lead to avoidable 
disadvantages in health, and when they disproportionally affect those most in need (Gatrell & 
Wood 2012). 
 
Access issues are felt more acutely by those with the greatest need for healthcare, such as 
patients with chronic conditions who require regular hospital visits, those with lowest mobility 
such as elderly or disabled patients and also the most deprived (Bentham & Haynes 1985; 
Mungall 2005).  Poor access is also known to amplify the effect of deprivation, whereby 
patients with the longest travel times and also in the most deprived areas are least likely to have 
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a histological cancer diagnosis and optimal treatment (Crawford et al. 2009). In the UK, studies 
using individual level data have shown a negative association between travel to hospital and 
uptake for cancer treatment (Jones et al. 2008; Sauerzapf et al. 2008; Lau et al. 2013) and 
increased odds of diagnosis at death (A. P. Jones et al. 2010). Longer distance to specialist 
cancer centres has also been associated with higher cancer stage at diagnosis (Campbell et al. 
2001) and with poorer survival (Campbell et al. 2000). These findings have been replicated 
outside the UK; in France, road distance to the nearest cancer centre was associated with worse 
survival (Dejardin et al. 2008). Studies that have employed alternative measures of healthcare 
accessibility have reached similar conclusions. For instance, one North American study used a 
derivative of the gravity model to capture the availability (supply) as well as the attractiveness 
(demand) of services (Wang 2006), the study demonstrated an association between poor 
geographical access and advanced cancer stage (Wang et al. 2008).  
 
3.1.1 Multidisciplinary Teams (MDTs) 
MDTs in cancer care were suggested as model for managing cancer care by the Calman and 
Hine report (Calman & Hine 1995), and were later endorsed in subsequent cancer strategies. 
MDTs are made up of relevant specialists such as surgeons, oncologists, radiologists, 
pathologists, cancer nurse specialists and other specialist physicians who meet to discuss their 
patients and make treatment plans (Raine et al. 2014). There is an estimated 1500 cancer MDTs 
in England (National Cancer Action Team 2010). Their clinical effectiveness is disputed 
because of lack of evidence linking multidisciplinarity with more effective decision-making, 
rather, factors such as good team climate and clear goals and processes have been suggested as 
better indicators of effective decision making (Raine et al. 2014). MDTs have also been 
criticised for failing to implement decisions made at the meetings, particularly for patients 
living in more deprived areas (Raine et al. 2014). Despite their shortcomings, MDTs are 
beneficial because discussing each patient’s care at these meeting ensures their treatment is 
considered by professionals with specialist knowledge of their cancer type. These discussions 
also provide a safeguard against errors (Raine et al. 2014) and they ensure continuity of care 
by promoting good communication along the care pathway.  
 
3.1.2 Chemotherapy, Radiotherapy and Surgery 
Chemotherapy, radiotherapy and surgery are the three main types of curative cancer treatments 
available on the NHS that will be considered in this chapter. Chemotherapy is administered as 
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a single or a combination of drugs that aim at killing cancer cells. Radiotherapy treatment can 
be administered externally using x-ray or particle beams. It can also be administered internally 
(brachytherapy) where radioactive implants are put inside or close to a tumour, or radioactive 
liquids are given as a drink or injection (Cancer Research UK 2016c). Surgery is one of the 
main treatments for cancer and it may provide a cure where cancer has not spread. The 
treatment involves removing the tumour and/or some normal tissue and lymph nodes nearest 
the cancer cells in case they contain cancer cells (Cancer Research UK 2016c). These three 
treatments are used separately or in combination. As an example, chemotherapy and 
radiotherapy may be used to shrink a cancer before surgery, or to prevent it from spreading 
after surgery. These three treatments may also be used as palliative treatment where the aim is 
to relieve symptoms by reducing pain, or to help patient live longer and more comfortably 
where curing the cancer is not possible (Cancer Research UK 2016c). 
 
3.1.3 Estimating geographical access, equity and need 
This chapter will investigate geographical inequities in access at a population level. Previous 
evidence that shows the association between poor access and poorer outcomes may be an 
indication of geographical inequities in the location of cancer services, however, such 
inequities have not been demonstrated in research.  
 
Geographical access will be defined as travel times in minutes from area of residence to the 
nearest hospital for cancer management or treatment. Equity in healthcare normally 
encompasses three principles; ‘equal access to health care for those in equal need’, ‘equal 
utilisation of health care for those in equal need’ and ‘equitable health outcomes’ for example 
as measured by quality adjusted life expectancy (Oliver & Mossialos 2004). This analysis will 
use the first principle ‘equal access for equal need’ as this is the definition of equity that is most 
generally accepted by policy makers (Oliver & Mossialos 2004; Allin et al. 2007). 
 
Need is a problematic concept to define because it does not have a universally accepted 
definition (Haynes 1987; Oliver & Mossialos 2004; Allin et al. 2007). The earliest definition 
of need takes a humanitarian perspective and focuses on the identification of human suffering 
without taking into account the limitation of resources (Acheson 1978). This chapter will adopt 
a more agreeable definition that suggests that need for medical care exists only when an 
individual has an illness or disability for which there is effective and acceptable intervention 
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to prevent or treat it (Matthew G 1971; Wright et al. 1998). Healthcare need at a population 
level can be measured by the ‘level of ill health’ (Allin et al. 2007) and epidemiological 
measures such as prevalence or incidence can be used to describe ‘how much of it there is’ and 
‘where it is located’ (Acheson 1978; Wright et al. 1998). 
 
In this study, geographical inequities in access will be determined where areas with higher need 
also have poorer access to cancer services. Additionally, geographical access will be associated 
with relative survival rates to determine whether areas with poor access also have the worst 
outcomes. Lung, breast and colorectal cancers are among the commonest cancers totalling to 
about 40% of all cancer incidence the England, and amounting to approximately 120,000 cases 
annually (Cancer Research UK 2016b). Treatment for these requires access to MDT, 
chemotherapy and radiotherapy, and so they are appropriate cancer sites for this work.  
 
3.2 Methodology 
The study will be a cross sectional ecological design, with measurements and inferences at the 
level of NHS Primary Care Trust (PCT), as this is the scale at which data was available. It was 
not possible to obtain data on lower geographies for this study. 
 
The information on the location of cancer hospital sites was obtained from multiple sources. In 
England, this information is collected by the National Peer Review Team (National Peer 
Review Programme 2013) which holds details on the location of hospital sites that provide 
cancer treatment (chemotherapy and radiotherapy), and sites providing cancer management via 
multidisciplinary teams (MDTs). The Peer Review Programme collects this information as a 
part of a quality assurance process to ensure clinical teams comply with national measures on 
quality improvement, safety and patient experience (National Peer Review Programme 2013).  
 
In order to account for the ‘edge-effect’ whereby patients in some parts of England may receive 
treatment in Wales and Scotland, similar data was obtained from the Welsh Health Directory 
(NHS Wales Informatics Services 2014). At the time of the analysis, the Welsh Health 
Directory had complete information on the North Wales Cancer Network, but information was 
incomplete on the South Wales Cancer Network. Missing information was supplemented by 
Freedom of Information (FOI) requests from the Welsh Health Boards that are part of the South 
Wales Cancer Network. Data was also obtained from the Information Services Division 
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Scotland (Information Services Division 2015) on hospital sites located in the southern 
Scotland Health Boards that may serve some English patients; Dumfries and Galloway, 
Borders, Ayrshire and Arran, Lanarkshire, Lothian and Greater Glasgow and Clyde. The 
Scottish data did not have information on MDT presence, and therefore hospitals offering 
chemotherapy were used as a proxy for presence of a MDT. Finally, information on hospital 
sites offering cardiothoracic surgical for lung cancer treatment in England, Wales and Scotland 
was obtained from the Society for Cardiothoracic Surgery in Great Britain and Ireland (SCTS) 
(Society for Cardiothoracic surgery 2015). 
 
3.2.1 Geographical units and measurements  
Geographical access was estimated as travel times in minutes from all LSOA population 
weighted centroids in England to the nearest hospital site offering treatment or management 
for the specified cancer. LSOAs are small geographic areas in England and Wales that are 
designed to improve the reporting of small area statistics. There are 32,844 LSOAs in England 
each with a population range of 1,000 to 3,000 residents (Office of National Statistics 2015c). 
Population weighted centroids are summary reference points at the centre of the population in 
a geographical unit, they represent the spatial distribution of the population in a given 
geography such as an LSOA in this instance (Office of National Statistics 2013d). The most 
recent 2011 LSOA centroids were obtained from the Office of National Statistics digital 
geographical boundaries (Office of National Statistics 2013d).  
 
A geographical Information System (GIS) (ArcGIS 10.3, Esri Inc.) was used to estimate the 
travel times. This part of the research was done by creating a road network using Ordnance 
Survey Meridian 2 data, which included all motorways, A, B and minor roads (Ordnance 
Survey 2013). The road network was then intersected with Developed Land Use Area (DLUA) 
boundaries (also obtained from the Meridian 2 data) to delineate urban areas, and to determine 
which road sections were in urban and in rural settings. Thereafter, each section of the road 
was assigned an average speed based on its road classification and whether it was in a rural or 
urban area, this was done using the average speeds developed in a previous study (Bateman et 
al. 1996). The road network was used within the Network Analyst module of the ArcGIS 
software, and travel times were estimated from all 2011 LSOA population centroids in 
England, to all postcodes from the identified hospital sites. 
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Postcodes are geographical reference points in the U.K that are used to identify postal delivery 
areas (Office of National Statistics 2015a).There are about 1.8 million postcodes in the U.K; 
around 1.75 million of these are ‘small user postcodes’ and 0.7 million are ‘large user 
postcodes’ (Office of National Statistics 2015a). A single small user postcode may contain 
anywhere from 15 to 100 single addresses. Larger addresses that receive numerous mail items 
per day such as hospitals are normally be assigned to a single large user postcode (Office of 
National Statistics 2015a). 
 
The generated travel times were then aggregated to the PCT level. PCTs are English health 
administrations responsible for commissioning cancer services. They occupy a large 
geographical area with a median resident population of 203,000 (Office of National Statistics 
2013e). There were 152 PCTs in England at the time of this analysis. 
 
The National Radiotherapy Advisory Group (NRAG) recommend travel of no longer than 45 
minutes for radiotherapy treatment (National Radiotherapy Advisory Group 2007) and 
therefore this was used as an important threshold for radiotherapy and surgical treatment. For 
travel to MDT and Chemotherapy, 20 minutes marked an important threshold as this was the 
approximate average travel time to hospitals in England during the study period (Department 
for Transport 2014b). The proportion of the population in England whose travel may exceed 
these thresholds was further quantified using ONS 2009 mid-year population estimates (Office 
of National Statistics 2013e; Office of National Statistics 2013c).  
 
3.2.2 Statistical analysis 
The measure of population need adopted for this analysis was the number of cases of (breast 
(ICD-10 C50), colorectal (ICD-10 C17-21 and C26) and lung (ICD-10 C33-34) cancer in a 
PCT. This was obtained as a three year average for 2008 - 2010 from the publicly available 
National Cancer Intelligence Network (NCIN) dataset of newly diagnosed cancer cases per 
year (National Cancer Intelligence Network 2010).  
 
Primary outcomes were identified as one and five year PCT relative survival rates for each 
cancer, also obtained from the NCIN public dataset (National Cancer Intelligence Network 
2014a). These relative survival rates were estimated nationally by NCIN using the actuarial 
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method that divides observed with expected survival rates to give a population level relative 
survival rate (Parkin & Hakulinen 1991; National Cancer Intelligence Network 2014b). The 
‘observed one year survival rates’ were estimated as the number of persons diagnosed with the 
specified cancer between 2010 and 2012 with mortality follow up to the end of 2013. The 
‘observed five year survival rates’ were also estimated in the same way but for patients who 
had a diagnosis between 2002 and 2004 and followed up to 2009. The ‘expected survival rates’ 
were based on the population life tables matched by age, sex and period of observation (Parkin 
& Hakulinen 1991; National Cancer Intelligence Network 2014b). 
 
Every effort was made to match the timescale covered by the estimated travel times with that 
of the incidence and survival data. This was achieved for travel to radiotherapy as there were 
fewer sites involved. Thus, travel time to radiotherapy was restricted to sites in operation before 
2010 to match the incidence data. The three new radiotherapy hospital sites that opened after 
2010 were excluded from the analysis; Bracknell Clinic, Fazackerley site of Clatterbridge 
Cancer Centre and The Christie at Royal Salford. For the regression analysis, hospital sites 
identified as above were also used in the analysis, because the cancer cases used to estimate 
relative survival rates would have been diagnosed in  the same decade as the incidence data; 
2010 - 2012 for 1 year survival and 2002 - 2004 for 5 year survival. It was however not possible 
to discern MDT and chemotherapy sites by year of operation, and therefore the most recent 
data at the time of the analysis (November 2014) was used. The discrepancies between the time 
of data collection and study period might have a slight effect on the results, but this effect may 
not be substantial because English hospital sites would not have changed substantially during 
this decade. 
 
Deprivation and ease of obtaining a general practitioner (GP) appointment were identified as 
potential confounders as they are independently associated with cancer survival. PCT level 
deprivation data was obtained from the English indices of multiple deprivation (Department 
for Communities and Local Government 2010). Good access to primary care is important in 
the early diagnosis and later prognosis of cancer and has previously been associated with lower 
rates of emergency admissions to secondary care (Cowling et al. 2013). Ease of obtaining a GP 
appointment was measured as the percentage of patients in a GP practice who were able to get 
an appointment to see or speak to a health professional during their most recent appointment, 
without the need to call back closer to or on the preferred appointment date. This information 
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is collected on an annual basis by the national GP Patient Survey of 2.75 million adults 
registered with a GP in England (NHS England 2013) 
 
Statistical analysis was conducted on using Stata (Version 13.1; StataCorp, College Station, 
TX, USA). Spearman’s rank correlation was used to correlate the unadjusted PCT cancer cases 
(need) with the estimated mean PCT travel times (access). Linear regression was used to 
examine the association between cancer relative survival rates and PCT level mean travel 
times, adjusting for age, sex, year, area deprivation and ease of GP access. Models were tested 
to ensure they met the following assumptions of the linear regression models; linearity, 
normality and homoscedasticity of the residuals. Sensitivity analysis was performed by 
modelling travel times both as a continuous measure and a grouped measure and examining 
any changes in the results. Standard errors of the relative survival rates were estimated to help 
determine the extent to which they were influenced by sampling variation (Ederer et al. 1961). 
A p-value (<= 0.05) was used to identify statistical significance in all analyses. 
 
3.3 Results 
The distribution of the estimated mean PCT travel times is shown on Table 3.1. Radiotherapy 
and surgery were provided at the fewest number of hospital sites and therefore incurred the 
longest journey times 23.70 minutes and 31.93 minutes respectively. Aggregating travel time 
to PCT level conceals the variation experienced at lower geographies. As an example, the 
highest LSOA level travel times are; 76.33 (Breast MDT), 85.14 (Colorectal MDT), 76.33 
(Lung MDT), 83.91 (Chemotherapy), 102.69 (Radiotherapy) and 172.84 (Lung Surgery). The 
PCT equivalents are markedly lower (Table 3.1). Thus, it is likely that PCT level analysis 
underestimates the full extent of geographical access issues. This is illustrated in Figure 3.1 
that shows how PCT level averages mask areas with the longest estimated travel times in the 
peripheral parts of the country. 
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Table 3.1 - Number of cancer services and estimated PCT mean travel times in England, Wales and Scotland* 
 
 
Type of 
service 
Number of 
hospital sites 
Travel times in minutes PCT (LSOA) 
 
  Lowest Mean Highest 25th Quartile Median 75th Quartile 
Breast MDT 214 3.97 (0) 13.5 (15.2) 35.2 (76.3) 9.5 (8.2) 12.4 (12.7) 17.1 (19.6) 
Colorectal 
MDT 226 3.84 (0) 13.3 (15.0) 35.2 (85.1) 9.1 (8.0) 12.2 (12.5) 16.3 (19.6) 
Lung MDT 219 3.84 (0) 13.5 (15.2) 35.2 (76.3) 8.9 (8.0) 12.4 (12.7) 16.4 (19.9) 
Chemotherapy 231 3.55 (0) 13.1 (14.9) 35.2 (83.9) 8.7 (7.8) 11.9 (12.3) 15.7 (19.4) 
Radiotherapy 61 3.97 (0) 23.7 (25.6) 61.0 (102.7) 13.8 (14.0) 22.4 (23.6) 32.0 (34.5) 
Lung Surgery 41 4.4 ( 0.4) 31.9 (36.1) 151.8 (172.8) 15.8 (17.2) 26.3 (29.0) 41.1 (46.8) 
 
*Scottish data was obtained from the southern Health Boards only; Dumfries and Galloway, Borders, Ayrshire and Arran, Lanarkshire, Lothian and Greater Glasgow and Clyde. MDT, 
multidisciplinary team. LSOA, Lower Super Output Area 
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The population estimates were grouped by travel time thresholds Table 3.2 to determine the 
percentage of the population in England living in the longest travel categories.  The PCT level 
analysis for MDT and Chemotherapy suggests that on average between 1% and 2% of the 
population in England live more than 30 minutes from a facility (this estimates is markedly 
higher (around 9%) when examined at the LSOA level (Table 3.2).  
 
Likewise, PCT level analysis shows that an estimated 6% and 24% of the population lived 
longer than 45 minutes from a radiotherapy and surgical facility for lung cancer (respectively). 
Again, this is markedly higher when using LSOA estimates (10% and 27% respectively) 
(Table 3.2). The distribution of travel times to cancer services in England are mapped in Figure 
3.1(A&B), the areas with the poorest access are highlighted in red.  
 
In Table 3.3, access to radiotherapy services is used as an example to demonstrate the 
distribution in deprivation score by travel time categories in the three cancer sites examined. 
Using the mid-2009 PCT population, an estimated 3 million (5.72%) people and of whom over 
6,000 were breast, colorectal and lung cancer patients, lived more than 45 minutes from a 
radiotherapy facility during the study period 
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Figure 3.1 (A) Map of mean travel times to MDT and chemotherapy services estimated at PCT and LSOA level 
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Figure 3.2 (B) Map of mean travel times to radiotherapy and surgical services estimated at PCT and LSOA level 
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Table 3.2- LSOA and PCT populations in England grouped by estimated travel times to 
a) Breast MDT, b) Colorectal MDT, c) Lung MDT and d) Chemotherapy e) 
Radiotherapy and f) Surgical services 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
PCT, Primary Care Trust. LSOA, Lower Super Output Area 
 
 
Table 3.3 - Population estimates and cancer cases grouped by travel times to 
radiotherapy services. Cancer cases are estimated using PCT mid-2009 population 
estimates and three year annual cancer cases (2008 – 2010) 
 
Travel times to 
radiotherapy 
services (minutes) 
PCTs by 
Travel time 
categories 
PCT Overall 
IMD average by 
Travel time 
categories 
PCT Population mid 
2009 estimates 
(% of total) 
Estimated 
breast, colorectal 
and lung cancer 
cases 
0 – 14.99 43 28.11 11,451,308 (22.00%) 23,647 
15 – 29.99 65 22.26 24,010,852 (46.12%) 49,574 
30 – 44.99 34 21.24 13,616,842 (26.16%) 28,119 
45 plus 8 21.36 2,979,018 (5.72%) 6,148 
 
Population mid 2009 estimates  (% of total) 
LSOA Level 
Travel times 
(minutes) a) Breast MDT 
b)  Colorectal 
MDT c) Lung MDT d) Chemotherapy 
0 – 9.99 18,453,676 (35.53%) 19,301,918 (37.17%) 18,920,250 (36.43%) 19,748,856 (38.03%) 
10 – 19.99 20,900,582 (40.24%) 20,019,626 (38.55%) 20,027,080 (38.56%) 19,828,896 (38.18%) 
20 – 29.99 8,157,819 (15.71%) 8,005,732 (15.42%) 8,205,517 (15.80%) 7,794,951 (15.01%) 
30 plus 4,421,540 (8.51%) 4,606,342 (8.87%) 4,780,772 (9.21%) 4,560,916 (8.78%) 
 
PCT Level 
0 – 9.99 10,765,508 (20.68%) 12,186,756 (23.41%) 11,976,508 (23.01%) 12,074,690 (23.19%) 
10 – 19.99 29,963,086 (57.56%) 28,700,932 (55.13%) 29,249,622 (56.19%) 28,812,996 (55.35%) 
20 – 29.99 10,800,810 (20.75%) 10,327,228 (19.84%) 9,697,036 (18.63%) 10,641,717 (20.44%) 
30 plus 528,616 (1.02%) 843,105 (1.62%) 1,134,854 (2.18%) 528,616 (1.02%) 
Population mid 2009 estimates  (% of total) 
LSOA Level 
Travel times 
(minutes) a) Radiotherapy b) Surgery 
0 – 14.99 14,648,231   (28.21%) 10,760,925   (20.72%) 
15 – 29.99 19,538,424   (37.62%) 16,258,171   (31.31%) 
30 – 44.99 12,606,802   (24.27%) 10,870,102   (20.93%) 
45 – 59.99   3,611,327     (6.95%) 6,665,957   (12.84%) 
60 plus   1,528,835     (2.94%) 7,375,266   (14.20%) 
 PCT Level 
0 – 14.99 11,451,308   (22.00%) 9,653,462 (18.54%) 
15 – 29.99 24,010,852   (46.12%) 17,170,464 (32.98% 
30 – 44.99 13,616,842   (26.16%) 12,597,047 (24.20%) 
45 – 59.99 2,614,793     (5.02%) 6,315,879 (12.13%) 
60 plus 364,225        (0.70%) 6,321,168 (12.14%) 
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3.3.1 Correlations 
The number of cancer cases in a PCT across the three cancer types were positively and 
significantly correlated with longer PCT mean travel times to all hospital sites (p<0.01) (Table 
3.4). The correlations were higher in chemotherapy and MDT, than radiotherapy or surgery. 
 
 
Table 3.4 - Correlation coefficient of mean PCT mean travel time to cancer services and 
PCT cancer incidence (number of new cases, annual average for 2008-2010) 
 
Number of new 
cases per year 
Breast 
MDT 
Colorectal 
MDT 
Lung 
MDT 
Chemotherapy Radiotherapy 
 
Surgery 
Breast  0.68**   0.68** 0.45**  
Colorectal   0.72**  0.72** 0.46**  
Lung    0.58** 0.58** 0.41** 0.35** 
Surgery      0.30** 
         ** p<0.01, * p<0.05. MDT, multidisciplinary team 
 
 
3.3.2 Testing assumptions of linear regression 
The test for linearity using the Stata ‘nlcheck’ tool (Jann 2008) showed that continuous ‘travel 
time’ and ‘ease of GP access’ variables failed to meet this assumption, which supported the 
decision to model these variables as categories. The ‘Shapiro-Wilk’ test for the normality of 
residuals also showed that some models failed to meet this assumption. However, this does not 
invalidate the analysis because the inferences in linear regression are robust to violations of 
normality so long as the sample size is reasonably large (Agresti 2015; Yan & Su 2009). 
Although it is recognised that non-normality does not affect the validity of the models, 
heteroscedasticity may affect it  (Lumley et al. 2002). Four out of eighteen of the fully adjusted 
models did not meet this homoscedasticity assumption, these four models are for lung cancer 
access to MDT and Chemotherapy services (Tables 3.5 and 3.6), and hence these findings 
should be treated with caution. Modelling travel times as a continuous rather than categorical 
measure, did not alter the conclusions. Estimated standard errors of the relative survival rates 
across the three cancer sites, and for both one and five years were generally small compared to 
their associated estimates, and ranged from 0.004 to 0.049. 
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3.3.3 Regression results before adjustment 
When estimated PCT mean travel times were regressed on cancer relative survival rates, the 
unadjusted models for breast and colorectal cancers showed that longer travel was positively 
associated with longer survival. This was mostly evident for travel to MDTs (Table 3.5) and 
to chemotherapy services (Table 3.6), and was statistically significant for five year relative 
survival rates. For example, for travel to breast and colorectal MDTs, PCTs with the longest 
mean travel had a significantly higher five year survival rates (breast coefficient = 1.79; SE = 
0.79; t (148) = 2.26; p<0.05), and (colorectal coefficient = 4.10; SE = 1.16; t (148) = 3.54; 
p<0.01) (Table 3.5). Longer travel to radiotherapy was also positively associated with breast 
cancer survival although this was only statistically significant for the five year survival rates 
(1.27; SE = 0.59; t (148) = 2.15; p<0.05) (Table 3.7). In contrast, the lung cancer analysis 
showed that PCTs with the longest mean travel had significantly lower one and five year 
relative survival rates, this was the case across all treatment types examined (Table 3.5, Table 
3.6, Table 3.7 and Table 3.8). 
 
3.3.4 Results after adjustment 
Adjusting for deprivation and ease of GP access revealed a clear survival gradient whereby 
PCTs with longer mean travel times consistently had poorer relative survival rates. This 
survival gradient was observed in travel to all services across the three cancers. As an example, 
Table 3.7 shows the regression output for the models of survival and access to radiotherapy 
treatment. The coefficients are percentage point differences in relative survival associated with 
each explanatory variable. The lung cancer output for example, shows that an increase in travel 
times from the reference category ‘less than fifteen minutes’, to the highest category ’45 plus 
minutes’, is associated with a predicted reduction in one year survival by -3.43 percent, p<0.05 
(before adjusting), -4.02 percent, p<0.01 (after adjusting for deprivation only) and -4.60 
percent, p<0.01 (after adjusting for deprivation and ease of obtaining a GP appointment).  
 
In the lung cancer analysis, the travel – survival association was generally greater for one year 
than five year relative survival rates. For example, the lung cancer output in Table 3.7 shows 
the corresponding predicted reduction in the five year relative survival is -2.40 percent, p<0.05 
(before adjusting), -2.72 percent, p<0.05 (after adjusting for deprivation only) and -2.98 
percent, p<0.01 after adjusting for deprivation and ease of obtaining a GP appointment. Lastly, 
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the association between travel time to radiotherapy and relative survival was greater in 
colorectal and lung cancer compared to breast cancer (Table 3.7).   
 
The results on Table 3.8 shows the same pattern whereby PCTs with longer estimated travel 
to lung cancer surgical sites have significantly poorer relative survival rates. After adjusting 
for deprivation and ease of obtaining a GP appointment, PCTs in the longest travel time 
category ’45 minutes plus’ have a -5.42 percent and -3.43 percent predicted reduction in 1 and 
5 year lung cancer survival respectively, in comparison to PCTs with the shortest estimated 
travel. 
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 Table 3.5 - PCT mean travel times to the nearest MDT site, associated with 1 and 5 year breast, colorectal and lung cancer relative survival rate. 
The table shows linear regression model outputs using 150 PCTs in England, adjusted for deprivation and ease of obtaining a GP appointment 
 
 
 
 
 
Numbers show the regression coefficients (standardized β). All relative survival rates are adjusted for age, sex and year. ** p<0.01, *p<0.05  
‡ Lung cancer output should be interpreted with caution because these models violated the homoscedasticity linear regression assumption  
 Not adjusted for deprivation or ease 
of GP appointment 
Adjusted for deprivation Adjusted  deprivation & ease of GP 
appointment 
 Breast CRC Lung‡ Breast CRC Lung‡ Breast CRC Lung‡ 
Explanatory variables          
Outcome: 1 Year Relative Survival 
Travel times to MDT 
<10 minutes (reference) 
10 – 19.99 minutes 
20 minutes plus 
 
 
0.15 
0.32 
 
0.42 
1.41 
 
-2.18** 
-2.20* 
 
 
-0.36 
-0.79* 
 
 
-0.76 
-0.46 
 
-3.02** 
-3.52** 
 
-0.30 
-0.59 
-0.81 
-0.98 
-3.10** 
-4.21** 
Deprivation (IMD)    -0.09** -0.16** -0.12** -0.09** -0.14** -0.10* 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy       
-0.26 
-0.46 
-0.54 
-0.17 
0.15 
1.21 
0.07 
0.28 
1.67 
Intercept (Y) 96.34** 75.94** 34.31** 98.81** 80.57** 37.69** 99.23** 80.01** 36.84** 
R-squared 0.01 0.02 0.07 0.27 0.18 0.12 0.30 0.21 0.14 
Outcome: 5 Year Relative Survival 
Travel times to MDT 
<10 minutes (reference) 
10 – 19.99 minutes 
20 minutes plus 
 
 
0.75 
1.79* 
 
 
0.43 
4.10** 
 
     
    -1.16** 
-1.25* 
 
 
-0.47 
-0.87 
 
 
-1.51 
1.04 
 
 
-1.65** 
-2.01** 
 
 
-0.65 
-1.63* 
 
 
-1.67* 
-0.10 
 
 
-1.62** 
-2.37** 
Deprivation (IMD)    
 
-0.21** -0.26** -0.07** -0.19** -0.23** -0.06* 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy       
0.12 
1.03 
1.61* 
0.04 
0.57 
2.71* 
-0.17 
-0.39 
0.74 
Intercept (Y) 84.64** 53.02** 9.50** 90.59** 60.62** 11.44** 89.61** 59.25** 11.29** 
R-squared 0.03 0.09 0.05 0.29 0.26 0.10 0.32 0.30 0.13 
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Table 3.6 - PCT mean travel times to the nearest chemotherapy site, associated with 1 and 5 year breast, colorectal and lung cancer relative survival 
rate. The table shows linear regression model outputs using 150 PCTs in England adjusted for deprivation and ease of obtaining a GP appointment 
Numbers show the regression coefficients (standardized β). All relative survival rates are adjusted for age, sex and year. ** p<0.01, *p<0.05. 
‡ Lung cancer output should be interpreted with caution because these models violated the homoscedasticity linear regression assumption  
 Not adjusted for deprivation or ease of 
GP appointment 
Adjusted for deprivation Adjusted  deprivation & ease of GP 
appointment 
 Breast CRC Lung‡ Breast CRC Lung‡ Breast CRC Lung‡ 
Explanatory variables          
Outcome: 1 Year Relative Survival  
Travel times to chemotherapy 
<10 minutes (reference) 
10 – 19.99 minutes 
20 minutes plus 
 
 
0.33 
0.34 
 
 
0.48 
1.45 
 
 
-2.00** 
-1.97* 
 
 
-0.26 
-0.61* 
 
 
-0.61 
-0.34 
 
 
-2.77** 
-3.24** 
 
 
-0.18 
-0.40 
 
 
-0.68 
-0.87 
 
 
-2.90** 
-3.96** 
Deprivation (IMD)    -0.08** -0.15** -0.11** -0.09** -0.14** -0.09* 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy       
-0.24 
-0.47 
-0.57* 
-0.21 
0.15 
1.19 
0.04 
0.41 
1.71 
Intercept (Y) 96.24** 75.90** 34.17** 98.63** 80.37** 37.34** 99.06** 79.84** 36.48** 
R-squared 0.02 0.03 0.06 0.26 0.18 0.10 0.29 0.21 0.13 
Outcome: 5 Year Relative Survival 
Travel times to chemotherapy 
<10 minutes (reference) 
10 – 19.99 minutes 
20 minutes plus 
 
 
1.29* 
1.62* 
 
 
0.48 
4.13** 
 
 
-1.20** 
-1.13 
 
 
-0.14 
-0.71 
-1.33 
1.18 
-1.66** 
-1.89** 
-0.33 
-1.34 
-1.52 
0.03 
-1.64** 
-2.25** 
Deprivation (IMD)    -0.20** -0.25** -0.07* -0.18** -0.22** -0.06* 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy       
0.20 
1.00 
1.57* 
-0.01 
0.60 
2.70* 
-0.18 
-0.30 
0.75 
Intercept (Y) 84.41** 52.99** 9.49** 90.24** 60.38** 11.40** 89.20** 59.04** 11.21** 
R-squared 0.05 0.09 0.06 0.29 0.25 0.10 0.32 0.30 0.12 
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Table 3.7 - PCT mean travel times to the nearest radiotherapy site, associated with 1 and 5 year breast, colorectal and lung cancer relative survival 
rate. The table shows linear regression model outputs using 150 PCTs in England, adjusted for deprivation and ease of obtaining a GP appointment 
Numbers show the regression coefficients (standardized β). All relative survival rates are adjusted for age, sex and year. ** p<0.01, *p<0.05. 
 
Not adjusted for deprivation or  
ease of GP appointment Adjusted for deprivation 
Adjusted  deprivation &  ease of GP 
appointment 
 Breast CRC Lung Breast CRC Lung Breast CRC Lung 
Explanatory variables 
Outcome: 1 Year Relative Survival 
Travel times to Radiotherapy 
<15 minutes (reference) 
15 – 29.9 minutes 
30 – 44.9 minutes 
45 minutes plus 
 
 
-0.12 
0.24 
0.33 
 
 
-0.15 
-0.16 
-0.97 
 
 
-1.58* 
-3.08** 
-3.43* 
 
 
-0.59** 
-0.30 
-0.20 
 
 
-1.12* 
-1.29* 
-2.09* 
 
 
-2.09** 
-3.68** 
-4.02** 
 
 
-0.62** 
-0.30 
0.07 
 
 
-0.98 
-1.31* 
-2.67* 
 
 
-1.94* 
-3.71** 
-4.60** 
Deprivation (IMD)    -0.08** -0.17** -0.09* -0.09** -0.14** -0.07 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy       
-0.27 
-0.50* 
-0.81** 
 
-0.23 
0.05 
1.27 
 
-0.30 
-0.31 
1.14 
Intercept (Y) 96.44** 76.51** 34.39** 98.67** 81.15** 36.85** 99.42** 80.31** 36.24** 
R-squared 0.02 0.01 0.10 0.28 0.21 0.13 0.33 0.24 0.15 
Outcome: 5 Year Relative Survival 
Travel times to Radiotherapy 
<15 minutes (reference) 
15 – 29.9 minutes 
30 – 44.9 minutes 
45 minutes plus 
 
1.27* 
0.77 
1.07 
 
 
0.50 
-0.05 
-0.16 
 
 
-1.15* 
-1.32* 
-2.40** 
 
0.13 
-0.56 
-0.24 
 
 
-1.14 
-1.97* 
-2.05 
 
-1.44** 
-1.68** 
-2.72** 
 
0.20 
-0.55 
-0.72 
 
-0.84 
-2.03* 
-3.49* 
 
 
-1.34** 
-1.69** 
-2.98** 
Deprivation (IMD)    -0.19** -0.28** -0.05* -0.17** -0.22** -0.05 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy       
0.10 
0.84 
1.34* 
-0.04 
0.36 
3.28** 
 
-0.34 
-0.64 
0.40 
Intercept (Y) 84.54** 53.62** 9.614** 89.99** 61.50** 11.03** 88.75** 59.20** 11.05** 
R-squared 0.03 0.00 0.07 0.29 0.24 0.10 0.32 0.31 0.13 
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Table 3.8 - PCT mean travel times to the nearest cardio-thoracic hospital site for surgery, associated with 1 and 5 year lung cancer relative survival 
rate. The table shows linear regression model outputs using 150 PCTs in England, adjusted for deprivation and ease of obtaining a GP appointment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              Numbers show the regression coefficients (standardized β). All relative survival rates are adjusted for age, sex and year. ** p<0.01, *p<0.05
 Not adjusted for deprivation 
or  ease of GP appointment  
Adjusted for 
deprivation 
Adjusted  deprivation &  
ease of GP appointment  
Explanatory variables    
Outcome: 1 Year Relative Survival    
Travel times to Radiotherapy 
<15 minutes (reference) 
15 – 29.9 minutes 
30 – 44.9 minutes 
45 minutes plus 
 
 
-2.23** 
-3.37** 
-2.98** 
 
 
-3.35** 
-4.96** 
-4.78** 
 
 
-3.34** 
-5.10** 
-5.42** 
Deprivation (IMD)  -0.15**  -0.14** 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy 
 
 
 
  
 
-0.80 
-0.70 
1.05 
Intercept (Y) 34.92** 39.50** 39.55** 
R-squared 0.10 0.18 0.21 
Outcome: 5 Year Relative Survival    
<15 minutes (reference) 
15 – 29.9 minutes 
30 – 44.9 minutes 
45 minutes plus 
 
-1.36** 
-2.05** 
-1.89** 
 
-2.05** 
-3.05** 
-3.01** 
 
-2.09** 
-3.14** 
-3.43** 
Deprivation (IMD)  -0.09** -0.09** 
Ease of obtaining a GP appointment 
Quartile 1 - Difficult 
Quartile 2 
Quartile 3 
Quartile 4 - Easy 
   
 
-0.67 
-0.95 
0.38 
Intercept (Y) 9.98** 12.82** 13.32** 
R-squared 0.10 0.18 0.22 
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3.4 Conclusions 
This study shows that PCTs with more cases of breast, colorectal and lung cancer also have 
longer estimated mean travel times to the cancer management and treatment services identified. 
PCTs with longer mean travel times also have poorer relative survival rates after adjustment 
for area deprivation. These findings highlight the importance of examining inequalities in 
access to services and should inform NHS England’s mandate of ensuring equitable 
commissioning of specialised services (NHS England 2012). 
 
The analysis used an area level dataset. It is therefore likely that inference at this level will 
suffer to some extent from ecological fallacy by suggesting that relationships between areas 
may be related to individuals within them. Nevertheless, area based studies have several 
advantages, such as contributing to theory and hypothesis generation for future testing (Pearce 
2000). Use of publicly available datasets have highlighted issues in access that warrant further 
investigation using more robust individual level datasets. The study also offers a national 
perspective on geographical access and augments the evidence previously conducted using 
smaller regions. Although incidence data is available at lower geographies, confidentiality 
restrictions meant is was not possible to obtain this for the study. Relative survival rates on the 
other hand have not been computed at lower geographies in England, because the small number 
of cases and deaths at lower geographies introduces difficulties in standardising by age and 
sex. Whilst acknowledging that using relatively large PCT geographies conceals variation 
present at lower geographies, these findings are still informative because commissioning of 
cancer services in England took place at this level (Okello et al. 2011). 
 
By use of area level data, the study demonstrates that areas with the poorest access also have 
the highest cancer cases Table 3.4. This may be an indication that services in England may not 
be located according to population need. One explanation is that cancer services are more likely 
to be located in cities. This is contrary to the fact that the demand for these services is greater 
in less urban areas that carry a larger cancer burden due to larger percentage of older people. 
A programme commissioned by the National Cancer Action Team to model radiotherapy 
demand in England showed local area variation. Inner London PCTs with younger populations 
such as Tower Hamlets had a lower projected demand by the year 2020; 6,007 fractions per 
million in comparison to 20,827 fractions per million for more rural PCTs such as Devon 
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(Round et al. 2013). This variation is due to geographical variation in age distribution because 
older age carries an increased cancer burden (Round et al. 2013).  
 
Associating PCT level mean travel times with cancer survival rates showed that areas with 
longer travel times to MDT and treatment have worse cancer survival rates. The unadjusted 
models for breast and colorectal cancers showed that areas with longer travel were more likely 
to have better relative survival rates. However, when the confounding effect of deprivation was 
removed the opposite was apparent; areas with longer travel were more likely to have poorer 
relative survival rates. This may be because deprived populations are more likely to live in 
urban areas where most hospitals are located.  
 
The findings indicate that travel time – survival association was strongest in lung and colorectal 
cancers than in breast cancer, this is particularly so for radiotherapy treatment (Table 3.7). The 
travel time – survival associations for access to lung cancer surgical treatment had some of the 
strongest associations (Table 3.8). Increasing distance from a cancer centre has been 
previously associated with poorer survival in lung cancer (Campbell et al. 2000). Poor survival 
for those with poorer access may be explained by the increased likelihood of more advanced 
disease stage at diagnosis (Campbell et al. 2001), but why this might vary by tumour site is less 
clear. Other research suggests treatment uptake also appears to vary by tumour type; breast, 
rectal and lung cancers patients are all less likely to receive radiotherapy if they live farther 
from a radiotherapy site (Jones et al. 2008). Additionally, poor access to chemotherapy for 
rectal and lung cancer treatment (Jones et al. 2008) and poor access to surgical treatment for 
lung cancer has been associated with reduced likelihood for these treatments (Jones et al. 2008; 
Lau et al. 2013; Khakwani et al. 2013). There is also some evidence that geographical 
inequalities in cancer survival has declined for breast cancer but has persisted for other cancers 
(Walters et al. 2011),  our findings may to some extent support this conclusion. 
 
Geographical access to radiotherapy and surgery had a stronger association with relative 
survival rates than geographical access to MDT and chemotherapy services. This is most likely 
because there are fewer sites for radiotherapy and surgical treatment than for MDT and 
chemotherapy. For radiotherapy treatment, NRAG recommends a threshold of 45 minutes 
travel for radiotherapy treatment (National Radiotherapy Advisory Group 2007). Using ONS 
mid 2009 PCT population estimates and mean PCT travel times, an estimated 6% (3 Million) 
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of the population in England lives farther than the recommended 45 minutes. It is likely that 
this population estimate is greater, this is because analysis at large areas such as PCTs conceals 
the extent of variation observed at smaller areas. For example, similar analysis at LSOA level 
showed that an estimated 10% (5 million) of the population in England lives over 45 minutes 
from a radiotherapy hospital site.  
 
Surgical operation is the main treatment for colorectal cancer and non-small cell lung cancer 
(Cancer Research UK 2016c). This study shows acute geographical inequalities in access to 
surgical treatment for lung cancer patients, whereby over a quarter of the population in England 
may need to travel longer than 45 minutes to obtain this treatment. Fortunately, surgical 
treatment tends to involve fewer hospital visits than chemotherapy or radiotherapy that is 
delivered in multiple visits over a longer period of time, thus, it may be less burdensome for 
patients to travel to highly specialised surgical treatment centres (Independent Cancer 
Taskforce 2015).  
 
In recent decades, the role of radiotherapy in cancer treatment was understated and this resulted 
to an under-investment of radiotherapy services in the UK (Cancer Research UK 2009). 
However, its curative effectiveness is now increasingly being recognised, with nearly 40% of 
cured cancer cases being attributed to radiotherapy treatment (National Radiotherapy Advisory 
Group 2007). Where used curatively in lung cancer, it is generally reserved in the treatment of 
inoperable tumours often in elderly patients or those with other multiple morbidities (Louie et 
al. 2015). It is also used often to treat rectal but not colon cancers, whilst in breast cancer, 
radiotherapy is used after breast reconstruction and mastectomy (Cancer Research UK 2016c). 
A substantial under-provision of radiotherapy services in England has been reported with an 
estimated 63% gap between current activity levels and optimal treatment levels, however, 
improvements to increase provision are underway (National Radiotherapy Advisory Group 
2007). The findings in this study suggest that good access to radiotherapy treatment may be an 
important prognostic factor in breast, colorectal and lung cancer.  
 
This study has a number of limitations. It is a cross-sectional study and therefore causality 
cannot be determined; it is plausible for example, that longer travel times might have caused 
poorer survival because of later diagnosis or inadequate treatment, although no data was 
available to let enable this analysis. Another limitation is in using number of cancer cases to 
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indicate population need. It could be argued that the number of cases are only an indicator of 
the quantity of services needed, and not of the needs of individuals who have cancer. The 
analysis used aggregated PCT level data as individual level data or data from smaller 
geographies was not available at the time of the study. Aggregated data exposes the study to 
the ecological fallacy meaning the findings at a population level may not be inferred at 
individual level. Additionally, some of the data sources did not cover the same time period. For 
example, there was no information to identify the location of MDT and chemotherapy hospital 
sites operating in the period over which the outcomes were measured, although it is unlikely 
that the geographical provision of services will have changed substantially over the period of 
this study.  Data were not available on mobile chemotherapy units or GP surgeries offering 
chemotherapy services and so it was not possible to include them in the access measures. 
Another limitation is that PCTs are now obsolete geographies and have been replaced by CCGs 
(Clinical Commissioning Groups). At the time of this analysis it was not possible to obtain 
cancer specific five year relative survival rates at CCG level.  
 
In conclusion, this study has shown that despite equity in access being a key objective in the 
provision of healthcare, it remains an elusive goal in the provision of cancer services in 
England. The findings suggest that longer travel times to services might lead to inadequate 
treatment and therefore poorer survival. The study also identifies some research questions that 
warrant more in-depth future research. Firstly, colorectal and lung survival appear to be more 
sensitive to poor geographical access to radiotherapy than breast cancer Table 3.7. Secondly, 
in lung cancer, geographical access issues are more strongly associated with one year over five 
year survival rates. Thirdly, lung cancer survival appears to be more sensitive to geographical 
access to chemotherapy and MDT than both colorectal and breast cancer. 
 
Part of the challenge in meeting the equity goal may lie in the lack of a universal definition and 
monitoring criteria for equity in access (Allin et al. 2007). Another challenge lies in the trade-
off that results when attempting to meet contrasting goals such as equity and efficiency, with 
resources that are increasingly scarce. This has been recognised by the recent Cancer Strategy 
for England that is working to develop a five year cancer survival improvement strategy 
(Independent Cancer Taskforce 2015). The strategy has identified a need to revisit the issue of 
access to services in order to enable improvements in earlier diagnosis and quality of care. 
Additionally, the strategy recognises the inequitable commissioning and delivery of care, and 
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has urged the tackling of variation to be a priority over the next five years. To achieve this, two 
recommendations that are relevant to this study have been put forward; an evaluation of 
evidence to determine whether service configuration of surgery merits further centralisation 
and, an evaluation of the impact on cancer outcomes of patients living distances from a cancer 
centre (Independent Cancer Taskforce 2015).  
 
It is plausible that some of the associations between access and survival shown in this chapter 
may be influenced by accessibility to primary care. Controlling for access to primary care using 
a measure of ease of obtaining a GP appointment had little impact on the travel time – survival 
associations (Table 3.5 - Table 3.8). With a few exceptions, relative survival was generally 
higher in PCTs where patients had the most ease in obtaining a GP appointment. For example, 
in access to radiotherapy treatment, a decrease in difficulty of obtaining a GP appointment from 
the reference category ‘quartile 1 (difficult)’ to the lowest category ’quartile 4 (easy)’, is 
associated with a predicted increase in five year survival by 1.34 percent, p<0.05 in breast 
cancer and 3.28 percent, p<0.01 in colorectal cancer (Table 3.7). The area level analysis used 
in this chapter may mask the variations that are observed at lower geographies or at the level 
of individual patients; data that are more granular are required to ascertain the relationships at 
these lower levels. The next chapter will use individual level data to examine the association 
between other measures of access to the GP (such as travel times), rurality and key process and 
clinical outcomes.  
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Chapter 4                      
Impact of travel time and 
rurality on presentation and 
outcomes of symptomatic 
colorectal cancer: a cross-
sectional cohort study in 
primary care 
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4.1  Background 
 
Chapter One described how previous studies examining the relationship between access and 
cancer outcomes have had a focus on secondary services, whereas primary care services has 
been overlooked. Studies conducted in the UK have reported that people who live rurally and 
further away from health services have poorer cancer outcomes (Jones et al. 2008; Campbell 
et al. 2000). Chapter Three supported these findings by showing that areas with the poorest 
access also have worse survival rates, and found that this may be linked to inequities in 
accessing management and treatment services.  
 
It was not possible to ascertain how access to primary service contributed to the findings in 
Chapter Three, although some work conducted in Australia suggests causative mechanisms 
may be at the general practice level; particularly with regards to rural accessibility (Emery et 
al. 2013). This is because rural populations may be impacted disproportionately by overall poor 
accessibility and by long distances travelled to obtain primary and secondary healthcare 
(Douthit et al. 2015; Emery et al. 2013). For example, longer distance to health services has 
been associated with fewer in-patient admissions (Haynes & Bentham 1982), with poorer 
uptake of cancer diagnosis and treatment (Jones et al. 2008; Lau et al. 2013; Crawford et al. 
2009), and with lower survival (Campbell et al. 2000). Secondly, socio-cultural factors could 
manifest as different attitudes or stoicism in rural dwellers, with correspondingly lower rates 
of primary care consultation, and as a consequence, lower likelihood of general practitioners 
(GPs) being enabled to detect early symptoms of cancer (Emery et al. 2013; Farmer et al. 2006). 
Geographical location and considerations of access could also influence GP decision making 
if they take into account patients’ journey to hospital when making referral decisions (Haynes 
& Bentham 1982; Sladden & Thomson 1998).  
 
Acting together, these mechanisms could conspire against rural patients and their GPs and lead 
to disproportionately longer diagnostic delays, later stage presentation and poorer survival. A 
study from the early 2000s in Northern Scotland supports this notion by showing that longer 
straight-line distances from patients’ homes to a cancer centre was associated with later stage 
at diagnosis and poorer survival from colorectal cancer (Campbell et al. 2001; Campbell et al. 
2000). Rural patients are therefore more likely to experience longer distances and worse access 
because health services are located more sparsely in these areas. However, poorer access in 
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rural areas may not always translate to worse outcomes; research from the USA has provided 
contradictory findings by reporting increased likelihood of late stage cancer amongst urban 
patients (McLafferty & Wang 2009; McLafferty et al. 2011).  
 
Achieving a true understanding of the relationship between rural residence and cancer 
outcomes is hindered by a focus on outcomes, survival and stage, rather than process. There 
have been few meaningful attempts to compare urban and rural cancer diagnosis at the level of 
patient - GP interactions. Cancer is easier to detect and refer when alarm symptoms are present 
(Jensen et al. 2014; Hamilton 2009), and harder when symptoms are atypical (Lyratzopoulos 
et al. 2014).  
 
When grouped by diagnostic difficulty, cancer sites such as breast and melanoma are 
considered easier to detect because they present with signs and symptoms that are fairly 
specific. In contrast, cancers such as lung, myeloma and stomach present with non-specific 
symptoms that are frequently seen in primary care and this makes diagnosis of the cancer 
difficult (Lyratzopoulos et al. 2014). The diagnosis of colorectal cancer lies in the middle of 
this spectrum of diagnostic difficulty because some patients with this cancer present with 
specific symptoms but others present atypically (Table 4.1) (Lyratzopoulos et al. 2014) 
 
 
Table 4.1 - Categories of diagnostic difficulty 
 
Category Definition 
Harder to suspect Most patients present with non-specific symptoms (e.g. 
multiple myeloma, pancreas, stomach, lung) 
Intermediate Some patients present with specific symptoms, but other 
present atypically (e.g. colon, renal, lymphoma) 
Easier to suspect Most patients present with highly specific symptoms or signs 
(e.g. breast, melanoma, endometrial, testicular, bladder) 
Source; Lyratzopoulos et al (2014) 
 
Subsequent diagnosis after presentation with non-alarm symptoms may therefore require more 
frequent engagement with health services, which may be hindered by poor accessibility; 
difficulties in accessing secondary care services could mean rural GPs might delay referral 
until symptoms are more obvious (Vedsted & Olesen 2011). It seems plausible therefore, that 
for rural populations, geographical inaccessibility and socio-cultural differences would 
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manifest as a greater likelihood to be diagnosed with colorectal cancer following presentation 
with alarm symptoms to GP, or following an emergency admission.  
 
4.1.1  Referral guidelines for suspected cancer 
In the UK, GP referral for suspected cancer is informed by referral guidelines such as the 
National Institute for Health and Clinical Excellence (NICE) and the Scottish referral 
guidelines for suspected cancer (NICE 2005; Health Improvement Scotland 2013; NICE 2015). 
The 2005 NICE referral guidelines were criticised for concentrating on typical presentations of 
cancer, which may have delayed diagnosis in patients with atypical presentations (Hamilton et 
al. 2009). These guidelines have been recently revised (NICE 2015). One key recommendation 
in the revised guidelines has been to lower the symptoms threshold to include any symptoms 
with a 3% or higher positive predictive value (PPV); the previous guidelines had few symptoms 
with a PPV of lower than 5% (NICE 2015). 
 
The revised referral guidelines also aim to standardise clinical practice by minimising 
unwarranted variations such as in making referrals and testing for cancer (NICE 2015). 
Variations in clinical practice are well documented; for instance, there are known age, gender, 
ethnic, and tumour site variations in the number of pre-referral consultation (Lyratzopoulos et 
al. 2012). Patients with tumours in the pancreas, stomach, lung, colon, ovarian as well as 
Hodgkin’s lymphoma, and multiple myeloma are more likely to consult their GP three or more 
times before hospital referral (Lyratzopoulos et al. 2012). Similarly, younger patients, females, 
and  ethnic minorities are also more likely to have multiple consultations before a referral in 
comparison to older patients, men, and white patients, respectively (Lyratzopoulos et al. 2012). 
Variations in referral to secondary care that arise due to issues in access are also plausible. 
These may emanate from poor access to both primary and secondary services or from poor 
access influencing GPs referral behaviour (Carr-Hill et al. 1997; Haynes & Bentham 1982), 
but these relationships have not been well researched. 
 
4.1.2 Study Objectives 
This study examines rural urban differences in the diagnosis of colorectal cancer using a 
historical, but highly detailed database from Northern Scotland (Robertson et al. 2004). The 
CRUX (Comparing Rural and Urban Cancer Care) database linked detailed information from 
the primary care records of people diagnosed with colorectal cancer, to cancer registry and 
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service use data from NHS Scotland. Using this linked dataset, this chapter explores the 
association between rurality, travel to services and symptoms at presentation, emergency 
presentation, stage and survival for 926 people diagnosed with colorectal cancer between 
1997/8. Also, for the first time the analysis investigates the interaction between rurality, 
urbanity and travelling time on these important colorectal cancer outcomes, as well as the 
relationship between symptoms, emergency admissions and survival. 
 
4.2  Methodology 
The study used the CRUX (Comparing Rural and Urban Cancer Care) linked dataset that 
contains primary care data from Northern Scotland. CRUX holds records of cancer cases 
diagnosed between 1997 and 1998 (Murchie et al. 2014; Robertson et al. 2004) and followed 
up until 2011. The GP records hold clinical information on symptoms presented at the index 
consultation, referral route, other comorbidities, information on diagnosis and treatment. These 
have been linked with data from the Scottish Cancer Registry to provide information on 
demographics, Dukes’ stage and GP practice of registration at the time of colorectal cancer 
diagnosis. A final linkage with the General Register Office for Scottish Death Registry 
provided the date of death. We only used colorectal cancer records as this was the focus of the 
study.  
 
The index consultation was determined as the first visit to the GP with a recording of potential 
symptoms of colorectal cancer that preceded diagnosis (Murchie et al. 2014).  Patients with 
symptoms recorded two years before treatment were excluded, as it was judged unlikely that 
these symptoms were associated with the tumour (Robertson et al. 2004; Murchie et al. 2014). 
The presence of alarm symptoms, non-alarm symptoms, emergency admissions, later (C or D 
versus A or B) Dukes’ stage and survival were identified as the primary outcomes. Admission 
types recorded as emergency and/or A&E (Accident and Emergency) were grouped into 
‘emergency admissions’, whilst all inpatient and outpatient admissions as well as day cases 
and domiciliary visits were grouped as ‘other admissions’. Stage at diagnosis was recorded as 
Dukes’ stage (A, B, C or D). Survival time was measured from date of first presentation to 
primary care (Murchie et al. 2014). 
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4.2.1 Alarm and non-alarm symptoms  
Expert opinion was sought on the definition of alarm symptoms (Hamilton, 2015 Personal 
Communication). Alarm symptoms were defined as serious symptoms that are most likely to 
result in a patient seeking a consultation or a GP making an urgent referral. These are rectal 
bleeding, palpable mass and weight loss. This grouping was consistent with a previous other 
study (Van Hout et al. 2011). Patients with any of these symptoms were categorised as ‘Alarm’. 
The opposite end of the spectrum to alarm symptoms are ‘non-alarm’ symptoms. These are 
considered ‘low risk, but not no risk’ (Hamilton 2010); they most probably do not indicate 
cancer but cancer cannot be excluded (Vedsted & Olesen 2015) and are important to investigate 
because referral decisions are considered particularly difficult for them (Hamilton 2010; 
Vedsted & Olesen 2015). Following expert advice (Hamilton 2015), we identified these non-
alarm symptoms as constipation, diarrhoea, abdominal pain and anaemia. Patients with any of 
these non-alarm symptoms (but excluding alarm symptoms above) were grouped as ‘Non-
alarm’. 
 
4.3  Statistical Analysis 
Geographical access was defined as estimated travel times in minutes from the patients’ home 
postcode to the postcode of their GP practice of registration at diagnosis. These were computed 
using a Geographical Information System (GIS) (ArcGIS 10.3, Esri Inc.), see section 3.2.1 for 
more information on the methodology.  
 
Road travel time was selected as the most appropriate measure of accessibility; a previous study 
had demonstrated that over 87% of cancer patients travel to hospital by motor vehicle (Haynes 
et al. 2006). Travel times estimated using GIS have previously been closely related to the times 
of actual car journeys reported by cancer patients (Haynes et al. 2006). Lastly, patients were 
grouped according to rural or urban residence using the (2003-04) Scottish rural-urban 
classifications (Scottish Executive 2004). 
 
All data were analysed using Stata Version 13 (StataCorp College Station, TX, USA). 
Estimated travel time was analysed as a continuous variable. Symptoms and admissions and 
stage data were binary coded as ‘alarm symptoms vs not’, ‘emergency vs not’, ‘early stage 
(CD) vs late stage (AB)’. Logistic regression was used to examine how travel time was 
associated with the likelihood of these outcomes. So that parameter estimates were 
 100 
 
conservative, the models were adjusted for variables deemed to have a relationship with the 
outcomes; age, sex, Carstairs deprivation score (Morris & Carstairs 1991) and Charlson 
comorbidity index (Charlson et al. 1987). Odds ratios (OR) and 95% CI were calculated in all 
four models. Cox survival analysis was used to examine the relationship between travel time 
to GP and survival. For each patient, follow-up began at the date of their index presentation 
(see definition above) and ended at the date of death or was censored after three years. Hazard 
ratios (HR) and 95% confidence intervals (CI) were calculated and this model was also adjusted 
for the above confounders. 
 
Based on the differences in geographical accessibility and socio-cultural acceptability of care 
seeking between rural and urban areas (Douthit et al. 2015; Bain & Campbell 2000; Farmer et 
al. 2006), it was hypothesised that travel times may have a different relationship with the 
outcomes of interest for those living in rural compared to urban settings. To test this, interaction 
terms were fitted to examine if rurality moderated associations between travel times and the 
outcomes. Urban and rural associations were then separately plotted, and statistical significance 
of the differences was tested; a p-value (<= 0.05) was used to show statistical significance. 
 
4.4  Results 
The CRUX dataset had 1489 cases with a colorectal cancer diagnosis. Of these, 531 were 
excluded because their initial symptoms were recorded as having been presented two years 
before treatment, and 31 were excluded because they did not have any GP recorded symptoms. 
One case was missing postcode (zip code) and was also excluded. A total of 926 patients with 
symptomatic colorectal cancer had complete data and were used in this analysis. Just over half 
of these were male (56.3%) and majority (83.1%) were above 60 years of age (Table 4.2). Over 
half of the patients (52.4%) had one or more comorbidities, 825 (89.1%) had between one and 
three symptoms, whilst the remaining 101 (10.9%) had over more than four symptoms 
recorded.  There were 373 patients with one or more alarm symptom, 507 patients with one or 
more ‘non-alarm symptom’, 243 patients were admitted to hospital via an emergency route and 
424 patients had Dukes’ stage C and D (Table 4.2). 
 
The median travel time was 5.5 minutes, whereas 75% of all patients could access their GP 
within 10 minutes. Nearly a third (32.2%) lived in a rural area and travel times to GPs were 
longest for those living in rural vs urban areas (12.0 vs 6.2 minutes) and those with four or 
 101 
 
more symptoms vs one to three symptoms at the index presentation (10.7 vs. 7.7 minutes) 
(Table 4.2). There was little variation in mean travel times between the other variables. Figure 
4.1 is a map showing the geographical location of the patients, the GPs as well as the rural 
urban localities in the region of study. The map reveals that most of the region of study 
(Northern Scotland) is predominantly rural. 
 
 
               Table 4.2 - Sample characteristics and outcome variables 
 
Variable Frequency 
(%) 
Mean travel 
time (minutes) 
25th and 75th 
travel time 
percentile 
Male 521 (56.3%) 8.8 2.8, 10.7 
Female 405 (43.7%) 7.1 2.7, 10.0 
Under 59 years 157 (17.0%) 8.8 3.0, 11.6 
60 – 69 years 240 (25.9%) 7.6 2.2, 10.0 
70 – 79 years 347 (37.5%) 8.5 2.9, 10.6 
80 years plus 182 (19.7%) 7.1 2.8, 8.7 
Rural 298 (32.2%) 12.0 2.6, 16.3 
Urban 628 (67.8%) 6.2 2.8, 8.1 
Travel time to GPs 
  
 
25th percentile 232 (25%) 2.8  
50th percentile 463 (50%) 5.5  
75th percentile 695 (75%) 10.3  
99th percentile 917 (99%) 43.8  
Least deprived Q1 191 (20.6%) 8.6 3.1, 12.7 
Q2 191 (20.6%) 7.8 2.2, 10.1 
Q3 171 (18.5%) 9.1 3.0, 11.2 
Q4 188 (20.3%) 8.1 1.9, 9.1 
Most deprived Q5 185 (20.0%) 6.5 3.9, 8.6 
0 comorbidity 441 (47.6%) 7.8 2.6, 10.1 
1-2 comorbidities 312 (33.7%) 8.3 3.0, 10.5 
3 plus comorbidities 173 (18.7%) 8.3 2.5, 11.1 
1 – 3 symptoms 825 (89.1%) 7.7 2.9, 10.3 
4 plus symptoms 101 (10.9%) 10.7 2.1, 11.8 
Alarm Symptoms 373 (40.3%) 7.9 2.6, 10.3 
Emergency Admissions 243 (26.2%) 7.7 2.8, 10.1 
Dukes’ stage CD* 424 (48.9%) 7.9 2.9, 10.3 
             *Information on disease stage was missing in 58 patients 
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Figure 4.1 - Map of the study area in Northern Scotland, showing location the 
geographical location of patients, GP services and rural and urban areas 
 
 
 
 
4.4.1 Regression analysis 
In the model without travel time – rurality interaction terms, there were no independent 
associations between travel time to GP, rural-urban residence, and the first three primary 
outcomes (alarm symptoms, emergency admissions and Dukes’ stage). However, both longer 
travel and rural residence were significantly associated with better survival (HR 0.81 and 0.71, 
p<0.01 respectively) (Table 4.3, model 4a&b). 
 
The addition of an interaction term to each model (Table 4.3, models 1d - 4d) showed that 
associations with travel time and each outcome differed between urban and rural patients. This 
difference was statistically significant for alarm symptoms (OR 0.62, p<0.05) and emergency 
admissions (OR 1.69, p<0.05). As an example, Table 4.3, model 1d, shows longer travel in 
urban areas increased the likelihood of presenting with alarm symptoms (OR 1.34, p=0.06), 
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but this likelihood was reduced in rural areas (OR 0.83, p=0.08, obtained by multiplying OR 
of the estimate of travel time to GP with the interaction term). Conversely, longer travel time 
in urban areas reduced the likelihood of having an emergency admission (OR 0.62, p<0.05) 
(Table 4.3, 2d) and of death within three years of diagnosis (HR 0.75, p<0.05) (Table 4.3, 4d).  
 
Figure 4.2 graphically illustrates the output from Table 4.3, models 1d – 4d. Figure 4.2 (1a - 
4a) shows the differences in association between rural and urban areas; the lines indicate 
modelled association between travel time and the primary outcomes. Figure 4.2 (1b – 4b) 
shows the scale of the rural – urban difference in outcomes (solid line). This difference is 
statistically significance at the p<0.05 level where the 95% CI does not the cross zero marker 
(dashed line). 
 
The odds of emergency admission was significantly lower in the presence of alarm symptoms 
(0.36, p<0.01) (Table 4.3, model 2c). Alarm symptoms were not significantly associated with 
survival, and there was no significant interaction between alarm symptoms and rural residence 
in the models with emergency admission and survival as outcomes.   
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Table 4.3 - Association between rurality, travel times to the GP, alarm symptoms and primary outcomes. Travel time is the 
predictor in ‘a’, rurality is the predictor in ‘b’, and alarm symptoms is the predictor in ‘c’. Travel times are interacted with 
rurality in ‘d’. All models are adjusted for age, gender, deprivation and comorbidity. For brevity, the coefficients for the 
covariates are only shown in the models with the interaction term (d). 
 
Explanatory variables 
1)       Alarm 
symptoms 
2)     Emergency 
admission 
3)  Dukes’ Stages 
4)    Hazard ratio of 
death  
OR (95%CI) OR (95%CI) OR (95% CI) HR (95%CI) 
        
 Outcome variables without interaction terms 
a)  Travel time to GP (minutes) 0.98 (0.84 - 1.14)     0.91 (0.75 - 1.09)    0.91 (0.78 - 1.07)    0.81** (0.72 - 0.92)    
 b)                                         Rural 1.08 (0.80 - 1.46)    0.83 (0.58 - 1.18)   0.99 (0.72 - 1.34)     0.71** (0.57 - 0.88)    
c)                     Alarm Symptoms  N/A 0.36* (0.25 - 0.53) 0.85 (0.64 - 1.14) 1.15 (0.94 - 1.41) 
 Outcome variables with interaction terms fitted 
d)                     Travel time to GP 1.34 (0.98 - 1.82) 0.62* (0.39 - 0.97)     0.94 (0.68 - 1.29) 0.75* (0.59 - 0.96) 
Rural 1.62* (1.05 - 2.48) 0.61 (0.36 - 1.02) 1.11 (0.72 - 1.70) 0.69* (0.51 - 0.94) 
Travel time / rurality interaction  0.62* (0.43 - 0.90) 1.69* (1.02 - 2.79) 0.95 (0.65 - 1.38) 1.18 (0.88 - 1.57) 
Alarm Symptoms N/A 0.37** (0.26 - 0.54) 0.84 (0.63 - 1.12) 1.17 (0.95 - 1.43) 
Age (years) 1.00 (0.98 - 1.01) 1.02* (1.00 - 1.03) 0.97** (0.96 - 0.99) 1.03** (1.02 - 1.04) 
Female 0.95 (0.72 - 1.23) 0.89 (0.63 - 1.24) 0.76 (0.57 - 1.01) 0.74** (0.60 - 0.90) 
Index of deprivation (Carstairs) 0.99 (0.94 – 1.04) 0.99 (0.93 - 1.05) 1.05 (0.99 - 1.11) 1.02 (0.99 - 1.06) 
0 comorbidities (Charlson Score) 
(reference) 
1 1 1 1 
1 – 2 comorbidities (Charlson) 0.53** (0.39 - 0.71) 4.87** (3.27 - 7.26) 0.87 (0.63 - 1.19) 1.20 (0.95 - 1.50) 
3 plus comorbidities (Charlson) 0.29** (0.20 - 0.44) 7.26** (4.63 - 11.39) 1.44 (0.97 - 2.14) 2.53** (1.98 - 3.25) 
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Figure 4.2 - ‘1a - 4a’ show differences in association between rural and urban areas (Table 2, models 1d – 4d). The lines show 
modelled association between travel time and alarm symptoms (1a), emergency admission (2a), Dukes’ stage (3a) hazard ratio of 
death (4a). 1b – 4b show the difference in the rural vs. urban slope along with 95% CI. These differences are statistically 
significant where the confidence intervals do not cross the zero line. 
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4.5  Conclusions 
This study has examined the potential influence that rurality has on how patients present to 
their GP with symptomatic colorectal cancer and their subsequent outcomes. Additionally, the 
study has considered how rurality, urbanity and estimated travel time interact to influence the 
same outcomes. This work is novel because it considers for the first time whether symptomatic 
presentation of colorectal cancer to GPs is different in rural compared to urban areas.  
 
One of the main finding was that rural patients had superior three year survival than their urban 
counterparts (OR 0.71, p<0.01). The association between longer travel and the primary 
outcomes was opposite in rural areas to that observed in urban localities. The difference was 
statistically significant for alarm symptoms (OR 0.62, p<0.05) and emergency admissions (OR 
1.69, p<0.05). The moderation by travel times was statistically significant in urban areas but 
not in rural areas and may suggest that rural and urban patients may perceive geographical 
inaccessibility differently (Field & Briggs 2001). The presence of alarm symptoms 
significantly reduced the odds of emergency admissions (OR 0.36, p<0.01), whilst alarm 
symptoms were not associated with survival at three years. 
 
Rural patients had better three year cancer survival, confirming some reports of better cancer 
outcomes in rural areas from the USA (McLafferty & Wang 2009). Travelling farther to GPs 
in urban areas increased the odds of presenting with alarm symptoms; this supports our 
hypothesis that poor access results in greater odds of cancer diagnosis resulting from an alarm 
symptom presentation. Patients presenting with alarm symptoms were less likely to be 
diagnosed with cancer following emergency admission, perhaps because patients with 
alarming symptoms are more likely to be referred using standard referral pathways (Jensen et 
al. 2014). Unlike previous studies that associated alarm symptoms with better survival (Dregan 
et al. 2013; Stapley et al. 2006), this present analysis could not confirm this finding. 
 
The hypothesis expected that travelling farther in rural areas would also have higher odds of a 
diagnosis after presenting with alarm symptoms, rather, the analysis showed the opposite; 
longer travel time to GPs in rural areas reduced the odds of presenting with alarm symptoms. 
It is plausible that at the onset of such symptoms, those with the poorest geographical access 
in rural areas will delay seeking healthcare in comparison to their urban counterparts. Such 
rural - urban differences may be driven by social cultural differences in health seeking 
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behaviour, where the most remote rural patients may be displaying stoicism when seeking help 
(Emery et al. 2013; Douthit et al. 2015; Farmer et al. 2006; Elliott-Schmidt & Strong 1997). 
This may be supported by studies from Northern Scotland that found rural patients were more 
likely to present later, had lower expectations  of healthcare, and may pursue their care less 
tenaciously (Bain et al. 2002; Bain & Campbell 2000).  
 
Urban patients with shorter travel to their GP had the worst outcomes. This may be related to 
disadvantages amongst patients living in inner city deprived areas. Although area deprivation, 
was controlled for, the findings may suffer from residual confounding by deprivation; the 
Carstairs index may not fully capture individual level deprivation. Further, a measure of car 
ownership used in the index may not appropriately capture deprivation in rural areas where a 
car can be an essential possession (Information Services Division 2010).  
 
The study has several strengths; the sample has high levels of linkage to high quality routine 
datasets which includes all patients diagnosed within the study period. Record linkage has 
enabled a detailed analysis using clinical, demographic and geographical information, and 
adjustment for a greater array of potential explanatory variables. Finally, the long follow-up 
period has made it possible to examine associations with long-term survival.   
 
The study has a number of limitations. Except for survival analyses, it is a cross-sectional study 
hence the directions of cause and effect cannot be inferred. In order to allow for adequate follow 
up of deaths, the data is based on diagnoses made over a decade ago. Further, defining 
symptoms as either alarm or non-alarm is problematic in the absence of information on 
symptom severity. For instance, abdominal pain and anaemia have been grouped as non-alarm 
symptoms, but severe cases of these symptoms may be alarming enough to instigate a GP 
consultation or referral to hospital. Another limitation is not considering the availability of 
public transport, although previous work suggests this is infrequently used by cancer patients 
(Haynes et al. 2006). 
 
It was hypothesised that living in rural areas and having longer travel to a GP would be 
associated with greater likelihood of obtaining a diagnosis from alarm symptoms, and via 
emergency admissions. This in turn would lead to later stage colorectal cancer diagnosis and 
poorer three year survival.  Unexpectedly, the analysis found that rural patients and urban 
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patients with longer travel generally had better outcomes, were less likely to have emergency 
presentations, and had better survival. Further, the association between longer travel, alarm 
symptoms and emergency presentation was reversed between rural and urban areas.  
 
These findings suggest that the interplay between attitudes and location is more complex than 
has previously been considered in research into cancer and rurality. Socio-cultural attitudes and 
geographical location may influence how patients present to GPs with symptomatic colorectal 
cancer, and this may influence differences in outcomes in ways that may be counterintuitive. 
Most existing research has tended to make straight comparisons between urban and rural 
populations or considered distance separately from constructs of rurality or urbanity. Future 
research should explore the mechanisms driving the interaction between location, access and 
outcomes. Such mechanisms may include time delays occurring at various stages of the 
diagnostic pathway such as patient, primary care or system delays (Neal 2009). There is also 
scope for more research to better understand how time delays (Weller et al. 2012) and 
frequency of consultation (Lyratzopoulos et al. 2013; Dregan et al. 2013) may mediate the 
causal pathway between geographical access and reporting of symptoms. Future research 
should also examine how symptoms related to cancer mediate the association between access 
and the other primary outcomes examined in this study.  
 
These findings should reassure most rural cancer patients and their GPs that where they live 
may not be conferring the widely perceived rural diagnostic and survival disadvantages. In 
contrast, longer travel in urban areas may be associated with better outcomes. This has potential 
implications for urban GPs whose patients travel the least distance; such patients are more 
likely to live in the inner cities and may experience other access barriers such as longer delays 
due to larger GP list sizes. This has implications for defining catchment areas for urban 
practices that encapsulate travelling distances as well as transport options. Considering these 
in the context of practice list size and appointment availability could facilitate more efficient 
and effective healthcare access and outcomes. 
 
The better survival amongst rural patients and patients with longer travel may be explained by 
the fact that these patients were also less likely to have emergency presentations. The next 
chapter will build on this hypothesis by undertaking an in-depth exploration of the association 
between access to the GP and the mode by which a cancer diagnosis was attained.   
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Chapter 5                
Geographical access to 
general practitioners and 
modes of cancer diagnosis in 
England: a cross-sectional 
study of linked cancer 
registry and hospital data 
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5.1  Introduction 
The previous chapter found that rural patients in Northern Scotland and patients with longer 
travel to their GP had better outcomes indicated by lower odds of obtaining a diagnosis via an 
emergency presentation and by better survival from colorectal cancer. This analysis was based 
on a small sample of data collected in the late 1990s; thus, it is necessary to examine whether 
those findings would be replicated using a more recent and detailed national dataset, with 
records from eight different cancer sites. This dataset will enable investigations on whether 
geographical accessibility and rurality predict the route by which a cancer diagnosis is 
obtained; the relationship between access and survival will be considered in the next chapter. 
 
Identifying the pathways that lead to a cancer diagnosis is an important approach to improving 
access to care and consequent cancer survival. This is because the route that a patient takes to 
a cancer diagnosis has been shown to strongly predict survival (Elliss-Brookes et al. 2012; 
McPhail et al. 2013). Routes such as emergency presentations are associated with poorer 
survival (McPhail et al. 2013), whereas tumours detected via screening programmes have better 
outcomes (Brenner et al. 2014; Peto et al. 2004). There is also evidence associating increase in 
the GP use of two week wait (TWW) referrals with better survival (Møller et al. 2015). 
 
In addition to potential effects on survival, there are cost-effectiveness benefits associated with 
specific diagnostic routes. Emergency presentations represent approximately 65% of all 
hospital bed-days in England, incurring heavy costs to the health services and causing 
significant disruption to planned inpatient admissions (King’s Fund 2010a). They also account 
for an estimated 24% of all cancer diagnoses in England, ranging from around 5% in breast 
cancer to 62% in cancers of the central nervous system (Elliss-Brookes et al. 2012). Two 
specific diagnostic routes have been credited to the successful reduction of emergency 
admissions; diagnosis following screening for certain cancers and TWW GP referrals. The 
former increase the chances of cancer detection at the earliest stage whilst the latter ensure 
patients with expedited GP referrals are seen by a specialist within a two-week window. Indeed, 
the decline in emergency presentations in lung cancer from 39% in 2006 to 35% in 2013 may 
be due to increases in TWW referrals from 22% to 28% in the same time period (Public Health 
England 2015b). Similarly, the 3% drop in colorectal cancer emergency presentations may be 
explained by corresponding 4% and 10% increases in TWW referrals and screen detected 
diagnosis (Public Health England 2015a). 
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Preventing avoidable emergency admissions and other routes associated with poor prognosis 
requires understanding of factors that determine diagnostic routes. Some emergency 
admissions are unavoidable as they result from biological factors such as aggressive tumours 
that require sudden critical attention; these cases do not necessarily indicate failure of earlier 
diagnosis (Abel et al. 2015; Mitchell et al. 2015). However, many emergency admissions are 
potentially avoidable and are likely related to a combination of factors that operate at patient 
and health services levels. Patient level factors have been studied before: living in a deprived 
area, being elderly or female or belonging to an ethnic minority group have been associated 
with higher risk of emergency admissions (Abel et al. 2015; Raine et al. 2010). Health system 
level factors may also influence mode of diagnosis; difficulties in obtaining a GP appointment 
have been associated with an increase in emergency visits (Agarwal et al. 2012; Cowling et al. 
2013). Geographical access to services may also determine how a cancer diagnosis is obtained. 
Two previous studies showed an association between poor access to hospital and screening 
sites and poor participation in screening programmes (Jensen et al. 2013; Maheswaran et al. 
2006), likewise, access to hospital has also been reported to increase the odds of post-mortem 
cancer diagnosis (A. P. Jones et al. 2010).  
 
There is limited evidence showing the relationship between access to primary care services and 
early cancer diagnosis. Previous work has shown that primary care inaccessibility reduces GP 
consultation rates (Haynes & Bentham 1982), suggesting that poor access may also determine 
how a cancer diagnosis is attained by lowering the likelihood of patients to engage with early 
diagnosis services, or by influencing GPs decision to refer patients to secondary care for 
diagnosis (Sladden & Thomson 1998; Haynes & Bentham 1982). Little research has looked at 
how associations differ between urban and rural areas. Rural areas are normally associated with 
poorer geographical access to services (DEFRA 2013a), but this does not necessarily translate 
to higher emergency department visits (Cowling et al. 2013), suggesting perhaps that rurality 
maybe a distinct variable that measures a different parameter to travel time.  
 
5.1.1 Chapter objective 
This is the first study to use individual patient level data to examine how travelling time to a 
GP, and living in a rural or urban area, is associated with the routes that patients take for a 
cancer diagnosis. The hypothesis is that longer travel and living in a rural area will increase the 
likelihood of obtaining a diagnosis from less desirable routes (emergency presentations and 
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death certificate only), but will decrease the likelihood of obtaining a diagnosis from routes of 
better prognosis (screen-detected and TWW). The findings may support early diagnosis efforts, 
by improving our understanding of how the prospect of longer travel determines interaction 
with services for a cancer diagnosis, or GPs decisions when making referrals. 
 
5.2  Methods 
The analysis uses cancer registry records of cases diagnosed between 2006 and 2010 in 
England. Eight cancer sites were examined; breast (ICD-10 C50), brain (C71), cervical (C53), 
colorectal (C18- C20), lung (C33-34), ovarian (C56-57), prostate (C61) and stomach (C16). 
These were selected to include both rare and commonly occurring tumours, those that are 
amenable to screening, and tumours with varying degrees of diagnostic difficulty 
(Lyratzopoulos et al. 2014). Each record contained information on the route that the patient 
would have taken prior to obtaining a diagnosis. This was obtained by linking data from routine 
datasets to provide details on interactions between the patient and the health services that 
preceded the diagnosis (Elliss-Brookes et al. 2012; National Cancer Intelligence Network 
2013).  
 
Record level data was retrieved from English cancer registries for all newly diagnosed 
malignant tumours, and linked to Hospital Episodes Statistics (HES) inpatient and outpatient 
records, the National Cancer Waiting Times (NCWT) monitoring dataset, and NHS Breast 
Screening Programme data. Screening information for cervical cancer was obtained from 
screening status held by cancer registries. Up to 71 distinct route combinations were identified 
by categorising contacts between the patient and health services according to the setting of 
diagnosis, the presence of inpatient and outpatient status, and the referral route (Elliss-Brookes 
et al. 2012). These were aggregated to give the following seven broad routes; screen-detected, 
Two Week Wait (TWW), GP Referral, Inpatient Elective, Other Outpatient, Emergency 
Presentations, Death Certificate Only (DCO) and Unknown. PHE (Public Health England) has 
produced a detailed description of the data linkage and methods (Elliss-Brookes et al. 2012; 
National Cancer Intelligence Network 2013). 
 
Information on routes to diagnosis, age, gender, deprivation quintiles and the Charlson 
comorbidity index (Charlson et al. 1987) was retrieved from this linked dataset. Further 
linkages were made with a geographical access variable that estimated travel time in minutes 
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from the patients’ home to their GP of registration. These travel times were computed in the 
ArcGIS Spatial Analyst module using the ‘Cost Distance’ (impedance surface) command 
ESRI. Firstly, roads depicted in the Meridian 2 road network (Motorway, A-road, B-road and 
minor roads) (Ordnance Survey 2013) were converted into a regular grid of 100 × 100 m cells, 
with each cell containing a value corresponding to travel-time-per-unit distance of traversing 
the cell. Road speeds were taken from an earlier work (A. Jones et al. 2010) and allowances 
were made for locations off the regular road grid (adjusted for walking speed). The resultant 
travel time map was used to calculate travel times from all postcodes (origins) in England to 
all GP practices (destinations) in England, Wales and some practices in the south of Scotland 
bordering England. Hospital travel times were also calculated using the same methodology, 
from all postcodes in England to all hospitals sites where cancer treatment was administered. 
ArcGIS model builder was used to iterate the computation of travel times from origins to 
destinations.  More information on the development of the impedance surface used in this study 
has been described in previous literature (Sen et al. 2013; Bateman et al. 2013). 
 
Annex A is a flowchart of the processes that were used to derive travel times for the English 
national cancer registry dataset obtained for this study. The entire process was computationally 
intensive and involved running the (GIS) software from several desktops over an estimated 
period of ten weeks. Road travel time was selected as the most appropriate measure of 
accessibility because a previous study has demonstrated that over 87% of cancer patients travel 
to hospital by motor vehicle (Haynes et al. 2006). Rural and urban status were assigned at 
postcode level using the 2011 rural-urban classification for small area geographies (DEFRA 
2013b). 
 
Primary outcomes were defined as two routes to diagnosis associated with good prognosis 
‘screen-detected’ and ‘TWW’ and two less desirable routes ‘emergency presentations’ and 
‘DCO’. These were binary coded as ‘screen-detected versus all other routes’, ‘TWW versus all 
other routes’, ‘emergency versus all other routes’ and ‘DCO versus all other routes’. All 
unknown routes and secondary tumours were excluded from the analysis. 
 
Data were analysed using Stata Version 13 (StataCorp College Station, TX, USA). For the 
purpose of analysis, estimated travel time was grouped into four categories; ‘<10 minutes’, 
’>10 - 20 minutes’, ’>20 - 30 minutes’ and ‘>30 minutes’. Logistic regression was used to 
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examine how travel time and rural – urban status was associated with the odds of each primary 
outcome. In a similar manner to Chapter Four (Section 4.3), interaction terms were fitted to 
examine whether travel times moderated the associations between rurality and the outcomes. 
All models were adjusted for variables deemed to have a relationship with the outcomes; age, 
deprivation, comorbidity, and gender (where applicable). Odds ratios (OR) and 95% CI are 
presented for all models.  
 
5.3  Results 
There were 749,451 unique records with a primary diagnosis of the specified cancers in 
England between 2006 and 2010. An estimated 88% of the population had access to their GPs 
within an estimated 10-minute drive (Table 5.1). Those with the poorest access (over 30 
minutes) comprise just 0.7% of the population. Rural patients accounted for about 22% of the 
sample, and this was highest in prostate cancers at 24%, and lowest in cervical cancer at 16%. 
Routes to diagnosis varied considerably by tumour type. Breast cancer had the lowest 
percentage of emergency presentations with 4.5% of cancers being diagnosed via this route, 
whereas 62% of brain tumours were diagnosed via this route. Lung cancer had the highest 
percentage of DCOs with 0.7% being diagnosed post mortem (Table 5.1).  
 
5.3.1 Association between travel times and primary outcomes 
In the unadjusted regression models (Table 5.2 A, B, C&D) longer travel times were associated 
with increased likelihood of both emergency presentations and DCO routes. The associations 
were stronger for DCO than emergency presentations, and the odds ratios progressively 
increased from the lowest travel time category to the highest. In the unadjusted models where 
screen-detected and TWW were the primary outcomes, those with longer travel were less likely 
to have a diagnosis from these two routes; the odd ratios progressively decreased from the 
lowest travel time category to the highest. 
 
After adjusting for covariates, DCOs and emergency admissions were more likely in female 
and older patients (Table 5.3 A&B). Deprivation and presence of comorbidities were also 
associated with higher odds of diagnosis via emergency routes but not a DCO (Table 5.3 
A&B). Adjusting for these covariates had a minimal effect on the associations with estimated 
travel time. For example, stomach cancer patients with estimated travel times of over 30 
minutes were more than 10 times likely to have a post mortem diagnosis (OR 10.58, p<0.01). 
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Corresponding findings were an eight fold (OR 8.31, p<0.01), and seven fold (OR 7.29, 
p<0.01) elevated odds for breast and colorectal cancer patients respectively (Table 5.3 B). The 
ORs for cervical cancer when the outcome was DCO could not be estimated due to small 
numbers.  
 
In the adjusted models with screen-detected and TWW as primary outcomes, female gender 
decreased the likelihood of diagnosis from both routes (Table 5.4 A&B). Deprivation was 
associated with lower odds of diagnosis via screening (Table 5.4 A). Longer travel was 
associated with lower odds of diagnosis via TWW, these associations were statistically 
significant for breast, colorectal, lung, prostate and ovarian cancers. For those travelling over 
30 minutes, the odd of diagnosis via TWW for these cancer sites were; 0.87 (p<0.05), 0.68, 
0.74, 0.70 and 0.53 (p<0.01) respectively compared to those with under 10 minutes of travel 
(Table 5.4 B). Longer travel was also associated with lower odds of diagnosis via screening 
for breast and colorectal cancer (Table 5.4 A).  
 
5.3.2 Regression results for rurality and primary outcomes 
Living in a rural area reduced the likelihood of a diagnosis from the emergency route but 
increased the likelihood for two week wait referral and screening. Adjusting for covariates had 
minimal effect on the associations with rurality. For example Table 5.5 A shows that rural 
patients had a lower odds of obtaining a cancer diagnosis via an emergency route, and this was 
statistically significant for breast, colorectal, lung, prostate (0.88, 0.93, 0.96, 0.87, p<0.01 
respectively) and stomach cancer (0.93, p<0.05). Rural patients also had significantly higher 
odds of attaining a diagnosis following a two week wait referral for the following cancer sites: 
colorectal, lung, prostate, stomach and ovarian cancers (ORs 1.12, 1.15, 1.12, 1.13, 1.15, 
p<0.01 respectively) (Table 5.6 B).  
 
Fitting a travel time – rurality interaction term suggested that the association between travel 
times and the outcome differed between rural and urban patients in some cancer sites. Table 
A.1 of Annex B gives an example of the moderating effect of longer travel in rural vs. urban 
areas, when the outcome was diagnosis following an emergency route. Taking the example of 
colorectal cancer (Model 2), the results show that associations with travel time and this 
outcome differed between urban and rural patients, and the difference is statistically significant 
(OR 0.95, p<0.05). Longer travel in urban areas increased the odds of obtaining a diagnosis via 
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the emergency route (OR 1.09, p<0.01). Longer travel in rural areas also increased the odds of 
obtaining a diagnosis via this route (OR 1.04, p<0.05) (obtained by multiplying OR of the 
estimate of travel time to GP with the interaction term).  In this colorectal cancer example, 
longer travel to the GP had a stronger moderating effect on emergency presentations in urban 
than in rural areas. The rest of the outcomes (TWW, DCO and screening have not been shown 
for brevity but they generally show similar patterns).  
 
 117 
 
Table 5.1 - Characteristics of the study cohort 
   Number of cases (% percentage) 
 
 
All cancers 
No. (%) 
Breast  
No. (%)  
Colorectal  
No. (%) 
Cervical  
No. (%) 
Lung  
No. (%) 
Prostate  
No. (%) 
Stomach  
No. (%) 
Ovarian  
No. (%) 
Brain  
No. (%) 
 
Age groups Under 59 years 
60 - 69 years 
70 - 79 years 
80 years plus 
 
190,796 (25.5)        
202,144 (27.0)        
211,440 (28.2)        
145,071 (19.4)      
85,152 (44.4)       
47,616 (24.8)       
31,733 (16.5)       
27,487 (14.3)       
28,079 (17.6)        
41,281 (25.8)        
51,082 (32.0)        
39,340 (24.6)     
9,032 (73.8)      
1,156 (9.4)        
1,112 (9.1)        
945 (7.7)       
25,755 (15.3)        
45,630 (27.0)     
58,492 (34.6)       
38,985 (23.1)       
21,929 (13.0)        
56,963 (33.6)        
60,999 (36.0)        
29,441 (17.4)       
4,836 (15.1)       
6,668 (20.8)    
11,212 (35.0)       
9,339 (29.1)     
10,756 (36.7)        
7,330 (25.0)      
6,499 (22.2)      
4,731 (16.1)      
8,962 (45.4)      
4,674 (23.7)      
4,018 (20.4)      
2,070 (10.5)       
 
Gender Male 
Female 
 
366,844 (49.0) 
382,577 (51.1)            
 
1,474 (0.8) 
190,514 (99.2) 
88,547 (55.4)        
71,221 (44.6)       
95,483 (56.6)        
73,369 (43.5)       
20,801 (64.9)        
11,254 (35.1)        
11,376 (57.7)        
8,348 (42.3)    
 
Travel time in 
minutes to the 
GP 
<= 10  
10.1 – 20 
20.1 – 30 
Over 30 
 
622,070 (88.1)  
70,852 (10.0) 
8,412 (1.2) 
4,707 (0.7)                           
159,910 (87.9)        
18,782 (10.3)        
2,167 (1.2)         
1,175 (0.7)         
132,383 (88.2)        
15,003 (10.0)       
1,705 (1.1)        
963 (0.6)     
10,276 (88.6)       
1,105 (9.5)   
126 (1.1)        
92 (0.8)       
141,112 (89.4)        
14,016 (8.9)        
1,626 (1.0)       
1,019 (0.7)       
140,337 (87.4)        
17,385 (10.8)        
2,010 (1.3)        
936 (0.6)       
26,743 (89.5)     
2,675 (9.0)        
317 (1.1)        
163 (0.6)       
24,063 (87.7)      
2,786 (10.2)      
365 (1.3)       
221 (0.8)       
15,459 (85.7)        
2,026 (11.2)       
323 (1.8)        
226 (1.3)       
 
Rural- urban 
status 
Rural 
Urban 
 
157,631 (21.0)       
591,820 (79.0)      
41,748 (21.8) 
150,240 (78.3) 
35,181 (22.0)       
124,601 (78.0)       
2,029 (16.6)      
10,216 (83.4)        
28,828 (17.1)       
140,034 (82.9)        
40,573 (24.0)       
128,759 (76.0)        
5,748 (17.9)     
26,307 (82.1)       
6,244 (21.3)     
23,072 (78.7)     
4,223 (21.4)      
15,501 (78.6)        
 
Deprivation 
quintile 
1 least deprived 
2 
3 
4 
5 most deprived 
148,868 (19.9) 
161,072 (21.5) 
157,338 (21.0) 
147,639 (19.7) 
134,534 (18.0)                       
         
42,500 (22.1)        
43,712 (22.8)        
40,839 (21.3)        
35,861 (18.7)        
29,076 (15.1)       
32,718 (20.5)        
35,285 (22.1)        
34,305 (21.5)        
31,070 (19.5)      
26,404 (16.5)      
1,851 (15.1)        
2,123 (17.3)       
2,369 (19.4)      
2,722 (22.2)       
3,180 (26.0)       
22,977 (13.6)       
29,580 (17.5)       
34,225 (20.3)        
38,428 (22.8)        
43,652 (25.9)       
39,763 (23.5)       
40,480 (23.9)        
35,567 (21.0)       
29,967 (17.7)      
23,555 (13.9)      
5,178 (16.2)        
6,193 (19.3)        
6,574 (20.5)      
6,936 (21.6)        
7,174 (22.4)      
5,951 (20.3)       
6,436 (22.0)       
6,340 (21.6)        
5,807 (19.8)       
4,782 (16.3)     
4,319 (21.9)      
4,448 (22.6)        
4,142 (21.0)     
3,696 (18.7)     
3,119 (15.8)     
 
Comorbidities 
0 comorbidity 
1-2 
comorbidities 
3+ comorbidities 
 
644,457 (86.0) 
89,336 (11.9) 
15,658 (2.1)                     
 
173,959 (90.6)        
16,022 (8.4)        
2,007 (1.1)       
 
133,908 (83.8)        
21,904 (13.7)        
3,970 (2.5)       
 
11,290 (92.2)        
849 (6.9)        
106 (0.9)       
 
131,650 (78.0)        
30,984 (18.4)        
6,228 (3.7)       
 
143,572 (84.8)        
22,116 (13.1)        
3,644 (2.2)       
 
25,786 (80.4)        
5,207 (16.2)     
1,062 (3.3)      
 
26,096 (89.0)        
2,841 (9.7)       
379 (1.3)      
 
17,507 (88.8)       
1,927 (9.8)       
290 (1.5)       
 
Routes to 
diagnosis 
Screen detected 
Two week wait  
Emergency 
DCO 
 
62,098 (8.3)        
218,648 (29.2)  
154,916 (20.7) 
 3,442 (0.5)                 
53,002 (27.6)       
80,773 (42.1)        
8,675 (4.5)         
608 (0.3) 
7,595 (4.8)        
42,197 (26.4)        
39,174 (24.5)       
737 (0.5)         
2,941 (24.0)      
2,005 (16.4)       
1,380 (11.3)       
16 (0.13)       
39,735 (23.5)        
62,931 (37.3)        
1,200 (0.7)        
47,947 (28.3)       
15,388 (9.1)        
341 (0.2)        
7,309 (22.8)      
10,191 (31.8)        
191 (0.6)         
6,838 (23.3)      
8,838 (30.2)       
176 (0.6)       
191 (1.0)        
12,196 (61.8)        
86 (0.4)         
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   A) Emergency Presentation   B) Death Certificate Only (DCO) 
 Urban Rural <= 10  10.1 – 20  20.1 – 30  Over 30  Urban Rural <= 10 10.1 – 20  20.1 – 30  Over 30  
Breast 1 
0.77**   
(0.73-0.82) 1 
0.96  
(0.89-1.04) 
1.34**  
(1.11-1.61) 
1.60**  
(1.26-2.04) 1 
1.12 
(0.93-1.35) 1 
1.63**  
(1.24-2.16) 
4.95**  
(3.14-7.80) 
8.51**  
(5.20-13.92) 
Colorectal 1 
0.85**  
(0.83-0.87) 
 
1 
0.92**  
(0.89-0.96) 
1.11  
(0.99-1.23) 
1.51**  
(1.31-1.74)    1 
1.05 
(0.88-1.25) 1 
1.25  
(0.94-1.64) 
1.74  
(0.90-3.37) 
7.00** 
(4.40-11.14) 
Cervical 1 
0.94 
(0.80-1.09) 1 
0.98  
(0.80-1.19)  
1.49 
(0.91-2.45) 
0.75 
(0.34-1.63)          1 
0.73 
(0.17-3.21)  
n/a n/a n/a 
Lung 1 
0.90** 
(0.87-0.92) 
 
1 
1.02  
(0.98-1.06) 
1.04  
(0.94-1.16) 
1.11  
(0.98-1.27) 1 
0.94 
(0.81-1.10) 1 
1.10  
(0.87-1.39) 
2.46**  
(1.57-3.85) 
2.44** 
(1.37-4.33) 
Prostate 1 
0.79** 
(0.76-0.83) 1 
0.92**  
(0.87-0.98) 
1.11  
(0.95-1.29) 
1.71**  
(1.42-2.08) 1 
1.03 
(0.80-1.32) 1 
1.44*  
(1.02-2.03) 
2.34*  
(1.10-4.98) 
6.16**  
(3.03-12.51) 
Stomach 1 
0.83** 
(0.78-0.89 
 
1 
0.95  
(0.87-1.04) 
1.15 
(0.90-1.46) 
1.05  
(0.75-1.49) 1 
1.27 
(0.90-1.80) 1 
2.38**  
(1.50-3.80) 
2.80  
(0.88-8.89) 
11.73**  
(5.05-27.22) 
Ovarian 1 
0.93* 
(0.87-0.99) 
 
1 
0.92  
(0.84-1.00) 
1.21  
(0.97-1.52) 
1.59**  
(1.19-2.13) 1 
1.11 
(0.78-1.59) 1 
1.30  
(0.76-2.24) 
1.34  
(0.33-5.44) 
3.62*  
(1.14-11.52) 
Brain 1 
0.95 
(0.89-1.03) 
 
1 
1.02  
(0.92-1.13) 
0.96  
(0.76-1.21) 
1.03 
(0.77-1.38) 1 
0.78 
(0.45-1.36) 1 
1.36  
(0.64-2.90) 
2.15  
(0.52-8.92) 
1.60 
 (0.22-11.64) 
   C) Two week wait (TWW)   D) Screening 
 Urban Rural <= 10  10.1 – 20  20.1 – 30  Over 30  Urban Rural <= 10 10.1 – 20  20.1 – 30  Over 30  
Breast 1 
0.97**  
(0.94-0.98) 1 
0.91**  
(0.88-0.94) 
0.86**  
(0.78-0.94) 
0.84**  
(0.74-0.96) 1 
1.22** 
(1.19-1.25) 
 
1 
1.15** 
 (1.11-1.19) 
0.98 
(0.89-1.08) 
0.72**  
(0.62-0.84) 
Colorectal 1 
1.16** 
(1.13-1.19) 
 
1 
1.03  
(0.99-1.07) 
0.97  
(0.86-1.08) 
0.69**  
(0.58-0.81) 1 
1.16** 
(1.10-1.22) 1 
1.21** 
 (1.13-1.30) 
1.00  
(0.80-1.26) 
0.45**  
(0.29-0.70) 
Cervical 1 
1.09 
(0.96-1.24) 
 
1 
0.99  
(0.84-1.18) 
0.70  
(0.41-1.20) 
0.69  
(0.36-1.35)      1 
0.93 
(0.83-1.04) 1 
1.07  
(0.92-1.23)  
0.83  
(0.54-1.29) 
1.06  
(0.64-1.76) 
Lung 1 
1.20** 
(1.17-1.24) 
 
1 
1.04  
(1.00-1.08) 
0.96 
 (0.86-1.09) 
0.79** 
(0.67- 0.92) 1      
Prostate 1 
1.14** 
(1.11-1.17) 
1 
 
1.03  
(0.99-1.06) 
0.95  
(0.86-1.05) 
0.71**  
(0.60-0.84) 1      
Stomach 1 
1.18** 
(1.10-1.26) 
 
1 
1.04  
(0.95-1.14) 
0.96  
(0.73-1.25) 
0.88  
(0.60-1.31) 1      
Ovarian 1 
1.21** 
(1.14-1.29) 
 
1 
1.11*  
(1.01-1.21) 
0.72*  
(0.55-0.95) 
0.54*  
(0.36-0.80) 1      
Brain 1 
1.42* 
(1.03-1.95) 
 
1 
1.40  
(0.93-2.12 
0.98  
(0.31-3.09) 
1.46  
(0.46-4.62) 1      
Table 5.2 - (A,B,C,D) – Association between travel times to GP, rurality and A) emergency presentations B) DCO C) TWW and D) Screen detected, for breast, 
colorectal, cervical, lung, prostate, stomach, ovarian and brain cancer. Unadjusted models. Results are reported as odds ratios OR (95% CI), **p<0.01, *p<0.05 
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A) Emergency Presentation 
Travel Time to the GP (minutes) 
 
Age 
 
Female 
 
Deprivation quintile 
 
Number of comorbidities 
 <= 10  10.1 – 20  20.1 – 30  Over 30    1 least 2 3 4 5 most 0  1 - 2  3+  
Breast 1 
1.13**  
(1.05-1.22) 
1.58**  
(1.30-1.92) 
1.81**  
(1.41-2.34) 
1.07** 
(1.07-1.07)  1 
1.09*  
(1.01-1.17) 
1.16**  
(1.08-1.25) 
1.40**  
(1.30-1.51) 
1.72**  
(1.59-1.85) 1 
1.20**  
(1.12-1.28) 
2.12**  
(1.86-2.41) 
Colorectal 1 
1.00  
(0.96-1.05) 
1.22**  
(1.09-1.36) 
1.68**  
(1.45-1.94)    
1.02**  
(1.02-1.02) 
1.30**  
(1.27-1.33) 1 
1.07**  
(1.02-1.11) 
1.15** 
(1.10-1.19) 
1.29** 
(1.24-1.34) 
1.55**  
(1.49-1.61) 1 
1.25** 
(1.21-1.29) 
1.75**  
(1.64-1.88) 
Cervical 1 
1.12  
(0.90-1.38) 
1.83*  
(1.07-3.11) 
0.84  
(0.37-1.89) 
1.05**  
(1.04-1.05)  1 
1.19  
(0.94-1.52) 
1.54** 
(1.23-1.94) 
1.58** 
(1.26-1.97) 
1.75**  
(1.41-2.17) 1 
1.07  
(0.88-1.32) 
1.76*  
(1.12-2.75) 
Lung 
 
1 
1.08**  
(1.04-1.12) 
1.13*  
(1.01-1.25) 
1.19*  
(1.04-1.36) 
1.03**  
(1.03-1.03) 
1.08**  
(1.06-1.10) 1 
1.06**  
(1.02-1.10) 
1.13** 
(1.09-1.17) 
1.22** 
(1.18-1.27) 
1.34**  
(1.29-1.39) 1 
1.23**  
(1.20-1.27) 
1.79**  
(1.70-1.89) 
Prostate 1 
1.00  
(0.94-1.06) 
1.26**  
(1.07-1.47) 
1.86** 
(1.52-2.29) 
1.09**  
(1.09-1.10)  1 
1.08*  
(1.0 -1.14) 
1.15** 
(1.09-1.22) 
1.31** 
(1.24-1.39) 
1.62**  
(1.52-1.71) 1 
1.42**  
(1.36-1.49) 
2.24**  
(2.05-2.44) 
Stomach 
 
1 
1.04  
(0.95-1.14) 
1.29*  
(1.01-1.65) 
1.15 
(0.81-1.64) 
1.03**  
(1.03-1.04) 
1.27**  
(1.20-1.34) 1 
1.04  
(0.9 -1.14) 
1.10*  
(1.01-1.20) 
1.27** 
(1.16-1.38) 
1.51**  
(1.39-1.64) 1 
1.28**  
(1.20-1.37) 
1.88**  
(1.65-2.14) 
Ovarian 
 
1 
0.98  
(0.90-1.07) 
1.30*  
(1.03-1.64) 
1.64**  
(1.22-2.21) 
1.03**  
(1.03-1.03)  1 
1.08  
(0.99-1.18) 
1.06  
(0.98-1.16) 
1.26** 
(1.15-1.37) 
1.34**  
(1.23-1.47) 1 
1.23**  
(1.13-1.34) 
1.98**  
(1.59-2.46) 
Brain 
 
1 
1.05  
(0.95-1.17) 
1.04  
(0.82-1.32) 
1.08  
(0.80-1.44) 
1.02**  
(1.01-1.02) 
1.14**  
(1.07-1.22) 1 
1.04  
(0.95-1.14) 
1.07  
(0.97-1.18) 
1.19** 
(1.08-1.32) 
1.42**  
(1.28-1.58) 1 
0.85**  
(0.76-0.95) 
1.16  
(0.87-1.54) 
B) Death Certificate Only 
Travel Time to the GP (minutes) Age Female Deprivation quintile Number of comorbidities  
 <= 10  10.1 – 20  20.1 – 30  Over 30     1 least 2 3 4 5 most 0  1 - 2  3+  
Breast 1 
1.84**  
(1.39-2.45) 
5.13**  
(3.18-8.27) 
8.31**  
(4.91-14.08) 
1.19**  
(1.17-1.20)  1 
1.07  
(0.79-1.46) 
0.89  
(0.65-1.24) 
1.23  
(0.90-1.68) 
1.08  
(0.76-1.53) 1 
0.66**  
(0.49-0.89) 
0.94  
(0.53-1.70)       
Colorectal 1 
1.36*  
(1.02-1.79) 
1.80  
(0.92-3.51) 
7.29**  
(4.53-11.75)    
1.12**  
(1.11-1.13) 
1.48**  
(1.23-1.78) 1 
0.81  
(0.61-1.06) 
0.91  
(0.70-1.19) 
0.88  
(0.66-1.16) 
0.94  
(0.70-1.26) 1 
1.01  
(0.8-1.28) 
0.61  
(0.33-1.11) 
Cervical  n/a n/a n/a n/a   n/a n/a n/a n/a  n/a n/a 
Lung 1 
1.15  
(0.91-1.45) 
2.66**  
(1.69-4.16) 
2.47**  
(1.39-4.40) 
1.07**  
(1.06-1.07) 
1.05  
(0.9 -1.20) 1 
1.25  
(0.97-1.60) 
0.98  
(0.76-1.27) 
1.18  
(0.92-1.51) 
1.43** 
(1.13-1.80) 1 
0.71**  
(0.59-0.86) 
0.69*  
(0.47-1.00) 
Prostate 1 
1.46*  
(1.03-2.08) 
2.29*  
(1.0 -4.92) 
4.42**  
(2.11-9.26) 
1.22**  
(1.20-1.24)  1 
0.94  
(0.67-1.32) 
0.63*  
(0.43-0.92) 
0.89  
(0.61-1.29) 
0.88  
(0.58-1.32) 1 
1.21  
(0.91-1.63) 
0.98  
(0.53-1.80) 
Stomach 1 
2.54**  
(1.58-4.07) 
2.84  
(0.89-9.13) 
10.58**  
(4.45-25.12) 
1.08**  
(1.06-1.10) 
1.91**  
(1.33-2.74) 1 
0.80  
(0.46-1.38) 
0.60  
(0.33-1.07) 
0.97  
(0.58-1.64) 
0.63  
(0.35-1.13) 1 
0.85  
(0.53-1.37) 
0.38  
(0.09-1.56) 
Ovarian 1 
1.45  
(0.84-2.53) 
1.21  
(0.29-5.02) 
3.17  
(0.98-10.35) 
1.13**  
(1.11-1.16)  1 
1.29  
(0.73-2.29) 
1.08  
(0.60-1.95) 
1.18  
(0.65-2.14) 
1.33  
(0.71-2.50) 1 
0.93  
(0.55-1.54) 
1.26  
(0.46-3.48) 
Brain 1 
1.52  
(0.71-3.25) 
2.42  
(0.58-10.11) 
1.71  
(0.23-12.52) 
1.02*  
(1.00-1.03) 
0.92  
(0.54-1.57) 1 
2.05  
(0.71-5.91) 
3.32*  
(1.21-9.08) 
2.94*  
(1.03-8.40) 
3.59*  
(1.25-10.28) 1 
1.23  
(0.58-2.65) 
0.89  
(0.1 -6.58) 
Table 5.3 - (A & B) – Association between travel to the GP and A) emergency presentations B) DCO, for breast, colorectal, cervical, lung, prostate, stomach, ovarian 
and brain cancer. Models are adjusted for age, gender (where applicable), deprivation and comorbidity. Results are reported as odds ratios (95% CI), **p<0.01, *p<0.05 
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B)       Two Week Wait  
Travel Time to the GP (minutes) Age Female Deprivation (quintile) Number of comorbidities 
 <= 10  10.1 – 20  20.1 – 30  Over 30     1 least 2 3 4 5 most 0  1 - 2  3+  
Breast 1 
0.94**  
(0.91-0.97) 
0.88**  
(0.81-0.97) 
0.87*  
(0.77-0.99) 
1.01**  
(1.01-1.01)  1 
1.11**  
(1.08-1.14) 
1.15**  
(1.12-1.18) 
1.19**  
(1.15-1.22) 
1.23**  
(1.19-1.27) 1 
1.08**  
(1.04-1.12) 
0.99  
(0.90-1.09) 
Colorectal 1 
1.01  
(0.97-1.05) 
0.94  
(0.84-1.05) 
0.68**  
(0.58-0.80) 
1.00  
(1.00-1.00) 
0.87** 
(0.85-0.89) 1 
1.03  
(1.00-1.07) 
1.04*  
(1.00-1.07) 
0.98  
(0.95-1.02) 
0.89**  
(0.85-0.92) 1 
0.66**  
(0.64-0.69) 
0.43**  
(0.39-0.47) 
Cervical 1 
1.03  
(0.8 -1.23) 
0.73  
(0.41-1.28) 
0.72  
(0.36-1.43) 
1.04**  
(1.04-1.04)  1 
1.12  
(0.93-1.34) 
1.03  
(0.86-1.24) 
1.20*  
(1.01-1.43) 
1.09  
(0.92-1.30) 1 
0.76**  
(0.63-0.93) 
0.65  
(0.40-1.06) 
Lung 1 
0.99  
(0.95-1.04) 
0.91  
(0.81-1.02) 
0.74**  
(0.63-0.86) 
0.98**  
(0.98-0.98) 
0.96** 
(0.93-0.98) 1 
1.04  
(0.99-1.08) 
1.01  
(0.96-1.05) 
0.95**  
(0.91-0.99) 
0.85**  
(0.82-0.89) 1 
0.55**  
(0.53-0.57) 
0.32**  
(0.30-0.35) 
Prostate 1 
1.01  
(0.93-1.05) 
0.93  
(0.84-1.03) 
0.70**  
(0.60-0.83) 
1.01**  
(1.01-1.01)  1 
1.06**  
(1.03-1.10) 
1.04*  
(1.01-1.08) 
1.02  
(0.98-1.05) 
0.94**  
(0.91-0.98) 1 
0.72**  
(0.69-0.74) 
0.49**  
(0.45-0.54) 
Stomach 1 
1.00  
(0.91-1.10) 
0.92  
(0.70-1.22) 
0.84  
(0.56-1.25) 
0.99**  
(0.99-1.00) 
0.71** 
(0.67-0.76) 1 
1.04  
(0.95-1.14) 
1.07  
(0.98-1.17) 
0.95  
(0.87-1.04) 
0.92*  
(0.84-1.00) 1 
0.58**  
(0.54-0.63) 
0.35**  
(0.28-0.42) 
Ovarian 1 
1.06 
(0.97-1.17) 
0.70*  
(0.53-0.92) 
0.53**  
(0.35-0.78) 
1.00*  
(1.00-1.00)  1 
1.06  
(0.97-1.15) 
1.03  
(0.94-1.12) 
0.90*  
(0.82-0.98) 
0.80**  
(0.73-0.88) 1 
0.58**  
(0.52-0.65) 
0.35**  
(0.25-0.50) 
 
Brain 1 
1.35  
(0.89-2.04) 
0.93  
(0.29-2.92) 
1.43  
(0.45-4.51) 
1.00  
(1.00-1.01) 
0.98  
(0.73-1.32) 1 
1.08  
(0.71-1.63) 
0.89  
(0.57-1.38) 
0.82  
(0.51-1.32) 
0.84  
(0.51-1.38) 1 
0.63  
(0.35-1.14) n/a 
 
 
A) Screen detected 
Travel Time to the GP (minutes) Age Female Deprivation (quintile) Number of comorbidities  
 <= 10  10.1 – 20  20.1 – 30  Over 30    1 least 2 3 4 5 most 0  1 - 2  3+  
Breast 1 
1.09**  
(1.05-1.12) 
0.92  
(0.84-1.02) 
0.68**  
(0.59-0.79)    
0.99**  
(0.99-0.99)  1 
0.92**  
(0.89-0.95) 
0.89** 
(0.86-0.92) 
0.80** 
(0.78-0.83) 
0.72**  
(0.69-0.74) 1 
0.68**  
(0.66-0.71) 
0.37**  
(0.32-0.43) 
Colorectal 
 
1 
1.11**  
(1.03-1.20) 
0.89  
(0.71-1.12) 
0.37**  
(0.24-0.58) 
0.97**  
(0.97-0.97) 
0.60**  
(0.57-0.63) 1 
0.96  
(0.90-1.03)    
0.92*  
(0.86-0.99)  
0.82** 
(0.76-0.88)   
0.67**  
(0.62-0.73)   1 
0.70**  
(0.65-0.76) 
0.37**  
(0.29-0.48) 
Cervical 
 
1 
1.02  
(0.88-1.19) 
0.67  
(0.42-1.06) 
0.97  
(0.57-1.65) 
0.95**  
(0.94-0.95)  1 
0.87  
(0.75-1.02) 
0.81*  
(0.69-0.94) 
0.70** 
(0.60-0.82) 
0.75**  
(0.65-0.87) 1 
0.82  
(0.65-1.03) 
1.10  
(0.56-2.14) 
Table 5.4 - (A & B) – Association between travel to the GP and A) screen-detected B) TWW, for breast, colorectal, cervical, lung, prostate, stomach, ovarian and brain 
cancer. Models are adjusted for age, gender (where applicable), deprivation and comorbidity. Results are reported as odds ratios (95% CI), **p<0.01, *p<0.05 
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A) Death Certificate Only 
Rural – urban status Age Female Deprivation Comorbidity 
 Urban Rural   1 least 2 3 4 5 most 0  1 - 2  3+  
Breast 1 
1.20  
(0.99-1.47) 
1.15**  
(1.14-1.16)     1 
1.01   
(0.79-1.30) 
0.85  
(0.66-1.10) 
1.09  
(0.85-1.41) 
1.04  
(0.78-1.38)  1 
0.55**  
(0.42-0.72) 
0.72  
(0.41-1.25) 
Colorectal 1 
1.09  
(0.91-1.30) 
1.09**  
(1.08-1.10) 
1.37**  
(1.18-1.59) 1 
0.83  
(0.66-1.04) 
0.93  
(0.75-1.16) 
0.95  
(0.76-1.20) 
0.94  
(0.74-1.21) 1 
0.71**  
(0.57-0.88) 
0.45**  
(0.25-0.79) 
Cervical n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Lung 1 
0.96  
(0.82-1.13) 
1.05**  
(1.05-1.06) 
1.00  
(0.89-1.12) 1 
1.07  
(0.87-1.31) 
0.91  
(0.74-1.12) 
1.06  
(0.87-1.29) 
1.23*  
(1.02-1.50) 1 
0.52**  
(0.43-0.62) 
0.57**  
(0.41-0.80) 
Prostate 1 
1.00  
(0.77- 1.30) 
1.21**  
(1.19-1.22)  1 
0.96  
(0.71-1.31) 
0.72  
(0.52-1.01) 
0.83  
(0.59-1.17) 
0.92  
(0.64-1.33) 1 
1.00  
(0.76-1.31) 
0.74  
(0.41-1.37) 
Stomach 1 
1.30  
(0.91-1.87) 
1.05**  
(1.03-1.06) 
1.78**  
(1.33-2.38) 1 
0.77  
(0.48-1.22) 
0.72  
(0.45-1.15) 
0.91  
(0.58-1.41)  
0.82  
(0.52-1.30) 1 
0.54**  
(0.34-0.85) 
0.25*  
(0.06-1.01) 
Ovarian 1 
1.08  
(0.74-1.57) 
1.10**  
(1.09-1.12)  1 
1.51  
(0.95-2.42) 
1.01  
(0.61-1.67) 
1.12  
(0.67-1.86) 
1.39  
(0.82-2.36) 1 
0.81  
(0.51-1.27) 
0.90  
(0.33-2.47) 
 
Brain 1 
1.01  
(0.98-1.04) 
1.02*  
(1.00-1.03) 
0.92  
(0.54-1.56) 1 
2.08  
(0.72-6.00) 
3.31*  
(1.21-9.04) 
2.87* 
 (1.01-8.16) 
3.46*  
(1.21-9.89) 1 
1.23  
(0.57-2.64) 
0.88  
(0.12-6.51) 
B) Emergency Presentation 
Rural – urban status Age Female Deprivation Comorbidity 
 Urban Rural   1 least 2 3 4 5 most 0  1 - 2  3+  
Breast 1 
0.88**  
(0.82-0.93) 
1.07**  
(1.07-1.07)  1 
1.09*  
(1.01-1.18) 
1.06** 
(1.08-1.25) 
1.36** 
(1.26-1.16) 
1.62**  
(1.51-1.75) 1 
1.20**  
(1.13-1.28) 
2.08**  
(1.84-2.36) 
Colorectal 1 
0.93**  
(0.90-0.96) 
1.02**  
(1.02-1.02) 
1.29**  
(1.27-1.33) 1 
1.07**  
(1.03-1.11) 
1.14** 
(1.10-1.19) 
1.28** 
(1.23-1.33) 
1.50**  
(1.45-1.56) 1 
1.25**  
(1.21-1.29) 
1.74**  
(1.63-1.86) 
Cervical 1 
1.00  
(0.85-1.19) 
1.04**  
(1.04-1.05)  1 
1.23  
(0.98-1.56) 
1.53** 
(1.23-1.92) 
1.60** 
(1.29-1.99) 
1.78**  
(1.44-2.21) 1 
1.07  
(0.88-1.31) 
1.71*  
(1.10-2.66) 
Lung 1 
0.96**  
(0.93-0.99) 
1.03**  
(1.03-1.03) 
1.08**  
(1.05-1.10) 1 
1.07**  
(1.03-1.11) 
1.13** 
(1.09-1.17) 
1.21** 
(1.17-1.25) 
1.32**  
(1.28-1.37) 1 
1.23*  
(1.2 -1.26) 
1.79**  
(1.69-1.89) 
Prostate 1 
0.87**  
(0.83-0.91) 
1.09**  
(1.09-1.10  1 
1.08**  
(1.03-1.14) 
1.14** 
(1.08-1.21) 
1.27** 
(1.20-1.34) 
1.54**  
(1.46-1.64) 1 
1.42**  
(1.36-1.48) 
2.21**  
(2.03-2.40) 
Stomach 1 
0.93*  
(0.87-0.99 
1.03**  
(1.03-1.03) 
1.26**  
(1.20 -1.33) 1 
1.04  
(0.95-1.13) 
1.11*  
(1.02-1.20) 
1.24** 
(1.14-1.34) 
1.47**  
(1.35-1.60) 1 
1.30**  
(1.22-1.38) 
1.87**  
(1.65-2.13) 
Ovarian 1 
0.95 
(0.89-1.02) 
1.03**  
(1.03-1.03)  1 
1.08  
(0.99-1.17) 
1.07  
(0.99-1.16) 
1.23** 
(1.14-1.34) 
1.31**  
(1.20-1.43) 1 
1.25**  
(1.15-1.36) 
1.97**  
(1.60-2.44) 
Brain 1 
0.99  
(0.91-1.06) 
1.02**  
(1.01-1.02) 
1.12**  
(1.05-1.19) 1 
1.04  
(0.95-1.14) 
1.06  
(0.97-1.16) 
1.19** 
(1.08-1.31) 
1.41**  
(1.27-1.56) 1 
0.84**  
(0.75-0.93) 
1.11  
(0.85-1.46) 
Table 5.5 - (A & B) – Association between rural – urban status and A) emergency presentations B) DCO, for breast, colorectal, cervical, lung, prostate, 
stomach, ovarian and brain cancer. Models are adjusted for age, gender (where applicable), deprivation and comorbidity OR (95% CI), **p<0.01, *p<0.05 
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A) Screening 
Rural – urban status Age Female Deprivation Comorbidity 
 Urban Rural   1 least 2 3 4 5 most 0  1 - 2  3+  
Breast 1 
1.15**  
(1.12-1.18) 
0.99**  
(0.99- 0.99)  1 
0.91** 
(0.88-0.94) 
0.89** 
(0.86-0.91) 
0.82** 
(0.79-0.84) 
0.74** 
(0.71-0.76) 1 
0.69** 
(0.66-0.72) 
0.37** 
(0.32-0.42) 
Colorectal 1 
1.08*  
(1.02-1.14) 
0.97**  
(0.97-0.97) 
0.60**  
(0.57-0.63) 1 
0.95  
(0.89-1.02) 
0.90**  
(0.84-0.97)  
0.82** 
(0.76-0.88) 
0.68** 
(0.63-0.74)      1 
0.71** 
(0.65-0.77) 
0.37** 
(0.29-0.47) 
Cervical 1 
0.93  
(0.82-1.06) 
0.95**  
(0.94-0.95)  1 
0.89  
(0.77-1.04) 
0.81** 
(0.69-0.94) 
0.71** 
(0.61-0.82) 
0.76** 
(0.66-0.88) 1 
0.83  
(0.66-1.03) 
1.03  
(0.53-2.01) 
 
 
B) Two Week Wait 
Rural – urban status Age Female Deprivation Comorbidity 
 Urban Rural   1 least 2 3 4 5 most 0  1 - 2  3+  
Breast 1 
0.99  
(0.97-1.01) 
1.01**  
(1.01-1.01)  1 
1.11** 
(1.08-1.14) 
1.15** 
(1.12-1.18) 
1.19** 
(1.16-1.23) 
1.23** 
(1.19-1.27) 1 
1.08** 
(1.05-1.12) 
0.99  
(0.90-1.08) 
Colorectal 1 
1.12**  
(1.09-1.15) 
1.00  
(1.00-1.00) 
0.87**  
(0.85-0.89) 1 
1.01  
(0.99-1.06) 
1.04*  
(1.00-1.08) 
0.99  
(0.96-1.03) 
0.91** 
(0.88-0.95) 1 
0.66** 
(0.64-0.69) 
0.43** 
(0.40-0.47) 
Cervical 1 
1.05  
(0.92-1.21) 
1.04**  
(1.04-1.04)  1 
1.12  
(0.94-1.35) 
1.06  
(0.88-1.26) 
1.23*  
(1.03-1.46) 
1.12  
(0.94-1.33) 1 
0.76** 
(0.63-0.91) 
0.71  
(0.44-1.13) 
Lung 1 
1.15**  
(1.11-1.18) 
0.98**  
(0.98-0.98) 
0.96**  
(0.94-0.98) 1 
1.02  
(0.99-1.07 
1.01   
(0.97-1.05) 
0.97  
(0.94-1.01) 
0.89** 
(0.85-0.92) 1 
0.56** 
(0.54-0.58) 
0.33** 
(0.30-0.36) 
Prostate 1 
1.12**  
(1.09-1.15) 
1.01**  
(1.00-1.01)  1 
1.05** 
(1.02-1.09) 
1.04*  
(1.00-1.07) 
1.03  
(0.99-1.06) 
0.98  
(0.94-1.02) 1 
0.72** 
(0.70-0.74) 
0.50** 
(0.46-0.54) 
Stomach 1 
1.13**  
(1.06-1.22) 
1.00**  
(1.00-1.00) 
0.71**  
(0.67-0.75) 1 
1.05  
(0.96-1.15) 
1.07  
(0.98-1.16) 
0.99  
(0.90-1.08) 
0.95  
(0.87-1.04) 1 
0.58**  
(0.53-0.63) 
0.34** 
(0.28-0.42) 
Ovarian 1 
1.15**  
(1.07-1.23) 
1.00**  
(1.00-1.00)  1 
1.04  
(0.96-1.13) 
1.03  
(0.95-1.12) 
0.93  
(0.85-1.02) 
0.83** 
(0.76-0.91) 1 
0.59** 
(0.53-0.65) 
0.36** 
(0.26-0.50) 
 
Brain 1 
1.35  
(0.97-1.88) 
1.00  
(0.99-1.01) 
0.99  
(0.74-1.32) 1 
1.11  
(0.74-1.67) 
0.94  
(0.61-1.45) 
0.82  
(0.51-1.31) 
0.97  
(0.60-1.59) 1 
0.67  
(0.38-1.18) n/a 
Table 5.6 - (A & B) -  Association between rural – urban status and A) screening B) Two Week Wait, for breast, colorectal, cervical, lung, prostate, stomach, 
ovarian and brain cancer. Models are adjusted for age, gender (where applicable), deprivation and comorbidity, OR (95% CI), **p<0.01, *p<0.05 
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5.4  Conclusions 
This study provides new evidence on how geographical access to GPs in England is associated 
with the routes that lead to a cancer diagnosis. Earlier diagnosis is recognised as an important 
approach to improving cancer survival (Cancer Research UK 2014), and the role of GPs is 
central because majority of cancer patients will present their symptoms to primary care (NICE 
2015). Across the eight cancer sites studied, longer travel to the patients’ GP significantly 
increased the likelihood of having a cancer diagnosis through routes that are associated with 
poor outcomes such as emergency or death certificate only pathways. Conversely, longer travel 
significantly decreased the likelihood of obtaining a diagnosis following routes that are 
associated with good prognosis such as screening or two week wait. When rural and urban 
patients were compared, the opposite was apparent; patients living in rural areas were more 
likely to obtain diagnosis through a route of good prognosis and less likely to have their cancer 
diagnosed via emergency admissions. Fitting an interaction term suggested that for some 
cancer sites, travel time may have a different association with the outcomes in rural compared 
to urban areas.  
 
These findings may support efforts such as the National Awareness and Early Diagnosis 
Initiative (NAEDI) work on achieving earlier presentation (Cancer Research UK 2016d). 
Efforts to improve earlier diagnosis in cancer should take consideration of geographical 
barriers that may impede implementation. Likewise, GPs should be vigilant of accessibility 
issues that some of their patients may face, as these are likely to determine receipt of earlier 
diagnosis. 
 
The findings presented in this study respond to requests for evidence to establish the role of 
access in explaining variations in the mode of diagnosis (Lyratzopoulos et al. 2015; Wallace et 
al. 2014). To our knowledge, this is the first study to simultaneously investigate four different 
routes to diagnosis and their association with geographical access to GPs. Previous studies have 
focused on access to hospital or screening sites or have examined single routes to diagnosis 
(Cowling et al. 2013; Jensen et al. 2013; Maheswaran et al. 2006). Two previous studies 
looking at access to screening and hospital sites showed that poor access was associated with 
poor participation in breast cancer screening programmes (Jensen et al. 2013; Maheswaran et 
al. 2006). Both studies used a smaller regional population than our study, so it is likely that 
their sample was more geographically homogenous. They also both estimated geographical 
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access using road distance rather than travel time; the latter is a better measure of access 
because it is closest to what patients experience (Lovett et al. 2002). Another study found 
longer travel times to hospital increased the odds of post mortem diagnosis (A. P. Jones et al. 
2010). Similar to the findings from Chapter Four, longer travel moderated the association 
between rurality and emergency presentations for breast, colorectal, prostate and stomach 
cancer. In these cancer sites, longer travel increased the odds of an emergency presentations in 
both rural and urban areas, but the association was stronger in urban compared to rural areas. 
This supports the view that rural and urban patients may perceive geographical inaccessibility 
differently (Field & Briggs 2001). 
 
These results suggest that travel to the GP may also influence patients’ engagement with health 
services in general, and this is not limited to services offered by the GP. As an example, poor 
access to the GP may impede the uptake of services such as colorectal and breast cancer 
screening that are not offered by GPs.  Similar to what other studies have reported (Abel et al. 
2015; McPhail et al. 2013; Wallace et al. 2014), this study found that women were more likely 
to have a diagnosis following a route associated with poor prognosis. This might be because 
women are reportedly more fearful and experience more discomfort when undergoing 
investigations such as colonoscopies (Farraye et al. 2004; Kim et al. 2000). 
 
Patients recorded to have the longest journey to their GP may indicate disconnection from 
primary care, such as failure to register with a GP after relocation. Although only 0.7 percent 
of the sample travelled longer than 30 minutes to see their GP, the poor outcomes amongst 
these patients is concerning. The magnitude of apparent effect for risk of diagnosis at death is 
particularly alarming; tenfold in stomach cancer (OR 10.58, p<0.01), eightfold in breast cancer 
(OR 8.31, p<0.01), sevenfold in colorectal cancer (OR 7.29, p<0.01) and over fourfold in 
prostate cancer (OR 4.42, p<0.01). 
 
It is likely that the prospect of longer travel influences how patients interact with primary care 
for a cancer diagnosis. Geographical inaccessibility may discourage engagement with the 
health services, and so decrease the likelihood of health seeking behaviour such as participation 
in screening. Poor access may also reduce the likelihood of reporting symptoms that may be 
related to cancer (Emery et al. 2013), consequently increasing emergency presentations or 
death at diagnosis. It is also likely that poor access may influence GPs’ decisions to refer for 
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further investigation; previous studies have shown that distance to hospital may be one of the 
things GPs consider when making referrals (Haynes & Bentham 1982; Sladden & Thomson 
1998). Conversely, it is plausible that when GPs do make urgent referrals, patients delay 
attending appointments due to barriers in access. 
 
Living in a rural area increased the likelihood of having a cancer diagnosis via screening or a 
TWW referral, but decreased the likelihood of emergency diagnosis. One explanation might 
be that rural GPs offer better continuity of care; a concept noted as one of the most essential 
component of general practice (Royal College of General Practitioners 2016). Continuity of 
care marks the extent to which patients experience an ongoing relationship with a preferred GP 
and how GPs assist patients with navigating complex health care systems (King’s Fund 2010b; 
Royal College of General Practitioners 2016). This has been shown to reduce emergency 
admissions (Christakis et al. 2001; Menec et al. 2006) and to increase screening participation 
(Flocke et al. 1998). Geographical variations of continuity have been reported; patients living 
outside urban areas are more likely to indicate preference for a specific clinician (King’s Fund 
2010b).  
 
Preference of a specific GP can however have the limitation of creating a barrier to alternative 
perspectives or second opinions from other clinicians (King’s Fund 2010b), and this may in 
some cases introduce delays in the diagnostic process (Ridd et al. 2015; King’s Fund 2010b). 
A study investigating the association between continuity of care, time to referral and time to 
diagnosis gave different findings for different cancer sites (Ridd et al. 2015). Patient–doctor 
continuity in the 24 months before diagnosis was associated with a slightly later diagnosis (time 
delay to diagnosis) of colorectal cancer, but not of breast or lung cancer. Conversely, patient-
doctor continuity after the index consultation reduced the time to referral in breast cancer 
patients only (Ridd et al. 2015). The effect of continuity of care on the diagnostic process in 
cancer in the UK remains to be fully explored. Another more probably explanation for higher 
rates of emergency presentations amongst urban patients is that these patients are more likely 
to use emergency services because most of the close proximity to these services (Magnusson 
1980). Additionally, urban patients have been shown to have a more ‘detached’ and 
‘consumerist’ approach which can manifest in using a range of health services and by switching 
and shopping around for the most suitable services (Farmer et al. 2006). 
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The most recent strategy on cancer has identified earlier diagnosis and narrowing inequalities 
as a key mechanism to improving overall cancer survival rates in England (Independent Cancer 
Taskforce 2015). The strategy has set recommendations with the aim of increasing ten year 
survival for an additional 30,000 patients by 2020, of which 11,000 will be achieved through 
earlier diagnosis (Independent Cancer Taskforce 2015). Furthermore, the strategy has issued a 
call for evaluating the impact of cancer outcomes on patients living different distances from a 
cancer centre (Independent Cancer Taskforce 2015). Our findings indicate that this call should 
also be extended to primary care. The gatekeeping role of GPs means they control access to 
other services and therefore it is likely that poor outcomes related to access observed in 
secondary care may have their origins from poor primary care access (Bentham & Haynes 
1985; Carr-Hill et al. 1997).  
 
An estimated 0.7% patients experiencing the highest odds of delayed diagnosis are more likely 
to live over 30 minutes from their GP; this represents around 2,420 annual cases of all cancers 
diagnosed in England (Cancer Research UK 2016b). Targeted action on improving access 
amongst these patients may help meet the goal of reducing cancer mortality and narrowing 
inequalities. This is because poor geographical access is disproportionally felt by those who 
are either elderly, have a disability or a chronic condition that renders them unable to drive, or 
are too deprived to be able to afford a car (Bentham & Haynes 1985; Mungall 2005). 
Supporting these groups of patients to engage with the health services may include use of 
telephone consultations or other aspects of telehealth that have been successfully implemented 
in cancer care and other disease areas (Schlachta-Fairchild 2001; Shepherd et al. 2017; Win 
2017; Barker et al. 2016). 
 
This study has several strengths. The use of a large national dataset provides sufficient 
statistical power and adequate variation of explanatory variables, which enables control for 
covariates. The large dataset also enables comparisons across cancer sites that may vary in 
rarity, ease of detection in primary care, or by their association with deprivation. This has made 
it possible to undertake stratified analysis to investigate how variation in access to early 
diagnosis differs by cancer type. The linking of various routine datasets to obtain information 
on routes to diagnosis has also made it possible to examine the four different routes in parallel; 
comparing routes associated with good outcomes and those associated with poor prognosis. As 
such, the results provide a more complete picture of how physical access to primary care may 
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determine how a cancer diagnosis is obtained. Lastly, the inclusion of all cases registered in 
England over five years enhances generalisability.  
There are some limitations to the study. Firstly, it is a cross-sectional study hence the directions 
of cause and effect cannot be inferred. Secondly, the measure of geographical access (travel 
time) is estimated and may not necessarily represent the actual journey time that patients might 
take, although previous work suggests that estimated travel times closely match the actual 
journeys (Haynes et al. 2006). The analysis did not consider other forms of transport such as 
public transport, walking or cycling although these are infrequently used for health service 
appointments, (Haynes et al. 2006). Also, the implications on survival were not considered, 
this will be examined in the next Chapter (Six). Lastly, cervical screening findings should be 
interpreted with caution because this data may be of poorer quality due to cancer registry 
variations in reporting screen detected records (National Cancer Intelligence Network 2013).  
 
Although living in a rural areas has been related with having poorer geographical access to 
most services (DEFRA 2013a), this inaccessibility may not necessarily translate to poorer 
health outcomes as shown by the findings in this chapter. Thus, it is likely that rurality may be 
a distinct concept that measures a different parameter than travel time. It is therefore plausible 
that there are separate mechanisms mediating the association between longer travel, rurality 
and survival. It may also be that similar mediators exert varying levels of mediation on the 
access - survival causal pathway, on the basis of how access is defined (travel time or rurality). 
Such mechanisms are likely to operate at the patient level, the level of health services or both.  
The next chapter will use causal mediation techniques to examine some underlying 
mechanisms that may explain how longer travel and rurality impacts on cancer outcomes. The 
two potential mediators that will be studied are disease stage cancer waiting time; operating at 
the patient and health services level, respectively. 
 
 
 
 
 
 
 
 
 128 
 
 
 
 
 
 
 
Chapter 6                            
Do time delays and advanced 
disease at diagnosis explain 
the association between 
access to health services and 
colorectal cancer survival? 
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6.1  Introduction 
The previous chapter demonstrated that geographical access to primary care for early diagnosis 
may have important consequences for how a cancer diagnosis is obtained. In that chapter, 
longer travel was associated with higher odds of diagnosis via an emergency presentation and 
post mortem diagnosis, but with lower odds of diagnosis via screening or urgent two-week 
referral. In contrast, living in a rural area mostly reduced the likelihood of a diagnosis from the 
emergency route, but increased the likelihood for two week wait referral and screening. As 
described in previous chapters, other studies have also reported that poor access to cancer 
treatment services determines lower treatment uptake and is associated with worse cancer 
survival (Jones et al. 2008; Campbell et al. 2000). Emerging evidence, as reported in Chapter 
Four, shows that access to primary care also impacts on cancer survival: rural patients, and 
those with greater travel to their GP in Scotland had better colorectal cancer survival rates. 
 
The exact causal mechanisms of how access determines cancer outcomes are unknown. It is 
likely they are at least in part related to the decisions that patients make about when to consult 
their GP, or that GPs make about referral to secondary care. One result of this decision making 
is time delay, between symptom onset and consultation or between referral, diagnosis and 
treatment.  
 
Time delays along the cancer care pathway can be defined using the Aarhus checklist that was 
developed to provide methodological consistency for early diagnosis research (Weller et al. 
2012). Figure 6.1 is adapted from this checklist and highlights two different time delays 
(referral and treatment intervals) that will be examined in more detail in the rest of this chapter. 
Time delays will be referred to as ‘time intervals’, so as to be consistent with the 
methodological guidance set by the Aarhus checklist (Weller et al. 2012). In England, time 
intervals can be derived from the Cancer Waiting Times (CWT) that were originally introduced 
by the NHS Cancer Plan (2000) (Department of Health 2000). It was hoped that monitoring 
cancer waiting times would improve outcomes by promoting rapid diagnosis and treatment. 
Reducing long waits was also expected to improve patient experience, and to reduce 
unacceptable variations in the quality and treatment type across the country (Department of 
Health 2000). Yet, the extent to which CWT have contributed to improving outcomes has been 
disputed (Neal 2009), and this has led to some suggestions for them to be abolished altogether 
(Department of Health 2011a).  
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Figure 6.1 - Time intervals in the route from first symptom until start of treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: - Adapted from Weller et al, 2012 
 
 
6.1.1  Waiting times and survival 
Evidence on the clinical effectiveness of reducing waiting times on outcomes such as cancer 
survival is so far inconclusive (Neal 2009; Neal et al. 2015). However, there is evidence that 
shorter waits may offer psychological benefits to patients (Department of Health 2011b), and 
monitoring them has helped to drive service improvements (Department of Health 2011b), 
although this has not necessarily reduced variations in treatment (Robinson et al. 2005; House 
of Commons Library 2015). A systematic review of the association between time to diagnosis 
or treatment and clinical outcomes provided conflicting results (Neal et al. 2015). For example, 
in lung cancer, five of the studies reviewed found that shorter diagnostic, treatment or referral 
intervals were associated with more favourable outcomes, indicated by better survival and 
earlier stage. In contrast, 13 studies found that shorter treatment intervals was associated with 
poor outcomes, whereas seven studies reported no associations (Neal et al. 2015). This lack of 
consensus was also shown across other cancer sites.  
 
The association between shorter delays with poorer outcomes is counterintuitive and has been 
referred to as the ‘waiting time paradox’. One study reported a u-shaped association between 
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the adjusted hazard ratio and diagnostic intervals, where patients with very short or very long 
waiting times from first presentation to diagnosis (known as the ‘diagnostic interval’) had the 
worst survival (Figure 6.2), (Tørring et al. 2012). This waiting time paradox may be explained 
by patients who present with more advanced disease or as emergencies being investigated more 
rapidly (Tørring et al. 2012; Neal et al. 2015). It is possible that any association between longer 
time intervals and poorer outcomes would only become apparent once the effect of expediting 
treatment for the most ill patients is removed. For instance, other studies have shown that the 
association between shorter waits and survival disappears when the analysis is controlled for 
emergency presentations (Neal 2009; Stapley et al. 2006), and this is because patients 
diagnosed via the emergency route are diagnosed more rapidly yet have worse outcomes 
(Tørring et al. 2012). 
 
 
Figure 6.2 - Estimated 5-year hazard ratios as a function of the diagnostic interval (time 
from the first presentation of symptoms in primary care until diagnosis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Tørring et al, 2012. Re-used with permission.  
Elsevier Licence, 4096160377256. 
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6.1.2  Stage as a mediator 
Disease stage very likely sits on the causal pathway between access and survival, and may 
therefore be an important mediator in the association between measures of access and survival. 
Studies that have examined the association between advanced stage and geographical access 
have shown that patients with the worst access to a cancer centre and to primary care also have 
a higher odds of having an advance disease stage at diagnosis (Campbell et al. 2001; Wang et 
al. 2008). The evidence on rural – urban differences in stage is inconclusive: research based in 
France and Scotland suggests later disease stage amongst patients living in rural areas 
(Campbell et al. 2001; Launoy et al. 1992), whereas, studies from the USA point to a higher 
risk of late disease stage amongst urban patients (McLafferty & Wang 2009). It is very 
plausible that disease stage is a mediator between geographical access and survival, but so far 
the causal mechanisms that may underlie this have not been elucidated. 
 
6.2  Chapter Objective 
The primary hypothesis in this study is that geographical inaccessibility results in longer 
referral and treatment intervals (Figure 6.1), and to more advanced disease stage at diagnosis 
or treatment, which then results in worse cancer survival.  Colorectal cancer was selected as an 
appropriate cancer site for this study because the association between poor access and more 
advanced disease stage in this cancer site has been documented in the literature (Campbell et 
al. 2001; McLafferty & Wang 2009), as described in Section 6.1.2. Furthermore, the 
association between access to the GP for colorectal cancer diagnosis is explored in detail in 
Chapter Four of this thesis. Also, as described in  Section 6.1.1, an association between 
colorectal cancer and diagnostic interval (time from first presentation of symptoms in primary 
care to diagnosis) has also been reported (Tørring et al. 2012). 
 
The chapter will begin by exploring the association between poor access and time intervals. 
The time intervals examined are time from referral to diagnosis (referral interval) and time 
from diagnosis to treatment (treatment interval), illustrated in Figure 6.1. Access will be 
defined as travel time from place of residence to the GP, to the hospital of initial treatment, and 
in terms of rural or urban status. There is only one known study that has examined the 
association between accessibility and time delays, which found that women living in the most 
remote areas of Australia were up to five times more likely to experience longer diagnostic 
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intervals; estimated as waiting time between the first presentation to the GP and diagnosis of 
ovarian cancer (Jordan et al. 2004).  
 
The second part of the analysis will examine whether living farther from a patient’s GP, and 
living in a rural area, is associated with survival from colorectal cancer; this too has not been 
investigated before in England. The chapter will also revisit the association between access to 
secondary services for treatment and survival. 
 
The analysis will conclude by investigating whether two identified mediators ‘time intervals’ 
and ‘Dukes’ stage’ can explain the association between access and cancer survival. Several 
predictor, mediator and outcome relationships have been identified for study and are illustrated 
on Figure 6.3 . These arrows show the direction of the associations and the colour indicate the 
variable predicting survival; travel time to the GP (red), rurality (green) and travel time to 
hospital (blue). The suffix ‘a’ is added to show mediated relationships. 
 
 
Figure 6.3 - Time intervals and disease stage as potential mediators of the association 
between geographical access to treatment and cancer outcomes 
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6.3  Methods and Materials 
The study uses the national cancer registry dataset that was used in Chapter Four. Data on 
colorectal cancer tumours (ICD10 C18- C20) diagnosed in England between 2006 and 2010, 
and followed up to December 2015 for survival status were obtained for the analysis in this 
chapter. These records were linked with information from the hospital episode statistics (HES) 
inpatient and outpatient records, and with the National Cancer Waiting Times (NCWT) 
monitoring data. All data linkage was undertaken by the PHE NCRAS Team (Public Health 
England National Cancer Registration and Analysis Service).  
 
Linkage with the HES provided information on the GP of registration, hospital of treatment, 
type of treatment and presence of comorbidity. Linkage to the Cancer Waiting Times (CWT) 
data provided information on key time points along the cancer care continuum, such as date of 
GP referral, date of diagnosis and treatment, and the date of death. In accordance to the Aarhus 
checklist Figure 6.1, time intervals between key time points (estimated in days) were used as 
a proxy for estimating time delays (Weller et al. 2012).  The two time intervals examined in 
this chapter are: intervals between referral and diagnosis and between diagnosis and treatment, 
henceforth referred to as ‘referral interval’ and ‘treatment interval’. Stage at diagnosis was 
recorded as Dukes’ stages (A, B, C or D) and binary coded as ‘early stage (CD)’ and ‘late stage 
(AB)’. Stage and the time intervals were used as the mediating variables.  
 
Geographical access was defined as travel time from the patient to GP of registration, and to 
the hospital of first treatment. The treatment types used in this analysis are surgery (curative 
and non-curative), radiotherapy, chemotherapy and hormone therapy. All records where 
treatment type was recorded as ‘imaging’, as well as records with treatment recorded as 
‘unknown’ were excluded in the travel to hospital analysis. Travel times were computed using 
a Geographical Information System (GIS) (ArcGIS 10.3, Esri Inc.), see Chapter Five for more 
information on the methodology used to compute travel times. The English rural – urban 
classifications were used to group patients according to rural or urban residence (DEFRA 
2013b). These measures, as well as the information on travel times were added to the linked 
dataset and were used as the predictor variables. 
 
The estimated travel times to GPs were grouped into four categories of ten minutes increment; 
‘less than 10 minutes’, ‘10.1 - 20 minutes’ and ‘20.1 - 30 minutes’ and ‘over 30 minutes’. The 
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average travel to hospital is normally longer than average travel to the GP and so travel times 
to hospital were grouped into four categories of 15 minutes increment; ‘less than 15 minutes’, 
‘15.1 - 30 minutes’ and ‘30.1 - 45 minutes’ and ‘over 45 minutes’.  
 
Logistic regression was used to examine the association between the access measures (travel 
time and rurality) and Dukes’ stage, estimated as odds ratios (OR) and 95% CI. Cox 
proportional hazards regression was used to examine the relationship between the access 
measures and time to event (time to diagnosis, treatment or death). To estimate the association 
between access, and time to diagnosis (referral interval), each record was followed up from the 
date of referral to the date of event (diagnosis), or censoring after 30 days. This was repeated 
to estimate the association between access, and the time to treatment (treatment interval), using 
date of diagnosis and date of treatment accordingly. Censoring at 30 days was selected to 
correspond with the national waiting times standard of no longer than one month wait from the 
date of decision to treat (diagnosis) and the definitive treatment (NHS England 2015). 
 
To estimate the association between the access measures and survival, each record was 
followed up from the date of diagnosis to the date of death or censoring after three years. This 
was deemed an appropriate duration for assessing any impact of engagement with the health 
services for disease management or treatment. Hazard ratios (HR) and 95% confidence 
intervals (CI) were calculated, and a 5% significance level was used in all the time to event 
models.  
 
All models were adjusted for variables that may potentially have a relationship with the 
outcomes; age, sex, deprivation and comorbidity. Additionally, where time intervals were the 
primary outcome (Figure 6.3, models 1, 2, 3 and 4), the route to diagnosis was used to remove  
the effect of the ‘waiting time paradox’ whereby care may be expedited for the most ill patients 
(Stapley et al. 2006; Neal 2009) (see Section 6.1.1). Two different routes were used in adjusting 
for this: where referral interval was the primary outcome, the waiting time paradox was 
corrected for by adjusting for the two week wait (TWW) route, whereas the emergency 
presentation route was used to correct for this paradox where treatment interval was the 
outcome. Linear and Cox regression analysis was conducted in Stata Version 13 (StataCorp 
College Station, TX, USA). 
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Counterfactual causal mediation analysis was conducted to estimate the direct and indirect 
effect of time intervals and Dukes’ stage on the association between travel time, rurality and 
survival. Conventional methods of mediation analysis, applicable when outcome and mediating 
variables are all continuous, are not applicable when mediators or outcomes are categorical or 
are censored survival times (Imai et al. 2010). Table 6.1 shows the mediator relationships that 
were examined and corresponds to Figure 6.3. Models 1a and 3a investigate the mediating 
effect of the referral interval when the predictor variables are travel time to GP and rurality 
respectively. Models 2a and 4a investigate the mediating effect of the treatment interval when 
the predictor variables are travel to hospital of treatment and rurality respectively. Lastly, 
models 5a, 6a and 7a investigate the mediating effect of Dukes’ stage on all the access – 
survival associations.  
 
Table 6.1 – List of all predictor, mediator and outcome relationships investigated 
Model
* Predictor Mediator Outcome 
Model 1 Travel time to the GP n/a Referral Interval  
Model 1a Travel time to the GP Referral Interval Survival 
Model 2 Travel time to the hospital n/a Treatment Interval 
Model 2a Travel time to the hospital  Treatment Interval Survival 
Model 3 Rurality n/a Referral Interval  
Model 3a Rurality Referral Interval Survival 
Model 4 Rurality n/a Treatment Interval 
Model 4a Rurality Treatment Interval Survival 
Model 5 Travel time to the GP n/a Dukes’ late stage 
Model 5a Travel time to the GP Dukes’ late stage Survival 
Model 6 Travel time to the hospital n/a Dukes’ late stage 
Model 6a Travel time to the hospital Dukes’ late stage Survival 
Model 7 Rurality n/a Dukes’ late stage 
Model 7a Rurality Dukes’ late stage Survival 
Model 8 Travel time to the GP n/a Survival 
Model 9 Travel time to the hospital n/a Survival 
Model 10 Rurality n/a Survival 
* See Figure 6.3 
 
All mediation analysis was conducted in R, using the mediate and survreg packages. The 
mediate package enables the estimation of the average direct effect (ADE), the total effect and 
the average causal mediation effect (ACME)  or indirect effect (Tingley et al. 2014; Imai et al. 
2015). This package can handle different combinations of data types including linear, binary, 
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ordered and time to event variables (Imai et al. 2015; Tingley et al. 2014). When the outcome 
is time to event, the survreg package is used alongside the mediate package to fit a parametric 
survival regression model of accelerated failure time (AFT) (Therneau 2016; Tingley et al. 
2014). 
 
The mediation analysis conducted on Models 1a - 7a (Table 6.1) involved the three steps 
illustrated on Figure 6.4. The first step involved specifying a ‘mediator model’ to examine the 
association between the mediator and the predictor variable, adjusted for covariates (as 
described earlier). The second step involved specifying the ‘outcome model’ to examine the 
association between the predictor and outcome, also adjusted for covariates. The third step 
involved entering the output from steps one and two into a mediate function to compute the 
direct (ADE), indirect effects (ACME) and total effects. 
 
Figure 6.4 - An illustration of the casual mediation analysis 
 
 
 
 
 
 
 
                                               Source: adapted from Imai, 2015 
 
The mediation analysis used in this analysis falls within the counterfactual framework of causal 
inference that estimates the difference between two potential outcomes (Imai et al. 2010). The 
goal is to answer the following question, ‘What change would occur to the outcome if one 
changes the mediator from the value that would be realized under the control condition Mi(0), 
to the value that would be observed under the treatment condition Mi(1), while holding the 
direct effect of the treatment constant?’ (Imai et al. 2010) (pg. 311). Causal mediation is zero 
when the predictor has no effect on the mediator, i.e. Mi(1) = Mi(0) (Imai et al. 2010). 
 
Thereby, in the analysis where the predictor was travel time (Table 6.1 models 1a, 2a, 5a and 
6a), the indirect effect (ACME) was estimated by capturing any changes occurring in survival, 
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if the mediator were to change from the value observed in the lowest travel time groups (control 
condition), to the value observed in the higher travel time groups (treatment condition).  
 
Similarly, in the analysis where rurality was the predictor (Table 6.1 models 3a, 4a and 7a), 
indirect effect (ACME) was estimated by capturing any changes occurring in survival if the 
mediator were to change from the value observed in the rural areas (control condition), to the 
value observed in urban areas (treatment condition). Further, a rurality-mediator interaction 
term was fitted in the ‘outcome model’ (Imai et al. 2015; Tingley et al. 2014) to determine 
whether the mediation effect varied based on rural or urban status. The statistical significance 
of the rurality-mediator interaction was tested using the function ‘test.TMint’ (Tingley et al. 
2014). 
 
 
6.4  Results 
There were 159,768 primary colorectal tumours diagnosed during the study period (2006 – 
2010). The majority of these were tumours located in the colon (102,446), followed by tumours 
located in the rectum (45,202), and tumours of the rectoid sigmoid junction (12,134) (Table 
6.2). Over 80% of patients were aged 60 years and older, and comorbidities were recorded in 
only a minority (17%). About half of the patients had an advanced Dukes’ late stage (CD) at 
the time of diagnosis (Table 6.2). 
 
Due to missing or incorrect GP or hospital site information, travel time to GPs was estimated 
for 150,054 (94%) records. Travel to hospital of initial treatment could only be estimated for 
114,349 (72%) records; of these, 31,691 (20%) were excluded from the analysis because the 
initial treatment was marked as ‘unknown’, or was described as ‘imaging’.  
 
The majority of patients were in the shortest travel time categories; in the analysis considering 
travel to the GP, 88% of the cohort lived within a 10 minute drive-time to their GP whereas, 
for travel to hospital, 44% of the cohort resided within a 15 minute drive-time to the nearest 
hospital of treatment (Table 6.2). About 0.6% of patients travelled longer than 30 minutes to 
their GP, and 9% of patients travelled longer than 45 minutes to the hospital of first treatment 
(Table 6.2). An estimated 78% of the study population lived in an urban area.  
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Treatment intervals were computed in only 84% of all records because information on date of 
diagnosis and/or date of treatment was missing in the rest of the records. Similarly, referral 
interval could only be computed in 22% of the records because information on the date of 
referral was only available for tumours diagnosed after 2009. Of those diagnosed after 2009, 
only 52% had information on referral interval. Comparing the characteristics of the access 
variables between complete records, and those with missing information on referral and 
treatment intervals (Annex C, Table A.2) shows that missing records did not significantly 
differ from those that were complete.  
 
 Table 6.2 shows that diagnosis and initial treatment took place on the same day in 38,096 
(48%) cases. Of these, 11,322 were emergency presentations, which makes it plausible for 
diagnosis and treatment to have taken place on the same day. For the rest of the cases, it is 
likely that a clinical histological diagnosis took place on the day of a surgical procedure. A 
cancer registration is based on the date a pathology sample was taken, which may also be the 
surgical date; even though this may have been preceded by earlier non-histological diagnosis. 
A smaller percentage of patients (6%) waited longer than three months for their initial treatment 
post obtaining a diagnosis, and nearly 5% of patients waited longer than three months from 
referral to obtaining a diagnosis (Table 6.2). 
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Table 6.2 - Characteristics of the study cohort 
Variable All cancers Colon Rectum Rectum-Sigmoid 
Travel times to GP (minutes) 
0 – 10  
10 – 20  
20 – 30  
Over 30  
 
 132,383 (88.2)    
    15,003 (10.0)        
      1,705 (1.1)    
          963 (0.6) 
84,873 (88.3)        
9,549 (9.9)  
1,109 (1.2)         
629 (0.7)        
 
37,461 (88.2)        
4,286 (10.1)        
475 (1.1) 
265 (0.6) 
10,049 (88.1)        
1,168 (10.2)        
121 (1.1) 
69 (0.6) 
Rural 
Urban 
  35,181 (22.0)        
124,601 (78.0)        
22,703 (22.2)        
79,743 (77.8)        
9,940 (22.0)  
35,262 (78.0)  
2,538 (20.9)        
9,596 (79.1)        
Travel time to hospital 
(minutes)* 
0 – 15  
15 – 30  
30 – 45  
Over 45 
36,486 (44.1)        
26,660 (32.3)        
11,802 (14.3)        
7,710 (9.3)         
24,598 (46.2)        
17,277 (32.5)        
7,077 (13.3)        
4,270 (8.0)         
9,240 (39.5)        
7,460 (31.9)        
3,862 (16.5)        
2,863 (12.2)        
2,648 (44.0)        
1,923 (32.0)        
863 (14.4) 
577 (9.6) 
Referral Interval (days) 
0 (same day) 
1 - 30  
31 - 90  
91 plus 
2,196 (6.3) 
20,748 (59.1) 
10,523 (30.0) 
1,654 (4.7)                               
1,662 (7.6)  
11,821 (54.2)  
7,125 (32.7)  
1,185 (5.4)  
410 (3.8)        
7,361 (68.7)               
2,590 (24.2)        
360 (3.4) 
124 (4.8) 
1,566 (60.1)        
808 (31.0) 
109 (4.2) 
Treatment Interval (days) 
0 (same day) 
1 - 30  
31 - 90  
91 plus 
 
38,096 (47.7)        
14,940 (18.7) 
21,750 (27.3) 
5,020 (6.3)                               
27,044 (52.8) 
10,627 (20.7) 
11,187 (21.8) 
2,396 (4.7)                              
8,767 (38.6) 
3,132 (13.8) 
8,598 (37.9) 
2,206 (9.7)                           
2,285 (39.1) 
1,181 (20.2) 
1,965 (33.6) 
418 (7.2)                      
Dukes’ Stage 
Stages A&B 
Stages C&D 
 
49,117 (49.6)  
50,011 (50.5)             
33,452 (48.8)        
35,090 (51.2)        
12,114 (52.6)        
10,930 (47.40        
3,551 (47.1)        
3,991 (52.9)        
Age groups (years) 
<= 60  
61 – 70  
71 – 80  
> 81  
 
28,079 (17.6)        
41,281 (25.8)        
51,082 (32.0)        
39,340 (24.6)        
15,971 (15.6) 
25,219 (24.6)        
33,721 (32.9)        
27,535 (26.9)               
9,776 (21.6)        
12,607 (27.9)        
13,535 (29.9)        
9,284 (20.5)        
2,332 (19.2)        
3,455 (28.5)        
3,826 (31.5)        
2,521 (20.8)        
Male 
Female 
88,547 (55.4)        
71,221 (44.6)        
53,261 (52.0)        
49,173 (48.0)        
28,239 (62.5)         
16,962 (37.5)       
7,047 (58.1)        
5,086 (41.9)        
Deprivation quintiles 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
32,718 (20.5)        
35,285 (22.1)        
34,305 (21.5)        
31,070 (19.5)        
26,404 (16.5)        
21,125 (20.6) 
22,739 (22.2)        
22,069 (21.5)        
19,844 (19.4)        
16,669 (16.3)               
9,139 (20.2)        
9,845 (21.8)        
9,679 (21.4)        
8,909 (19.7)        
7,630 (16.9)        
2,454 (20.2)        
2,701 (22.3)        
2,557 (21.1)        
2,317 (19.1)        
2,105 (17.4)        
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
 
133,908 (83.8)        
21,904 (13.7)        
  3,970 (2.5)         
 
84,588 (82.6)        
15,005 (14.7)        
2,853 (2.8)         
 
38,937 (86.1)        
5,381 (11.9)        
884 (2.0) 
 
10,383 (85.6)        
1,518 (12.5)        
233 (1.9) 
Emergency presentation 
Other routes to diagnosis 
39,174 (26.1)        
111,014 (73.9)        
30,922 (32.1)        
65,482 (67.9)        
5,731 (13.5)        
36,702 (86.5)        
2,521 (22.2)        
8,830 (77.8)        
* Excludes records where treatment is unknown or described as imaging 
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6.4.1 Association between travel time, rurality, and time intervals 
Those living farther from their GP of registration generally experienced shorter referral 
intervals (time from referral to diagnosis) (Table 6.3A).  There was evidence of a statistically 
significant trend (p<0.05) of shorter waiting time from referral to diagnosis with increasing 
travel to the GP of registration. Time to diagnosis also decreased with deprivation with those 
in the most deprived quintile experiencing the shortest wait (HR 1.05, p<0.05). On the other 
hand, older patients, females and those with comorbidities experienced significantly longer 
referral intervals.  
 
A separate analysis on the association between rurality and time intervals found that living in 
a rural area, compared to living in an urban area, was associated with a shorter time to diagnosis 
(HR 1.07, p<0.01) (table not shown for brevity). 
 
In contrast, patients with longer travel to the hospital of treatment experienced longer treatment 
intervals (Table 6.3B). The likelihood of obtaining treatment within 30 days progressively 
declined with longer travel and was lowest for those in the longest travel time category (HR 
0.78, p<0.01) (Table 6.3B).There was statistically significant evidence of a trend (p<0.01) of 
the increase in waiting time from diagnosis to treatment with increasing travel to the hospital 
of initial treatment. A sensitivity analysis excluding records where diagnosis and treatment 
took place on the same day was also conducted. Excluding these records this did not change 
the patterns observed in Table 6.3B, although it reduced the hazard ratios, once more, those 
with longest travel had the lowest likelihood of obtaining treatment within 30 days (HR, 
0.49**, p<0.01). A summary of the results are provided on Annex C, Table A.2. 
 
Older patients, females, those with comorbidities and having and emergency presentation were 
all associated with significantly shorter treatment intervals (Table 6.3B). Deprivation on the 
other hand was associated with shorter time to treatment (Table 6.3B). 
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Table 6.3 - Association between travel times, time to diagnosis and time to treatment. In 
A) the outcome is time to diagnosis and in B) the outcome is time to treatment. Cox 
proportional hazard models (hazard ratios (HR), 95%CI, ** p<0.01, * p<0.05). Larger 
hazard ratios indicate shorter time to event.  
  
A)  Outcome: time from referral to diagnosis  
       (Referral Interval) 
B)  Outcome: time from diagnosis to treatment    
 (Treatment Interval) 
Travel to the GP 
0 – 10 minutes 
10 – 20 minutes 
20 – 30 minutes 
Over 30 minutes 
 
Reference 
1.04 (0.99 - 1.08) 
1.12 (0.99 - 1.28) 
1.15 (0.95 - 1.39)    
  Travel to Hospital  
0 – 15 minutes 
15 – 30 minutes 
30 – 45 minutes 
Over 45 minutes 
 
Reference 
0.94** (0.92 - 0.96) 
0.80** (0.78 - 0.83) 
     0.78** (0.76 - 0.81) 
Age grouped 
<= 60 years 
61 – 70 years 
71 – 80 years 
> 81 years 
 
Reference 
0.93** (0.89 - 0.97) 
0.86** (0.83 - 0.90) 
0.88** (0.84 - 0.92) 
Age grouped 
<= 60 years 
61 – 70 years 
71 – 80 years 
> 81 years 
 
Reference 
1.02 (1.00 - 1.05) 
1.06** (1.03 - 1.09) 
1.16** (1.13 - 1.19) 
Gender 
Male 
Female 
 
Reference 
0.93** (0.90 - 0.95) 
Gender 
Male 
Female 
 
Reference 
1.10** (1.08 - 1.12) 
Deprivation 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
Reference 
1.01 (0.97 - 1.05) 
1.01 (0.97 - 1.05) 
1.02 (0.98 - 1.07) 
1.05* (1.00 - 1.10) 
Deprivation 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
Reference 
1.01 (0.98 - 1.03) 
0.98 (0.95 - 1.01) 
0.96* (0.94 - 0.99) 
0.89** (0.87 - 0.92) 
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
Reference 
0.93** (0.89 - 0.97) 
0.90* (0.81 - 0.99) 
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
 
Reference 
1.05** (1.03 - 1.08) 
1.06* (1.00 - 1.13) 
 
Routes to diagnosis 
Other routes  
Two Week Wait 
 
 
Reference 
1.02 (1.00 - 1.05)  
 
Routes to diagnosis 
Other routes  
Emergency presentation 
 
 
Reference 
1.67** (1.64 - 1.71) 
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6.4.2 Association between travel times, rurality, and Dukes’ stage 
Longer travel to the GP and to the hospital of initial treatment increased the odds of having an 
advanced disease at diagnosis (Table 6.4 A&B). The odds of having late stage disease at 
diagnosis increased progressively with farther travel, for example, in comparison to those in 
the lowest travel time group, patients travelling between 30 – 45 minutes had a 5 % (p<0.05) 
risk of having Dukes’ stage CD, the odds were highest for those travelling over 45 minutes, 
1.07 (p<0.05) (Table 6.4B).  
 
When access was measured in terms of rural-urban status, living in a rural area, compared to 
living in an urban area, also increased the odds of having an advanced disease at diagnosis (OR 
1.04, p<0.05) (table not shown for brevity).  
 
Table 6.4 - Association between travel times and Dukes’ late stage. In A), stage is 
associated with travel to the GP and in B), stage is associated with travel to hospital. 
Logistic regression models, (odds ratios (OR), 95%CI, ** p<0.01, * p<0.05) 
 
Outcome: late Dukes’ stage 
A) Model with travel time to the GP of 
registration 
Outcome: late Dukes’ stage 
B) Model with travel time to hospital of first 
treatment 
Travel times  
0 – 10 minutes 
10 – 20 minutes 
20 – 30 minutes 
             Over 30 minutes 
Reference 
1.07** (1.03 - 1.12)  
1.16* (1.03 - 1.31) 
1.15 (0.98 - 1.37)   
Travel times  
0 – 15 minutes 
15 – 30 minutes 
30 – 45 minutes 
Over 45 minutes 
Reference 
0.95* (0.92 - 0.99) 
1.05* (1.00 - 1.11) 
1.07* (1.01 - 1.14)  
Age grouped 
<= 60 years 
61 – 70 years 
71 – 80 years 
> 81 years 
 
Reference 
0.79** (0.76 - 0.82) 
0.74** (0.71 - 0.77) 
0.75** (0.72 - 0.79)    
Age grouped 
<= 60 years 
61 – 70 years 
71 – 80 years 
> 81 years 
 
Reference                                
0.77** (0.74 - 0.81) 
0.67** (0.64 - 0.70) 
0.59** (0.56 - 0.62) 
Gender 
Male 
Female 
 
Reference 
1.00 (0.97 - 1.03)  
Gender 
Male 
Female 
 
Reference 
1.01 (0.98 - 1.05)  
Deprivation 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
Reference 
1.05* (1.01 - 1.09) 
1.06** (1.02 - 1.10) 
1.04* (1.00 - 1.09) 
1.12** (1.08 - 1.17) 
Deprivation 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
Reference 
1.00 (0.95 - 1.05) 
0.99 (0.94 - 1.04) 
0.95 (0.90 - 1.00) 
1.01 (0.95 - 1.06) 
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
Reference 
0.90** (0.87 – 0.94) 
0.92 (0.84 – 1.01) 
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
 
Reference 
0.89** (0.85 - 0.94) 
0.85* (0.75 - 0.95) 
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6.4.3 Associations between rurality, travel times, and survival  
Longer travel to the GP and to hospital was associated with worse cancer survival within three 
years of diagnosis (Table 6.5 A&B). The risk of death associated with longer travel gradually 
increased with longer travel time. For example when travelling to access the GP, the hazard 
ratio increased from 1.04 (p<0.01) for those travelling for 10 – 20 minutes, to 1.21 (p<0.01) 
for those travelling longer than 30 minutes (Table 6.5 A).  
 
In contrast, when access was measured in terms of rural-urban status, patients living in rural 
areas had a lower risk of death within three years of diagnosis (HR 0.96, p<0.01) (not shown 
in table for brevity). 
 
Table 6.5 - Association between travel times and three year survival. In A) travel to the 
GP is associated with survival at three years. In B) travel to hospital is associated with 
survival at three years. Cox proportional hazard models, (HR, 95%CI, ** p<0.01, * 
p<0.05) 
 
Explanatory variable 
 
A) Travel time to the GP of registration 
Explanatory variable 
 
B) Travel time to hospital of first treatment 
Travel times 
0 – 10 minutes 
10 – 20 minutes 
20 – 30 minutes 
Over 30 minutes 
 
 
Reference 
1.04** (1.02 - 1.07) 
1.16** (1.08 - 1.24) 
1.21** (1.11 - 1.32) 
Travel times 
0 – 15 minutes 
15 – 30 minutes 
30 – 45 minutes 
Over 45 minutes 
 
 
Reference 
1.02 (0.99 - 1.04)   
1.10 ** (1.07 - 1.14) 
1.13** (1.09 - 1.18) 
Age grouped 
<= 60 years 
61 – 70 years 
71 – 80 years 
> 81 years 
 
Reference 
1.08** (1.05 - 1.11)  
1.64** (1.60 - 1.68)   
3.17** (3.10 - 3.25)    
Age grouped 
<= 60 years 
61 – 70 years 
71 – 80 years 
> 81 years 
 
Reference                               
1.01 (0.97 - 1.05) 
1.42** (1.37 - 1.47) 
2.29** (2.21 - 2.37) 
Gender 
Male 
Female 
 
Reference 
0.99 (0.98 - 1.01 
Gender 
Male 
Female 
 
Reference 
0.92** (0.90 - 0.94)  
Deprivation 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
Reference 
1.07** (1.05 - 1.10) 
1.13** (1.10 - 1.16) 
1.23** (1.20 - 1.26) 
1.38** (1.35 - 1.42) 
Deprivation 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
Reference 
1.02 (0.99 - 1.06)  
1.07** (1.04 - 1.11) 
1.14** (1.10 - 1.19) 
1.27** (1.22 - 1.32) 
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
Reference 
1.22** (1.20 - 1.25) 
1.65** (1.59 - 1.71) 
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
 
Reference 
1.23** (1.20 - 1.27) 
1.68** (1.57 - 1.79) 
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6.4.4 Indirect effects of travel times and rural residence on time to death, 
mediated through referral interval, treatment intervals and Dukes’ 
stage 
The results of the mediation analysis are summarised in Table 6.6. The columns give the 
estimated indirect effect (average causal mediated effect, ACME), average direct effects 
(ADE), total effect, and the percentage of the total effect that is explained by the indirect effect. 
The package ‘survreg’ (described in section 6.3) only fits accelerated failure time (AFT) 
models, not proportional hazards (PH) models (Therneau 2016). The coefficients are 
differences in mean natural logarithms of survival times, so a negative coefficient means 
shorter survival.  
 
Where travel time was the predictor variable (Table 6.6 models 1a, 2a, 5a and 6a), the ACME 
shows how the indirect effect changed as a function of travel time. Using the example of model 
1a, the results show about 50% of the association between travelling to the GP and survival is 
mediated by time from referral to diagnosis (referral interval). In this model, the ACME value 
for those in the highest travel group (-2.20), can be interpreted as the decline in survival that 
would occur if those in the lowest travel group (0-10 minutes) had the same mediator 
(distribution of referral intervals) as those in the highest travel group (over 30 minutes). 
Another way of interpreting this is, if patients in the lowest travel group had the same referral 
intervals as those in the highest travel time group, whilst holding the travel time constant, their 
survival at three years would decline by 89%, (e-2.20)§. Similarly, Dukes’ late stage also 
significantly mediated the association between travel to the GP and survival, and explained 
nearly a third of this association (Table 6.6, model 5a). Once again, if patients in the lowest 
travel category had the same stage distribution as those in the highest travel group, their 
survival would decline by 86% (e-1.97).  
 
Treatment interval also mediated on average about 17% of the association between travel to 
hospital and survival (Table 6.6 models 2a). It was however not possible to ascertain the 
proportion of the indirect effect of Dukes’ late stage on the travel to hospital – survival 
association (Table 6.6, model 6a), this is because the direct and indirect effect cancel each 
                                                          
§
 Survival time ratio of 1 corresponds to no treatment difference (Gelfand et al. 2016). Survival time ratio of -2.20 
= 0.11, therefore the difference in expected time to event (death) is 89% greater in the highest travel time group, 
than in the lowest travel time group. 
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other out when they have opposite signs (Imai et al. 2010). The positive ADE (Table 6.6, 
model 6a) suggests that longer travel to hospital may be associated with better survival at three 
years when the effect of Dukes’ stage is controlled for. 
 
Similarly, in the analyses where rural or urban residence was the explanatory variable (Table 
6.6, models 3a, 4a and 7a), the percentage mediated could not be estimated, because the direct 
and indirect effects had opposite signs. For example, when Dukes’ stage was the mediator 
(Table 6.6, model 7a), the results suggest that living in a rural area has a positive effect on 
survival, but higher Dukes’ stage has a negative effect on survival. 
 
Fitting a mediator – treatment interaction term in this analyses (Table 6.6 models 3a, 4a and 
7a) revealed that the indirect effect of Dukes’ stage was significantly different between rural 
and urban areas (ACME in Rural – ACME in Urban = -0.36, p<0.01) (Table 6.6, model 7a). 
The indirect effect of referral and treatment intervals did not differ between rural and urban 
areas. 
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Table 6.6 - Causal mediation estimates showing average direct effects (ADE), average 
causal mediation effects (ACME) or indirect effects, total effects, and percentage of total 
effect that is explained by the mediation effect, 95% CI, **p<0.01, *p<0.05. Coefficients 
are differences in mean natural logarithms of survival times, so a negative coefficient 
means shorter survival 
Predictor and mediator variables 
ACME 
average 
ADE 
average 
Total 
effect 
% 
mediated 
 
Mediation of effect of travel time to the GP of registration 
Model 1a) Travel time-survival, 
association mediated by referral 
interval 
10 – 20 mins -0.91* -0.76 -1.68* 54.2%* 
20 – 30 mins -1.64* -1.45 -3.09* 51.8%* 
Over 30 mins -2.20* -2.04 -4.24** 51.0%* 
 
Model 5a) Travel time -survival 
association, mediated by Dukes’ 
stage 
10 – 20 mins -0.71**   -1.47**    -2.19**   32.9%**         
20 – 30 mins -1.33**   -2.81**      -4.14**     31.9%**      
Over 30 mins -1.97**    -4.04**   -6.01**  32.9%**         
Mediation of effect of travel time to the hospital of first treatment 
 
Model 2a) Travel time - survival 
association, mediated by treatment 
interval 
15 – 30 mins -0.12       -0.74**       -0.86**       15.6% 
30 – 45 mins -0.26       -1.42**       -1.68**       17.1% 
Over 45 mins -0.15 -2.07** -2.21* 18.5% 
 
Model 6a) Travel time - survival 
association, mediated by Dukes’ 
stage 
15 – 30 mins -0.11*   0.06      -0.06      N/A     
30 – 45 mins -0.24*     0.10       -0.13       N/A      
Over 45 mins -0.34* 0.16       -0.36       N/A 
Mediation of effect of rural residence 
Model 3a) Rurality-survival 
association, mediated by referral 
interval 
Rural -1.50** 0.65 -0.82 N/A 
Model 4a) Rurality-survival 
association, mediated by treatment 
interval 
Rural -0.11 1.16 1.13 N/A 
Model 7a) Rurality-survival 
association, mediated by Dukes’ 
stage 
Rural -1.87** 5.81** 4.29* N/A 
In 1a and 3a, the mediating variable is referral interval, in 2a and 4a, the mediating variable is treatment interval, 
and in models 5a, 6a and 7a, the mediating variable is Dukes’ stage. Percentage mediated cannot be estimated 
when ACME and ADE are in the opposite directions, these entries are marked as N/A in the table. 
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6.5  Conclusions 
This chapter begun by assessing how measures of accessibility (travel time and rurality) are 
associated with time intervals along the cancer care pathway. It found that travelling to health 
services was associated with waiting times to diagnosis and to treatment. Counterintuitively, 
longer travel to the GP was associated with shorter waiting time between referral and diagnosis 
(referral interval), whereas longer travel to hospital was associated with longer waiting time 
between diagnosis and treatment (treatment interval). This is believed to be the first study to 
examine these associations in England. The covariates used in this analyses had opposite 
associations when the outcome was referral or treatment intervals; older age, female gender, 
and having more than one comorbidity was associated with longer referral intervals, but with 
shorter treatment intervals. Presence of emergency presentations was also associated with 
shorter treatment intervals.  
 
The analysis went on to investigate the association between access and two important health 
outcomes: stage and survival. The results supported findings from previous studies that showed 
travelling farther to hospital to obtain cancer treatment continues to have implications for 
colorectal cancer outcomes (Campbell et al. 2000; Dejardin et al. 2008). Furthermore, results 
suggested that patients who travelled farther to their GP also experienced poorer outcomes; 
higher odds of having advanced Dukes’ stage, and worse survival at three years. Patients living 
in rural areas also had higher odds of having an advanced disease (OR 1.04, p<0.05). However, 
this did not translate to a higher risk of mortality as these patients had a significantly lower risk 
of death within three years of diagnosis (HR 0.96, p<0.01).  
 
The final part of the analysis employed causal mediation inference to explore the extent by 
which potential mediators (disease stage and time intervals) explained the aforementioned 
associations. The results suggested that the indirect effects of distance to GP were most 
apparent. For instance, referral interval explained just over half of the association between 
travel to the GP and survival, and Dukes’ stage mediated nearly a third of this association.  
 
These findings have implications that may inform cancer policy and practice. Firstly, the 
evidence contributes to the recent call for up-to-date evaluation of the impact of living farther 
from a cancer centre on cancer outcomes (Independent Cancer Taskforce 2015). There is a 
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recognition that the current evidence may be outdated (Independent Cancer Taskforce 2015), 
which makes the findings in this research timely. 
 
Secondly, the findings make a strong case for adhering to the cancer waiting times guidelines. 
The lack of consensus on the effectiveness of waiting times on improving cancer outcome is 
well documented (Neal et al. 2015; Neal 2009; Tørring et al. 2012). However, the relationship 
between access and waiting times has not been established, nor has the potential mediating role 
of waiting times on cancer outcomes. This study shows for the first time that patients who have 
worse access to services may also experience longer waiting times, and may therefore not be 
receiving some of the benefits of timely treatment, such as the previously documented 
psychological benefits of prompt treatment (Department of Health 2011b). The NHS 
operational standard for 31 days waiting time between diagnosis and treatment (treatment 
interval) is 96% (NHS England 2015). Healthcare providers who fall short of this standard, and 
other standards associated with waiting times, may be interested in understanding how 
alleviating barriers to access may help improve overall waiting times. 
  
It is not clear why longer travel to the GP amounted to shorter waiting time between referral 
and diagnosis (referral interval). This finding will need further investigation in the future with 
more complete data on waiting times between referral and diagnosis, and across other cancer 
sites.  
 
The results from mediation analysis suggested that a proportion of the total effect of access on 
survival is mediated through time intervals. The significance of this finding can be seen in the 
context of previous studies that have shown inconclusive results on the association between 
time intervals and survival (Neal et al. 2015; Neal 2009). More specifically, the finding on the 
mediating effect of cancer waiting times on cancer survival adds a new perspective in the 
understanding these previously inconclusive findings, by demonstrating the importance of 
examining both direct and indirect effects in future research, and emphasising the importance 
of adhering to Government cancer waiting times targets. The analysis also found that Dukes’ 
stage had a stronger indirect effect when the estimates of travel time to the GP, rather than 
travel time to hospital predicted survival. This suggests that there are other prognostic factors 
besides disease stage that may have a stronger indirect effect on the association between 
travelling to hospital and survival; some suggested factors include access to a specialised vs. 
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generalised units, which were not examined in this analysis. The strong indirect effect of the 
time intervals and Dukes’ stage on travelling to GP – survival association is not surprising, 
although it is striking that when travelling to GPs, referral intervals had a slightly larger indirect 
effect than Dukes’ stage. 
 
Living in a rural area was associated with having a higher odds of Dukes’ stage at diagnosis 
(OR 1.04, p<0.05), despite this, survival in rural areas remained higher than in urban areas (HR 
0.96, p<0.01). Additional analysis revealed that this survival advantage of living in a rural area 
diminished when effect of Dukes’ stage was controlled for (HR 1.02, p=0.07). 
 
The mediation analysis confirms this effect of Dukes’ stage in rural areas, by showing that 
living in a rural area was associated with better survival, but higher Dukes’ stage in rural areas 
was associated with a poorer survival. It was however difficult to estimate the proportion 
mediated because the direct and indirect effects of Dukes’ stage and rurality on survival had 
opposite signs (Table 6.6, model 7a). Nevertheless, fitting an interaction term suggested that 
the indirect effect of Dukes’ stage varied as a function of rurality, suggesting some differences 
in how rural and urban residents experience the effect of Dukes’ stage. There is some indication 
that these differences may in part be explained by the social-cultural differences in the 
perception of illness, which is further compounded by poor accessibility of services in rural 
areas. For instance, some studies have found rural – urban differences in colorectal cancer 
diagnosis, characterised by delays in presentation of symptoms and in diagnosis amongst rural 
patients (Launoy et al. 1992; Emery et al. 2013). Some mechanisms have been postulated to 
explain these delays, such as the loneliness experienced by rural patients, particularly women 
(Launoy et al. 1992), and the stoicism shown by rural patients in the presence of illness, which 
is characterised by a higher threshold of enduring hardship or pain (Emery et al. 2013). The 
interaction between these social-cultural factors and geographical factors such as the inverse 
relationship between distances to services and utilisation adds further complexity health 
seeking decision making in rural areas, and this has noticeable impact on health outcomes. 
 
The study benefitted from the use of a large national dataset which provided enough statistical 
power, adequate variation for explanatory variables, and enabled adjustment for confounding 
variables. The analysis was enabled by data linkage across different datasets. For example, 
linking cancer waiting times data with the hospital episodes statistics, and with geographical 
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information, made it possible to examine causal effects on several models, using variables that 
were specific to primary care, secondary care or to both. Lastly, the inclusion of all colorectal 
cancer cases diagnosed in England across five years makes the findings generalizable. 
There are some limitations to the study. The mediation analysis should be interpreted with 
caution; it was not possible to conduct sensitivity analysis that is advised in causal mediation 
analyses (Imai et al. 2010; Imai et al. 2015), because the ‘mediate’ package does not currently 
support sensitivity analysis for time to event models (Tingley et al. 2015). This means that the 
validity of the average causal mediation effect (ACME) has not been tested. Nevertheless, 
adjusting for as many confounders as possible (as done in this study) is a means of attaining 
model validity (Imai et al. 2010; Caro 2015). Furthermore, the mediation analyses investigated 
only one intermediate variable at a time, whereas it is plausible that indirect effects could have 
operated through multiple mediators, for example, travel time => referral interval => Dukes’ 
stage => treatment interval => time to death. Modelling of multiple mediators is 
methodologically challenging, however, and the results presented here at least indicate which 
of those intermediate variables are most important. The study was also limited by the 
incomplete records in some variables. For example, time from referral to diagnosis was only 
available for two out of the five years of the study period, and travel to hospital could not be 
computed for 28% of the study sample. Another limitation is that use of public transport was 
not considered, although previous research suggests this is mode of transport is not frequently 
used by cancer patients (Haynes et al. 2006).  
 
In conclusion, this Chapter contributes to the current evidence in two main ways. Firstly, it 
demonstrates that times intervals along the cancer care continuum may be predicted by 
accessibility to health services. Secondly, it shows that good access to GPs is just as important 
as good access to hospital of treatment in improving cancer survival. The application of novel 
techniques to estimate causal mediation on time to event variables provides some insight into 
the mechanisms of how access might determine cancer survival. The findings suggest that a 
significant proportion of this association is mediated by cancer waiting times and Dukes’ stage. 
Crucially, the availability of linked data from both primary and secondary care enables a 
comprehensive analysis along the cancer care continuum. Following from this, one important 
finding is that Dukes’ stage is an important an mediator in the association between accessing 
the GP, living in a rural or urban area, and colorectal cancer survival, but, stage may have no 
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mediating effect in the association between access to secondary care for treatment and cancer 
survival.  
 
The study has also generated new questions for future investigation. There is a need to quantify 
and characterise patients who have poor access to both primary and secondary care. Such work 
should estimate the need, and identify which sub-groups and areas most at risk, across all 
cancer sites. More research is also needed to identify other important mechanisms in the causal 
pathway between access and survival; this study has identified time delays and disease stage 
as potential mediators, others may include social-cultural factors that influence how patients 
seek healthcare, or how health professionals provide care. The successful implementation of 
efforts to improve access can only be achieved by fully understanding the underlying 
mechanisms by which poor access leads to poor outcomes.    
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Chapter 7                         
Final discussion and new 
directions for future 
research on access to cancer 
care 
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7.1  Contribution of thesis and significance of findings 
The studies presented in this thesis are comprehensive investigations demonstrating 
associations between geographical access to cancer services and important outcomes along the 
cancer care continuum. These studies have identified several ways by which poor access to 
cancer services may be impinging on the overall goal of improving cancer outcomes.  
 
The findings confirmed the associations between longer travel to hospital and poor cancer 
outcomes that are reported in previous studies. The research then goes a step farther to 
demonstrate that longer travel to the GP also has implications on outcomes such as cancer 
stage and survival, but also in terms of influencing the pathways that patients take to attain 
a cancer diagnosis.  
 
By examining the relationships between access and outcomes from the angle of travel time and 
rurality, the results suggest that these two are distinct concepts that measure two different 
dimensions. For instance, rural patients had better survival and lower odds of presenting as 
emergency presentations in comparison to urban patients. Thus, rurality should not be used 
in place for geographical inaccessibility.  Fitting a travel – rurality interaction term found 
the association between travel and outcomes differed between rural and urban areas, 
suggesting that perhaps rural and urban patients and GPs may perceive geographical 
inaccessibility differently. 
 
In examining potential mediations to explain the above findings, the research found that a 
significant proportion of the access effect on cancer outcomes was mediated through 
cancer waiting times and disease stage. These had a significant mediating effect in the 
association between travelling to the GP and survival, but had little mediating effect when 
travelling to hospital. The indirect effect of late stage on cancer survival may vary by rural 
or urban status. The mediation analysis offers new insights in unravelling some of the 
complex causal pathways in the access – survival associations, and offers new directions for 
future research on access to cancer care 
 
These findings are timely: the most recent national strategy on cancer (Independent Cancer 
Taskforce 2015) has shown that the role  of service accessibility in determining cancer 
outcomes continues to be of interest to policy makers, health practitioners and service users, 
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but the evidence to inform decision making remain is dated or lacking. The Strategy has thereby 
identified key recommendations to respond to the knowledge gap (Table 2.3). The evidence 
generated by this research, will undoubtedly fill the gap in evidence, furthermore, the measures 
of travel times to GPs and hospitals in England generated from this work have been shared 
with PHE NCRAS who are currently using them in their response to the aforementioned 
recommendations. Additionally, the author works on an advisory capacity with PHE NCRAS 
to input on methodological issues associated with meeting the Strategy’s recommendations on 
geographical access to cancer services. 
 
7.2  Chapter overview 
Chapter Two of this research was a narrative review of the five cancer strategy documents to 
assess how access of cancer services has been shaped by the policy making process. The 
development of the policy objective on improving access to cancer services was systematically 
mapped out, alongside other competing policy priorities. The review also identified gaps in 
evidence where further research may promote a better understanding of the access – cancer 
outcomes relationship; these findings helped formulate relevant research hypotheses which 
were then explored in the rest of the chapters.  
 
Reviewing the five cancer strategies revealed the varying level of importance accorded by 
policies on geographical access over the last two decades. Only two of the five strategies 
recognised the important role that geographical access plays in determining cancer outcomes; 
incidentally, both strategies were authored independent of any government involvement. 
Exactly twenty years have elapsed between the publication of the first cancer strategy (Calman 
and Hine report), and the latest cancer strategy (Achieving World Class Cancer Outcomes). 
Despite progress in the delivery of cancer care, which has led to improvements in outcomes, 
the complex issue of how to deliver a geographical equitable service whilst maintaining the 
best possible outcomes remains to be resolved. The latest strategy has re-ignited focus on the 
geographical access by making four explicit recommendations that range from evaluating 
evidence of the impact of access on outcomes, to determining the merit of further service 
centralisation, and for the first time, an assessment on the impact of poor geographical access 
to services on children, young people and their families (Table 2.3). 
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Chapter Three, the first of the four analytical chapters, set the scene by examining the extent 
to which cancer services in England are equitably located. This Chapter began by identifying 
all hospital sites that may offer treatment and management for breast, colorectal and lung 
cancers. Correlating aggregated travel times to the identified hospital sites, and area level 
cancer incidence of the three cancer sites, revealed that cancer services tend to be located 
farther from areas with more cancer cases. This may be an indication that areas with the highest 
demand for services may also have the worst access. One explanation may be that cancer 
services are more likely to be concentrated in cities, whereas, demand for services is greater in 
less urban areas that carry a larger percentage of older people. Another finding from this chapter 
was that areas with longer average travel times are associated with worse survival after 
adjustment for age, sex, year, and area deprivation.  
 
Chapter Four enabled the investigation of the association between access to general practitioner 
and cancer outcomes. Chapter Two had found a consistent acknowledgement of the poorer 
outcomes in England in comparison to other countries of comparable wealth recognition. There 
was also a recognition that efforts to improve earlier diagnosis are crucial to improving 
outcomes, which was particularly emphasised in the latter two cancer strategies (Department 
of Health 2011a; Independent Cancer Taskforce 2015). Despite recent achievements, such as 
the awareness generated by the National Awareness in Early Diagnosis Initiative (NAEDI), 
there is little evidence on how geographical access to early diagnosis determines cancer 
outcomes: Chapter Four addresses this gap in evidence. The Chapter used a dataset from the 
North of Scotland that holds GP clinical records that are linked with cancer registry data. The 
linked dataset offered two key benefits; firstly, the identification of symptoms that may have 
instigated a GP consultation and onward referral into secondary care. Secondly, the study 
cohort enabled consideration of remoteness as Northern Scotland has some of the remotest 
rural areas in the UK and living in these areas may come with distinct socio-cultural attitudes 
towards health.  
 
The findings from Chapter Four suggested differences in outcomes between patients living in 
rural and urban areas, for instance, rural patients had significantly better survival within three 
years of diagnosis. The study also found the association between longer travel and the primary 
outcomes was opposite in rural areas to that observed in urban localities. For example, patients 
travelling farthest in urban areas were more likely to present with alarm symptoms, but this 
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was the opposite for patients with the longest travel in rural areas. These rural – urban 
differences in some of the outcomes examined may indicate socio-cultural differences in how 
patients present to their GP with symptoms that may be related to cancer. The most remote 
rural patients have previously been reported to display stoicism towards seeking healthcare, 
which makes them more likely to describe themselves as healthy and fit for work even when 
suffering from life threatening conditions (Elliott-Schmidt & Strong 1997), and to pursue their 
care less tenaciously (Bain et al. 2002).  
 
Chapter Five continued with the focus on access to early diagnosis and went a step further by 
exploring the relationship between access and process measures such as mode of diagnosis that 
straddle the interface between primary and secondary care. This chapter built on the findings 
of the previous chapter (Chapter Four) that found a rural - urban difference in diagnosis 
following emergency admissions in Scotland. Chapter Five revisited that finding using a larger 
and more recent dataset from England. Furthermore, the comprehensive linkage of the English 
dataset enables the investigation of other routes to cancer diagnosis such as screening, GP two 
week wait (TWW) referrals and death certificate only (DCO) routes, and enabled this to be 
replicated across eight different cancer sites. The findings showed significant associations 
between geographical access and routes into diagnosis. Longer travel to the GP significantly 
increased the odds of obtaining a diagnosis via less desirable routes (DCO or emergency 
presentations), but reduced the odds of obtaining a diagnosis through a route of better prognosis 
(two week wait and screening). Conversely, those travelling the farthest had a reduced 
likelihood of obtaining a screen detected diagnosis or a diagnosis via the two week wait route. 
The opposite was apparent for patients living in rural areas; they were more likely to obtain 
diagnosis through a route of good prognosis (screening and TWW), and were less likely to 
have their cancer diagnosed following an emergency presentation.  
 
These first three analytical chapters suggested that poor access may create a barrier to 
engagement with health services, resulting to reduced likelihood in presenting with symptoms 
that may be related to cancer (Chapter Four), or reducing the likelihood of participation in 
screening programmes, but, increasing the likelihood of emergency presentations and post 
mortem diagnosis (Chapter Five). These findings did not give any indication of the exact 
mediators that may explain the association between access and outcomes. The final analytical 
chapter (Chapter Six) addressed this by examining two potential mediators; time intervals 
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(delays) as derived from cancer waiting times, and disease stage. In addition to sitting on the 
causal pathway between access and survival, time intervals and stage may also mediate the 
association between access and routes to diagnosis. Although the latter was not explicitly 
examined, to investigate all the possible mediation relationships would require advanced 
statistical methodologies described in Section 7.5. Chapter Six did however find that 
emergency presentations were associated with shorter waiting times between diagnosis and 
treatment. This may explained by the ‘waiting time paradox’, whereby care for the most ill 
patients, such as those presenting as emergencies is fast tracked. 
 
The use of cancer waiting times as the primary means of monitoring progress on access to 
cancer services was advocated in at least three of  five cancer strategies ‘Cancer Plan’, ‘Cancer 
Reform Strategy’ and ‘Improving Outcomes’ (Department of Health 2000; Department of 
Health 2007; Department of Health 2011a). Although cancer waiting times measure an aspatial 
dimension of access, it is plausible that longer waits are partly predetermined by poor 
geographical accessibility, Chapter Six demonstrated this association using colorectal cancer 
as a case study. Rurality and longer travel to the GP were associated with shorter waits from 
referral to diagnosis, whereas travelling farther to the hospital of treatment was associated with 
longer waits in obtaining treatment within the one-month  recommended in the national 
guidelines (NHS England 2015). Longer travel to both the GP and hospital also increased the 
odds of presenting with advanced disease, and of poorer survival at three years. Although living 
in a rural area was also associated with advanced disease, rural patients had significantly better 
survival at three years. Lastly, waiting times and disease stage were identified as important 
mediators; time from referral to diagnosis explained about 50% of the association between 
travel to the GP and survival, whereas, time from diagnosis to treatment interval explained 
around 17% of the association between travel to the first hospital of treatment and survival.  
 
7.3  Main strengths and limitations 
The studies presented in this research had a number of strengths. The research benefited from 
use of linked datasets which enabled the examination of access issues along the cancer 
continuum. Healthcare delivery in the NHS has been criticised for being fragmented such as 
by lack of co-ordination between different parts of the health services (primary, community 
and secondary care), which results to missed opportunities for earlier intervention, poor patient 
experience and outcomes (King’s Fund 2015). The findings in this research offers decision 
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makers with some evidence that integrates different parts of the care continuum which can 
hopefully facilitate more joined up decision making. As an example, the mediation analysis in 
Chapter Six found that Dukes’ stage may be an important mediator in the travel to the GP - 
survival association, but less so in the travel to hospital – survival association. This evidence 
may help in the making targeted decisions whereby resources are allocated to the parts of the 
care pathway that are most likely to benefit from any given initiatives. 
 
Another major strength of the research was in obtaining data that enabled geographical 
accessibility to be examined from the perspectives of travel time and rurality. The evidence 
generated from this analysis has highlighted that these are measures of different parameters 
and should not be used interchangeably: with rurality possibly also capturing a social-cultural 
dimension in addition to physical accessibility. In addition to examining geographical aspects 
of access, data linkage also enable the exploration of how non-geographical dimensions of 
access such cancer waiting times may be impacted by proximity to cancer services. 
 
Lastly, a key strength was in using advanced statistical methodologies that went beyond simple 
regression techniques. This was in part made possible by the availability of the linked datasets, 
whose clinical, demographic and geographical variables enabled examination of previously 
unexplored relationships. For example, fitting interaction terms in Chapter Four made it 
possible to isolate the effect of longer travel in rural vs urban areas. Likewise, employing 
mediation techniques in Chapter Six furthered the understanding of the potential mediators on 
the access – survival causal pathway. 
 
The research has some limitations. Three of the five cancer strategy documents reviewed in 
Chapter Two were not independent of government, and so their content reflected the political 
ideologies of the governing political party. This presented methodological challenges of 
maintaining objectivity and keeping political persuasions at bay when reviewing the 
documents.  In addition, the limited evaluation of policy initiatives added further challenges in 
ascertaining progress on the policy objectives.  
 
There were also methodological limitations in the analytical Chapters Three to Six. Firstly, in 
Chapter Three, the use of area level data may have introduced ecological fallacies which means 
the  findings may not be inferred at an individual level (Diez-Roux 1998). Although the 
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findings did generate interesting hypotheses for testing with more granular data.  In Chapter 
Four, the absence of symptoms severity introduced challenges in the definition of alarming vs 
non-alarming symptoms: symptoms such as anaemia and abdominal pain were grouped as 
‘non-alarming’ even though they may be deemed alarming when severe. Also, the use of a 
dated dataset where a cancer diagnosis was made between 1997 and 1998 can be criticised. 
However, the fact that some of the findings from that study have been replicated in Chapters 
Five and Six (association between access, emergency presentation and survival) gives 
assurance to the validity the dataset.  
 
Chapter Six made use of recent advances in mediation techniques that use a counterfactual 
framework to estimate direct and indirect effects, which differ markedly from the traditional 
mediation analysis that use the framework of linear structural equation modelling (LSEM) 
(Imai et al. 2010). A major advantage of the counterfactual framework is that they can be 
applied on non-linear models (Imai et al. 2010). However, one limitation is the inability to test 
for potential violations of the assumptions** applied in identifying causal mechanisms when 
the outcome is time to event (Tingley et al. 2015). Approaches to investigate potential 
violations have already been developed for other model types (such as in discrete, binary 
outcomes) and it is anticipated this will be extended to all other model types (Imai et al. 2010). 
 
Other methodological limitations are related to estimating the travel times  used in the analyses; 
these were modelled estimates and not the actual times experienced by patients.  This may not 
introduce bias in the findings as a study looking at the validity of GIS modelled estimates found 
minimal variation between estimates and actual car journeys. (Haynes et al. 2006). That study 
also found reported journey times contained rounding and recall errors, and were affected by 
traffic conditions, which makes GIS modelled estimates more representative of average 
conditions. Lastly, the measure of physical accessibility did not consider the service 
availability, for instance, as determined by availability of appointments. Availability may 
determine the outcomes for those living in urban areas in particular. Some suggestions on how 
future research can incorporate service availability are discussed in more detail in Section 7.6. 
 
                                                          
** The assumptions are defined by the following four conditions:  (1) No unmeasured confounders of the 
relationship between X and Y; (2) No unmeasured confounders of the relationship between M and Y; (3) No 
unmeasured confounders of the relationship between X and M; (4) No measured or unmeasured confounders 
of M and Y that have been affected by X. (Gelfand et al. 2016) 
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7.4  Implications on policy and practice 
In addition to feeding into recommendations from the national strategy on cancer, it is 
anticipated that the evidence generated from this research will inform policy makers and health 
practitioners for example by feeding into ongoing local and national efforts such as the National 
Awareness in Early Diagnosis Initiative (NAEDI). Sections 7.4.1 and 7.4.2 summarises two 
specific ways in which the findings can shape current policy and practice, these are: improving 
our understanding of how to balance competing healthcare delivery and policy priorities, and, 
furthering the evidence on how rurality affects cancer health outcomes. 
 
7.4.1 Balancing competing priorities  
One issue that was apparent from this research was the challenge of providing equitable access 
to services without compromising quality of care and within the available resources. This is 
particularly relevant in relation to provision of access for specialist treatment such as surgery 
or radiotherapy. Health providers and policy makers need to reconcile three overlapping 
factors; the first one is the consideration of survival benefits of increased specialisation, for 
which there is now abundant evidence of its success. Specialisation is attained by increasing 
hospital and surgical volume, which is in turn achieved by concentrating services into fewer 
sites (Ke et al. 2012). This introduces the second factor: the benefits of increased centralisation 
of services as a means of improving efficiency through economies of scale (Ke et al. 2012). 
Whilst concentrating services in large hospitals may have the benefits of better outcomes and 
greater efficiencies, it also risks bringing about the dis-benefits of exacerbating inequalities in 
access, and consequently in outcomes. Thus, the third issue that health providers have to 
consider is how to organise services in a way that patients who travel farther continue to engage 
with services and do not experience poorer outcomes that may result from any disengagement, 
or from preferential treatment of those with better access. The recent strategy recognises this 
dilemma in the organisation of cancer services, and has recommended an evaluation of the 
evidence to determine whether service configuration for surgical treatment merits further 
centralisation (Independent Cancer Taskforce 2015).  
 
So far, the evidence on the economic benefits of centralisation of cancer services is 
inconclusive. A systematic review of the economic impact of centralisation found that 
increasing surgeon volume is associated with cost reductions (Ke et al. 2012), but, these 
benefits may not be linear as one study found a u-shaped relationship where costs decreased 
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then increased again with increase in surgical volume (Ke et al. 2012; Max Bachmann et al. 
2003). Although cost savings maybe an argument for improved efficiency, it may also bring 
about the additional costs associated with managing a larger organisation (Ke et al. 2012), and 
furthermore, any costs saved by health providers may be inadvertently transferred to patients 
and their carers who incur time and cost from travelling longer journeys (Ke et al. 2012).  
 
With regards to primary care services, it was interesting that access was found to significantly 
determine the mode of diagnosis and cancer survival.  This is because the relatively small land 
mass in England with approximately 7,900 GP practices (King’s Fund 2016) would suggest 
that most patients have relatively reasonable journey times. Despite the presumed lack of issues 
that a lower land mass would suggest, the research found that a minority of patients have poor 
access that results to significantly poorer outcomes. This may be an indication of patients who 
are disengaged with primary care. It is feasible to re-engage with these isolated groups by 
encouraging the use of telephone consultations or other aspects of telehealth care (Schlachta-
Fairchild 2001; Breen et al. 2015) in areas where these have not been applied. It is hoped that 
the relatively small population impacted by poor GP access would make the implementing such 
interventions attainable within the finite NHS resources. 
 
The higher cost of financing cancer services from increasingly scarce resources means that 
more innovative approaches are required to support service design that enables services to 
deliver equitable care. Equity and efficiency need not sit on opposing ends. For example, 
Chapter Five demonstrates that improving access to primary care services may offer some 
economic benefits by reducing costly emergency presentations, also, better access may help 
increase the uptake of planned admissions and may encourage screening uptake, which would 
improve overall outcomes. 
 
7.4.2 Rural health outcomes 
One consistent finding from this research was that rural populations in both England and 
Scotland had significantly better cancer survival rates than their urban counterparts. Rural areas 
generally have poorer geographical accessibility to services (DEFRA 2013a). However, this 
research suggests that rural areas may not necessarily experience poorer outcomes that may be 
attributed to geographical inaccessibility. The rurality – travel time interacted models presented 
in Chapter Four also revealed that longer travel in rural areas reduced the likelihood to report 
 163 
 
alarm symptoms related to cancer, but longer travel in rural areas was not associated with 
emergency admissions, stage or survival. On the contrary, urban patients appeared to be more 
sensitive to longer travel; this was an interesting finding that may indicate differences in how 
rural and urban patients perceive geographical inaccessibility (Field & Briggs 2001). One 
possibility is that rural patients have built resilience towards longer travel, accepting it as an 
inevitability of rural living. 
 
Chapter Six found that patients living in rural areas had better three-year survival from 
colorectal cancer Table 6.5. This is despite the fact that they were more likely to have advanced 
disease stage than their urban counterparts Table 6.4. The clue to understanding this intriguing 
finding may be found in the previous chapters that found lower odds of attaining a diagnosis 
via less desirable routes such as emergency admissions amongst rural patients (Chapters Four 
and Five), and higher odds of a diagnosis via a more desirable route such as screening and two 
week wait (Chapter Five). This suggests that there may be some important lessons to learn 
from rural GPs, possibly in relation to better continuity of care found in the patient – GP 
relationship in rural areas (King’s Fund 2010b). An ongoing relationship with a preferred GP  
which is a marker of better continuity of care has been previously associated with a reduction 
in emergency admissions (Christakis et al. 2001; Menec et al. 2006), and improvement in 
screening uptake (Flocke et al. 1998). It is therefore likely that continuity of care may play a 
role in improving cancer survival rates, this needs hypothesis to be fully investigated.  
 
The better outcomes amongst rural patients in comparison to their urban counterparts that was 
found in this research supports findings in the US that have reported the risk of worse cancer 
outcomes amongst urban populations (McLafferty et al. 2011; McLafferty & Wang 2009). One 
study in particular found a J shaped curve of the association between advanced disease stage 
and rurality, whereby the most urbanised and the remotest rural groups had a higher risk of late 
stage cancer diagnosis (McLafferty & Wang 2009). In comparing the findings from the rural- 
urban analyses and the travel time analyses, one apparent conclusion is that rurality and travel 
time may be measuring two distinct dimensions which should always be examined separately.. 
Rurality may be capturing social or cultural experiences of place and environment that 
influence health seeking behaviours that are distinct from urban areas (McLafferty et al. 2011), 
and this distinction may be more apparent in the most isolated rural residents. Any distinct 
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traits may also be extended to GPs working in rural or urban areas, and may influence practices 
such as making onward referrals to secondary care. 
 
7.5  Generalisability of findings outside UK 
The association between access and outcomes may be expected to vary internationally and by 
context – based on differential experience of access in countries with significantly larger 
landmasses, or with different healthcare systems. Some of the studies referenced in this thesis 
were conducted in countries like the USA, Australia where the magnitude of isolation may be 
higher than in the UK. In addition, these countries and others like France have health systems 
that are different from the NHS. Healthcare systems in Australia and France share some 
similarities with the NHS in terms of offering universal coverage (The Commonwealth Fund 
2016), however, there are some differences in the delivery of primary care, as neither system 
have a strict GP gate keeping role like that found in the UK (The Commonwealth Fund 2016). 
The USA healthcare system is substantially different from the UK, as it is characterised by a 
fragmented system of public and private funding. During the period covered by this study, 
healthcare in the USA was largely privately funded through personal health insurance, although 
those on low income and the elderly were covered by federal programmes such as Medicaid 
and Medicare (The Commonwealth Fund 2016). 
 
Despite the country-level differences described above, there were no major differences 
between the findings reported in this research, and those reported by research conducted 
outside the UK. One particular area of similarity was the inverse association between distance, 
service utilisation and health outcomes. Similar to the UK, longer distance in the US was also 
associated with lower levels of utilisation, whereby a 10-mile increase in distance led to an 
estimated 2% decline in outpatient visits (LaVela et al. 2004). Longer distance to treatment in 
the US was also associated with worse survival (HR, 1.10, 1.01-1.39) (Wan et al. 2012). In 
France, longer distance to a cancer centre resulted to an estimated 25 percent increase in risk 
of death amongst patients living in the highest distance quartile (HR 1.25, 1.07-1.43), estimated 
at three years from diagnosis (Dejardin et al. 2008). Similarly in Australia, distance to cancer 
treatment facilities was also associated with lower utilisation whereby patients with the longest 
distance were less likely to take up radiotherapy treatment (OR 0.41, 0.23-0.74) compared to 
those with the least travel (Hsieh et al. 2015). Survival was also shown to progressively decline 
with geographical remoteness in Australia, such that breast cancer patients living in the most 
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remote regions had the lowest survival (HR 1.30, 1.02-1.64), followed by those living in 
moderately remote areas (HR 1.22, 1.00-1.48), compared to those living in major cities (HR = 
1) (Chen et al. 2015). 
 
The rural and urban differences in disease stage at diagnosis in the UK (Chapter Six) has also 
been previously reported in France and Australia, whereby rural patients diagnosed with 
colorectal cancer are more likely to present with later disease stage (Baade et al. 2011; Launoy 
et al. 1992). In contrast, colorectal cancer patients living in rural areas in the US have been 
found to be more likely to have lower disease stage, which has been described as ‘rural-
reversal’ in outcomes (McLafferty & Wang 2009). Where the outcome of interest is cancer 
survival, living in a rural area in the USA in Australia and in France has been associated with 
worse cancer survival (Centers for Disease Control and Prevention 2017; Launoy et al. 1992; 
Yu et al. 2015). However, as shown in Chapters Four and Six of this thesis, the opposite was 
apparent for rural patients in the UK; they were significantly more likely to have better survival 
at three years since diagnosis. 
 
The mechanisms to explain the differences in associations between these countries are complex 
and beyond the scope of this present research. They may be related to differences in the level 
of rural remoteness, for instance, better rural survival in the UK may come about because 
geographical access is not as big an issue due to the relatively smaller land mass. As such then, 
rural patients in the UK may be reaping the benefits of living in a rural area and the relative 
ease of accessing services, in comparison to rural patients in Australia or the USA who have to 
endure more severe isolation from living in a country with a larger land mass. 
 
7.6  Suggestions for future research 
The evidence generated from this research will improve the understanding of the how travelling 
to services and living in either a predominantly rural or urban area may determine cancer 
outcomes. At the same time, the findings have generated new questions for future study. One 
area that warrants further investigation is the better outcomes found amongst rural patients as 
outlined in Section 7.4.2. 
 
The studies presented in this research were limited in their focus on estimated travel times to 
services. It was not possible to consider journey times using public transport using the time and 
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budget allowed for this research. Nor was it possible to consider other means such as cycling 
or walking. A study to validate the use of travel times generated by GIS (Geographical 
Information System) software found that up to 87% of journeys to hospital are by car (Haynes 
et al. 2006). The remaining 13% should not be overlooked particularly because as demonstrated 
in the Chapters Four and Six, urban patients had worse survival, and use of public transport has 
a higher prevalence in urban areas. Advances in the technology used in timetabling public 
transport means it may be possible to compute journey times from public transport with relative 
ease; this too needs to be considered in future studies. 
 
Future studies should also consider applying GIS tools available to geographers that may help 
health providers with planning services that maximise access to underserved populations. Use 
of location-allocation modelling for instance may be helpful in selecting the optimal location 
for services within a given catchment population. Future work should also take advantage of 
more advanced measures of accessibility such as those that factor in both physical accessibility 
and availability of services (Luo & Qi 2009; Luo 2004), or that use gravity models which 
assume a distance decay; that the attractiveness of a service diminishes with increase in 
distance. Some derivatives of gravity models such as the ‘enhanced two step floating catchment 
area’ factors in both the demand and supply of services and the distance decay (Luo & Qi 
2009). These more advanced techniques may be particularly relevant when studying access 
issues in urban areas where there access to services may be influenced by service demand that 
arise from larger practice list size, and longer waiting times for appointments. It is not clear to 
what extent these advanced techniques have been applied in designing cancer services in 
England, but it more likely they have not been routinely utilised (Allan 2014) perhaps because 
the complex set of skills required to use them may not be readily available to health providers. 
Collaborations between decision makers and researchers may be one way of addressing the 
skills shortage, and of ensuring that the research generated informs effective intervention 
programs. 
 
Another area that would benefit from more in-depth investigation is with regards to fully 
mapping the causal pathways of the association between access and cancer outcomes. In this 
thesis, work has been presented that reveals the complex nature of some of the associations, 
but unravelling the full nature of the complex causal webs at play will require advanced 
statistical techniques. For example, Chapter Six identified Dukes’ stage and time intervals as 
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two possible mediators, explaining some of the association between geographical access and 
survival. However, these mediation models were only able to accommodate one mediator at a 
time; the complex nature of the associations suggests a causal web of mediator, moderator and 
confounding relationships that occur concurrently. These relationships also operate at different 
levels; patient, health practitioner, health system. Furthermore, variables such as symptoms, 
routes to diagnosis, time delays and disease stage may all sit on the causal pathway between 
access and survival, but it not clear how they are associated with one another. Unpicking these 
relationships will require use of more advanced statistical techniques such as those found in 
structural equation modelling (SEM) that are built to handle complex relationships. Gaining a 
full understanding of this complexity will be crucial to implementing successful interventions. 
 
From a policy perspective, achieving full implementation of any intervention will require 
national coordination and monitoring of progress. It may be necessary to develop a metric or 
indicator that measures geographical accessibility to health services and that decision makers 
can use for monitoring purposes. The use of indicators has been credited with successfully 
highlighting key national priorities, with improving implementation and strengthening 
accountability (Baggott 2007). In 2010, the Coalition Government introduced three sets of 
outcome measures for health and social care; Public Health Outcomes Framework, NHS 
Outcomes Framework and Adult and Social Care Outcomes Framework (Department of Health 
2016a; Department of Health 2016b; Department of Health 2014). Annex D gives a summary 
of the indicators that may be used in evaluating the progress on cancer prevention, early 
diagnosis and treatment.  
 
In relation to access to services, the NHS Outcomes Framework has an indicator that monitors 
access to GP services by measuring the overall experience of making an appointment 
(Department of Health 2012b). There are also several indicators that monitor progress in 
meeting cancer waiting times, as summarised in Chapter Two (Table 2.2). The goal of these 
indicators is to hold different services accountable for the outcomes they deliver, in cancer 
services across the entire care pathway (Department of Health 2011a). The most recent strategy 
on cancer has ensured that geographical accessibility to services remains on the national agenda 
for at least until 2020. Hopefully, this will also provide some impetus into developing and 
adopting a national metric to measuring and monitor this objective, which is the surest way to 
ensure progress in achieving geographical equity access  
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travel times from postcodes of residence to GPs and 
hospitals in England, Scotland and Wales 
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 Step 1  Step 2
Cost Surface and
1.4 Million 
postcodes
Construct individual 
shapefiles (GP and 
hospital) grouped by region
Calculate Travel 
Times using cost 
surface
Extract values to a 
point (English 
postcodes)
Convert extracted 
values to GDB 
Tables 
(TT_Master folder) (1- Sfiles folder) (2- CosDis.gdb) (3 - Extract.gdb) (4 - Region.gdb)
Split by Attributes tool
Step 5
Convert to CSV fies Convert to DBF Delete unwanted 
fields (Easting, 
Northings)
Add unique 
GP/Hospital 
fieldname
(6 - CSV files folder) (5 - Region Tables folder)
Python code  
- Convert GIS missing 
values from '-9999' to '-'
- Convert DBF tables to 
CSV
Step 3
GIS Model Builder 
- Feature Class Iterator
- Cost distance tool
- Extract to point tool
- Convert to geodatabase tool
Step 4
GIS Model Builder 
- Table Iterator
- Calculator Tool
- Delete fields tool
- Convert to Database tool
And 
396 hospitals in England, 
Scotland and Wales
9635 CSVs
(250GB)
Region               # of GP Practices
East of England             778
South West                    714
South East 1095
East Midlands 620
North East                         400
North West                       1227
West Midlands 938
Yorkshire and Humber    773
London  1460
Scotland 597
Wales 637
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Table A.1 - Association between rurality, travel times to the GP and emergency presentations. Travel time is the predictor in ‘a’, 
rurality is the predictor in ‘b’. Travel times are interacted with rurality in ‘c’. All models are adjusted for age, gender, deprivation and 
comorbidity. For brevity, the coefficients for the covariates are only shown in the models with the interaction term (c). 
Explanatory variables 
1)       Emergency 
presentation: 
Breast 
2)     Emergency 
presentation: 
Colorectal 
3)  Emergency 
presentation: 
Cervical  
4)    Emergency 
presentation: 
Lung 
5)    Emergency 
presentation: 
Prostate 
6)    Emergency 
presentation: 
Stomach 
7)    Emergency 
presentation: 
Ovarian 
8)    Emergency 
presentation: 
Brain 
 Outcome variables without interaction terms 
A) Travel time to GP     
      (minutes) 
1.10** 
(1.06-1.14) 
1.06** 
(1.04-1.08) 
1.06 
(0.96-1.17) 
1.03** 
(1.01-1.05) 
1.08**  
(1.05-1.11) 
1.03 
(0.99-1.08) 
1.06**     
(1.02-1.11) 
1.02 
(0.98-1.06) 
B)  Rural 
0.88**  
(0.82-0.93) 
0.93**  
(0.90-0.96) 
1.00  
(0.85-1.19) 
0.96**  
(0.93-0.99) 
0.87**  
(0.83-0.91) 
0.93*  
(0.87-0.99 
0.95 
(0.89-1.02) 
0.99  
(0.91-1.06) 
 Outcome variables with interaction terms fitted 
C) Travel time to GP    
      (minutes) 
1.15**  
(1.10-1.20) 
1.09**  
(1.06-1.12) 
1.10  
(0.99-1.22) 
1.05** 
 (1.03-1.07) 
1.14** 
 (1.10-1.18) 
1.09**  
(1.03-1.16) 
1.07* 
 (1.02-1.12) 
1.01  
(0.96-1.07) 
Rural 
0.89** 
 (0.82-0.97) 
0.94**  
(0.90-0.98)    
1.05  
(0.82-1.35) 
0.97  
(0.93-1.01) 
0.88** 
 (0.83-0.94) 
0.98  
(0.89-1.08) 
0.89* 
 (0.81-0.98) 
0.93  
(0.84-1.04) 
Travel time / rurality 
interaction  
0.92*  
(0.85-0.99)     
0.95*  
(0.91-0.99)    
0.87  
(0.69-1.11) 
0.97  
(0.93- 1.01)    
0.91** 
 (0.86-0.98) 
0.88* 
 (0.79-0.97) 
1.02  
(0.94-1.16) 
1.04  
(0.94-1.14) 
Age (years) 
1.07**  
(1.07-1.07)    
1.02** 
 (1.02-1.02)    
1.05** 
 (1.04-1.05) 
1.03** 
 (1.03-1.03) 
1.09** 
 (1.09-1.10) 
1.03** 
 (1.03-1.04)    
1.03** 
 (1.03-1.03) 
1.02** 
 (1.01-1.02) 
Female  
1.30** 
(1.27-1.33)     
1.08** 
 (1.06-1.10)  
1.27** 
 (1.20-1.34)  
1.14** 
 (1.07-1.22) 
Deprivation quintiles 
 1 – least deprived 1 1 1 1 1 1 1 1 
2 
1.10*  
(1.02-1.19) 
1.07**  
(1.03-1.12) 
1.20  
(0.95-1.53) 
1.07** 
 (1.03-1.11) 
1.09** 
 (1.03-1.16) 
1.05  
(0.96-1.14) 
1.09* 
 (1.00-1.19) 
1.05 
 (0.95-1.15) 
3 
1.16**  
(1.08-1.26) 
1.15**  
(1.11-1.19) 
1.50** 
 (1.23-1.93)    
1.13** 
 (1.08-1.17) 
1.16** 
 (1.09-1.22)     
1.10* 
 (1.01-1.20) 
1.07  
(0.98-1.16) 
1.07 
 (0.97-1.18) 
4 
1.37**  
(1.27-1.48) 
1.28**  
(1.23-1.33) 
1.55** 
 (1.24-1.94) 
1.21** 
 (1.16-1.25) 
1.29** 
 (1.22-1.37) 
1.25** 
 (1.15-1.36) 
1.25** 
 (1.15-1.37) 
1.18** 
 (1.07-1.31) 
5 – most deprived 
1.66**  
(1.53-1.79) 
1.53**  
(1.47-1.59) 
1.72** 
 (1.38-2.14) 
1.32** 
 (1.27-1.37) 
1.57**  
(1.48-1.67) 
1.48** 
 (1.36-1.61) 
1.33**  
(1.21-1.45) 
1.40** 
 (1.26-1.56) 
0 comorbidities 
(Charlson) 1 1 1 1 1 1 1 1 
1 – 2 comorbidities  
1.20** 
(1.13-1.29)    
1.25**  
(1.21-1.29) 
1.07  
(0.87-1.31) 
1.23** 
 (1.20-1.27) 
1.42** 
 (1.36-1.49) 
1.28**  
(1.20-1.37) 
1.23**  
(1.13-1.34) 
0.85* 
 (0.76-0.95) 
3 plus comorbidities  
2.12** 
 (1.86-2.40)      
1.75**  
(1.63-1.88)    
1.75* 
 (1.11-2.74) 
1.79** 
 (1.70-1.89) 
2.23** 
 (2.05-2.43) 
1.88**  
(1.65-2.15) 
1.98**  
(1.59-2.46) 
1.16 
 (0.87-1.54) 
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Table A.2 – Comparison the frequency of travel times and rural urban status between 
records with and without referral and treatment intervals. A) travel to the GP, B) travel 
to hospital and C&D) rurality  
 All records 
All records with details 
on referral Interval  
All records without 
referral interval 
A) Travel times to GP 
of registration 
0 – 10 minutes 
10 – 20 minutes 
20 – 30 minutes 
Over 30 minutes 
 132,383 (88.2)    
    15,003 (10.0)        
      1,705 (1.1)    
          963 (0.6) 
 
30,269 (88.2) 
  3,547 (10.3)      
  364 (1.1)      
  157 (0.5)      
 
 
 
102,114 (88.2)     
11,456 (9.9)        
1,341 (1.2)       
806 (0.7)    
 All records 
All records with details 
on treatment Interval 
All records without 
treatment interval 
B) Travel time to 
hospital of first 
treatment 
0 – 15 minutes 
15 – 30 minutes 
30 – 45 minutes 
Over 45 minutes 
 
 
 
36,486 (44.1)        
26,660 (32.3)        
11,802 (14.3)        
7,710 (9.3)         
 
 
 
34,774 (44.2)     
25,333 (32.2)      
11,230 (14.3)        
7,335 (9.32)       
 
 
 
1,712 (43.0)       
1,327 (33.3)        
572 (14.4)       
375 (9.4)    
 All records 
All records with details 
on referral Interval 
All records without 
referral interval 
 
C) Rural or urban 
Rural 
Urban 
 
35,181 (22.0)        
124,601 (78.0)        
 
8,406 (23.9)   
 26,715 (76.1)         
 
26,775 (21.5)      
97,886 (78.5)      
 All records 
All records with details 
on treatment Interval 
All records without 
treatment interval 
 
D) Rural or urban 
Rural 
Urban 
35,181 (22.0)        
124,601 (78.0) 
 
 30,011 (22.4)       
103,884 (77.6)       
 
5,170 (20.0)       
20,717 (80.0)       
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Table A.3 – Sensitivity analysis of Table 6.3B, Chapter 6. Results show the association 
between travel time to hospital, rurality and time from diagnosis to treatment 
(Treatment Interval) 
Travel time to hospital of first treatment Rural vs urban residence 
0 – 15 minutes 
15 – 30 minutes 
30 – 45 minutes 
Over 45 minutes 
 
Reference 
0.88** (0.85 - 0.91) 
0.64** (0.61 - 0.68) 
0.49** (0.45 - 0.52)  
 Urban 
 Rural  
 
 
Reference 
1.01 (0.97 - 1.06) 
Age grouped 
<= 60 years 
61 – 70 years 
71 – 80 years 
> 81 years 
 
Reference 
0.96 (0.91- 1.00) 
0.98 (0.94 - 1.03) 
1.10** (1.05 - 1.16) 
Age grouped 
<= 60 years 
61 – 70 years 
71 – 80 years 
> 81 years 
 
Reference 
0.96 (0.92 - 1.01) 
1.00 (0.96 - 1.05) 
1.15** (1.09 - 1.21) 
Gender 
Male 
Female 
 
Reference 
1.19** (1.15 - 1.23) 
Gender 
Male 
Female 
 
Reference 
1.20** (1.16 - 1.24) 
Deprivation 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
Reference 
0.95 (0.91 - 1.00) 
0.92** (0.87 - 0.97) 
0.88** (0.83 - 0.93) 
0.80** (0.75 - 0.84) 
Deprivation 
1 – least deprived 
2 
3 
4 
5 – most deprived 
 
Reference 
0.94* (0.90 - 0.99) 
0.91** (0.87 - 0.96) 
0.92** (0.88 - 0.97) 
0.89** (0.85 - 0.94) 
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
Reference 
0.98 (0.93 - 1.03) 
1.01 (0.90 - 1.14) 
Comorbidity 
No comorbidity 
1 comorbidity 
2+ comorbidities 
 
Reference 
0.98 (0.94 - 1.03) 
1.06 (0.94 - 1.19) 
 
Routes to diagnosis 
Emergency presentation 
Other routes 
 
 
Reference 
2.35** (2.26 - 2.45) 
 
  Routes to diagnosis 
Emergency presentation 
Other routes 
 
 
Reference 
2.30** (2.21 - 2.39) 
Excludes records where diagnosis and treatment were on the same day.  
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Public Health Outcomes Framework (PHOF) 
 
Domain 1 : Improving the wider determinants of health 
1.08 Employment for those with long-term health conditions including adults with a learning disability or 
who are in contact with secondary mental health services 
1.16 Utilisation of outdoor space for exercise / health reasons 
 
Domain 2: Health improvement 
2.09 Smoking prevalence – 15 year olds  
2.10 Self-harm 
2.11 Diet  
2.12 Excess weight in adults  
2.13 Proportion of physically active and inactive adults  
2.14 Smoking prevalence – adults (over 18s)  
2.19 Cancer diagnosed at stage 1 and 2  
2.20 National screening programmes (breast, bowel and cervical cancers) 
 
Domain 3: Health protection 
3.01 Fraction of mortality attributable to particulate air pollution 
 
Domain 4: Healthcare public health and preventing premature mortality 
4.03 Mortality rate from causes considered preventable 
4.05 Under 75 mortality rate from cancer 
 
 
NHS Outcomes Framework (NHSOF) 
 
Domain 1: Preventing people from dying prematurely 
1a Potential years of life lost (PYLL) from causes considered amenable to healthcare  
1.4 Under 75 mortality rate from cancer (PHOF 4.05)  
i  One year survival from all cancers 
ii Five year survival from all cancers  
iii One year survival from breast, lung and colorectal cancer 
iv Five year survival from breast, lung and colorectal cancer 
v One year survival  from cancers diagnosed at stage 1&2 (PHOF 2.19) 
vi Five year survival  from cancers diagnosed at stage 1&2 (PHOF 2.19) 
1.6 ii Five year survival from all cancers in children 
 
Domain 2: Enhancing quality of life for people with long-term conditions 
2 Health-related quality of life for people with long-term conditions (ASCOF 1A)  
2.1 Proportion of people feeling supported to manage their condition 
2.2 Employment of people with long-term conditions (PHOF 1.8) 
2.7 Health-related quality of life for people with three or more long-term conditions (ASCOF 1A) 
 
Domain 3: Helping people to recover from episodes of ill health or following injury 
3.1 Improving outcomes from planned treatments - Total health gain as assessed by patients for elective 
procedures 
3.6 Helping older people to recover their independence after illness or injury 
 
Domain 4: Ensuring that people have a positive experience of care 
4a Patient experience of primary care 
4b Patient experience of hospital care 
4.4 Improving access to primary care services 
4.6 Improving the experience of care for people at the end of their lives 
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4.9 Improving people’s experience of integrated care 
 
Domain 5: Treating and caring for people in a safe environment and protecting them from avoidable 
harm 
5a Deaths attributable to problems in healthcare 
5b Severe harm attributable to problems in healthcare 
5.6 Improving the culture of safety reporting 
 
 
Adult and Social Care Outcomes Framework (ASCOF) 
 
Domain 1 – Enhancing quality of life for people with care and support needs 
1A. Social care related quality of life 
1I: Proportion of people who use services, and their carers, who reported that they had as much social 
contact as they would like 
 
Domain Three: Ensuring that people have a positive experience of care and support 
3A. Overall satisfaction of people who use services with their care and support 
3D. The proportion of people who use services and carers who find it easy to find information about  
support 
 
Domain Four: Safeguarding adults whose circumstances make them vulnerable and protecting them 
from avoidable harm 
4A. The proportion of people who use services who feel safe 
4B. The proportion of people who use services who say that those services have made them feel 
safe and secure 
 
Source: NHS Outcomes Framework (2016), Public Health Outcomes Framework (2016), and Adult and 
Social Care Outcomes Framework (2014) 
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Submitted Document Upload Date Requirement Criterion Description of the required evidence 
(UEA)_ODR_2014_229 _ Query on 
NHS IG Toolkit.msg 
09/11/2014 
18:46 
12-223 1b Secure transfer from PHE 
(UEA)_ODR_2014_229 _ Query on 
NHS IG Toolkit.msg 
09/11/2014 
18:46 
12-334 2b Documented report or project closure document. 
Certificate_Confidential Information.pdf 22/10/2014 
14:36 
12-120 1b Certificate - Secure Handling of Confidential Information 
Certificate_Confidential Information.pdf 22/10/2014 
14:36 
12-123 2a Training certificate - Confidential Information 
Certificate_Information Governance.pdf 22/10/2014 
14:35 
12-120 1b Certificate - Introduction to Information Governance 
Certificate_Information Governance.pdf 22/10/2014 
14:35 
12-123 2a Training reports or certificates of attendance. 
Certificate_Risk Management.pdf 22/10/2014 
14:37 
12-120 1b Certificate - Information Risk Management 
Certificate_Risk Management.pdf 22/10/2014 
14:37 
12-123 2a Training certificate - Risk Management 
FMH ethics application_Peninah.pdf 22/10/2014 
18:04 
12-220 1b UEA - Ethics Application Form (completed) 
GISP1- Risk Assessment and 
management.pdf 
22/10/2014 
19:11 
12-221 1b GISP1 - Risk Assessment and risk management 
GISP12 - Secure Areas.pdf 23/10/2014 
14:51 
12-332 1a UEA- Secure Areas Policy 
GISP12 - Secure Areas.pdf 23/10/2014 
14:51 
12-332 1b GISP12- Secure Areas 
GISP17 - IT and Information Assest 
Management.pdf 
22/10/2014 
20:36 
12-331 2a GISP17 IT and Information Asset Management 
GISP18 - Encryption use and key 
material handling.pdf 
22/10/2014 
19:42 
12-223 1b A document, staff handbook, or leaflet. 
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GISP3- Physical and Environmental 
Security.pdf 
23/10/2014 
14:51 
12-332 1a UEA - Physical and Environmental Security 
GISP3- Physical and Environmental 
Security.pdf 
23/10/2014 
14:51 
12-332 1b GISP3 Physical and Environmental Security 
Information Governance Certificate- 
Andy J.pdf 
14/11/2014 
13:18 
12-123 2a Training certificate (Andy) 
Information Governance Certificate- 
Max B.pdf 
09/11/2014 
18:10 
12-123 2a Training certificate (Max) 
PHE (potentially) identifiable data 
request FORM.docx 
11/11/2014 
18:22 
12-223 1c PHE Data Release Form 
PPD Modules_ Peninah Murage.pdf 22/10/2014 
14:34 
12-120 1b IG Training tool reports, certificates of attendance and 
attainments, or evidence of self-directed study. 
PPD Modules_ Peninah Murage.pdf 22/10/2014 
14:34 
12-123 1c Training records, for example, IG Training Tool reports, 
training certificates of attendance or attainment. 
Research Protocol_Peninah.pdf 23/10/2014 
16:48 
12-334 1a A documented plan. 
Research Protocol_Peninah.pdf 23/10/2014 
16:48 
12-334 2a Project documentation, eg project closure document or project 
report. 
Researcher's Safety 
Checklist_Peninah.pdf 
23/10/2014 
14:49 
12-332 1a A documented risk assessment including details of any 
required improvements. 
UEA - Conditions of Computer Use.pdf 22/10/2014 
15:16 
12-122 1b UEA- Conditions of Computer Use 
UEA - Conditions of Computer Use.pdf 22/10/2014 
15:16 
12-221 2a Minutes/notes of meetings, briefing and awareness session 
materials or a list of staff signatures that they have read, 
understood and will comply with the procedures. 
UEA - Conditions of Computer Use.pdf 22/10/2014 
15:16 
12-333 2a UEA - Conditions of Computer Use 
UEA - Data Protection Flyer.pdf 22/10/2014 
15:53 
12-123 1b UEA - Data Protection Flyer 
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UEA - Data Protection Training.pdf 22/10/2014 
15:52 
12-123 1b UEA - Data Protection Training 
UEA - Information Security Flyer.pdf 22/10/2014 
15:51 
12-123 1b UEA - Information Compliance Flyer 
UEA- Correspondence with data 
provider (UEA)_ODR_2014_229.txt 
23/10/2014 
16:51 
12-334 1b The minutes of a meeting where the plan was agreed or in a 
note that clarifies the organisation's support. 
UEA- Correspondence with data 
provider (UEA)_ODR_2014_229.txt 
23/10/2014 
16:51 
12-334 1c A note assigning responsibility, the job description of an 
individual or the terms of reference of a committee/group. 
UEA- Dealing with Misconduct in 
Research.pdf 
22/10/2014 
15:09 
12-122 1b UEA- Procedures for dealing with allegations for misconduct 
in research 
UEA- Information Classification Data 
Management.pdf 
22/10/2014 
19:43 
12-223 1b UEA - Information Classification and Data Management 
Policy 
UEA- Information Classification Data 
Management.pdf 
22/10/2014 
19:43 
12-331 2a UEA - Information Classification and Data Management 
Policy 
UEA- Research Students Handbook.pdf 22/10/2014 
15:07 
12-122 1b Examples of contract clauses. 
UEA- Research Students Handbook.pdf 22/10/2014 
15:07 
12-220 2a Inclusion in staff handbook, or published on the Intranet, or 
personal copies for staff (in the latter case there may be a list of 
staff signatures confirming receipt of the guidance) or the 
evidence may be a description of the dissemination process or 
minutes of the meeting where this was decided. 
UEA_ Good Practice in Research.pdf 22/10/2014 
15:15 
12-122 1b UEA- Good Research Practice Guidelines 
UEA_ Information Compliance 
Training.pdf 
22/10/2014 
15:50 
12-123 1b Written details of the training to be provided. 
UEA_ Research Ethics Policy, 
Principles and Procedures.pdf 
22/10/2014 
15:13 
12-122 1b UEA- Research Ethics Policy, Principles and Procedures 
UEA_ Research Ethics Policy, 
Principles and Procedures.pdf 
22/10/2014 
15:13 
12-122 1c UEA - Research Ethics Policy, Principles and Procedures 
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UEA_ Research Ethics Policy, 
Principles and Procedures.pdf 
22/10/2014 
15:13 
12-220 1a UEA - Research Ethics Policy, Principles and Procedures 
UEA_ Research Ethics Policy, 
Principles and Procedures.pdf 
22/10/2014 
15:13 
12-220 1b A document, staff handbook, or leaflet covering consent issues 
around the use and disclosure of personal information. 
UEA_ Research Ethics Policy, 
Principles and Procedures.pdf 
22/10/2014 
15:13 
12-220 1c Minutes of meetings, in a document or email or a personal 
endorsement in writing from an appropriately senior manager. 
UEA_ Research Ethics Policy, 
Principles and Procedures.pdf 
22/10/2014 
15:13 
12-333 1a UEA - UEA - Research Ethics Policy, Principles and 
Procedures 
UEA_ Research Ethics Policy, 
Principles and Procedures.pdf 
22/10/2014 
15:13 
12-333 2a UEA- Research Ethics Policy, Principles and Procedures  
UEA_General Infor Security Policy.pdf 14/10/2014 
16:09 
12-121 1a UEA- General Information Security Policy 
UEA_General Infor Security Policy.pdf 14/10/2014 
16:09 
12-121 1b UEA - General Information Security Policy 
UEA_General Infor Security Policy.pdf 14/10/2014 
16:09 
12-122 1c UEA - General Information Security Policy 
UEA_General Infor Security Policy.pdf 14/10/2014 
16:09 
12-123 1a A named individual's job description, or a signed note or e-mail 
assigning responsibility. 
UEA_General Infor Security Policy.pdf 14/10/2014 
16:09 
12-221 1a A named individual's job description, a note or e-mail 
assigning responsibility or the terms of reference of a group. 
UEA_General Infor Security Policy.pdf 14/10/2014 
16:09 
12-221 1b Documented confidentiality audit procedures which include the 
details of the named staff member, job role or responsible 
group. 
UEA_General Infor Security Policy.pdf 14/10/2014 
16:09 
12-221 1c Approval/sign off within the minutes of meetings, in a 
document or email or a personal endorsement in writing from 
an appropriately senior manager. 
UEA_High level Infor Security 
Policy.pdf 
14/10/2014 
16:08 
12-121 1a UEA- High Level Information Security Policy 
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UEA_High level Infor Security 
Policy.pdf 
14/10/2014 
16:08 
12-121 1b Sign off documented on the policy document (for example - 
the date that it was signed-off and by whom). 
UEA_High level Infor Security 
Policy.pdf 
14/10/2014 
16:08 
12-123 1a UEA - High Level Information Security  
UEA_Research Data Management.pdf 22/10/2014 
15:11 
12-122 1b UEA- Research Data Management Policy  
UEA_Research Data Management.pdf 22/10/2014 
15:11 
12-122 1c UEA - Research Data Management  
UEA_Research Data Management.pdf 22/10/2014 
15:11 
12-220 1a A named individual's job description, a note or e-mail 
assigning responsibility or the terms of reference of a group. 
UEA_Research Data Management.pdf 22/10/2014 
15:11 
12-220 1b UEA - Research Data Management Procedure and Guidance  
UEA_Research Data Management.pdf 22/10/2014 
15:11 
12-220 1c UEA - Research Data Management  
UEA_Research Data Management.pdf 22/10/2014 
15:11 
12-333 1a UEA - Research Data Management Procedures and Guidance 
UEA_Research Data Management.pdf 22/10/2014 
15:11 
12-333 2a UEA - Research Data Management Procedures and Guidance 
VACS - IG Contractual Clause - 
signed.pdf 
14/11/2014 
12:23 
12-122 2a Sample contract showing that appropriate IG clauses are 
included in contracts. 
VACS - IG Staff Declaration Form- 
signed.pdf 
18/11/2014 
11:27 
12-121 2a Inclusion in a staff handbook or by placing it on the intranet, or 
staff may be provided with their own copy of the policy.  In the 
latter case there may be a list of staff signatures confirming 
staff have read and understood the policy. 
VACS - IG Staff Declaration Form- 
signed.pdf 
18/11/2014 
11:27 
12-220 2b Notes or minutes of team meetings/awareness sessions or staff 
briefing materials. 
VACS - IG Staff Declaration Form- 
signed.pdf 
18/11/2014 
11:27 
12-223 2b Minutes/notes of team meetings, or briefing materials from 
awareness sessions. 
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VACS - IG Staff Declaration Form- 
signed.pdf 
18/11/2014 
11:27 
12-332 2b Minutes/notes of team meetings, briefing and induction 
materials. 
VACS - IG Staff Declaration Form- 
signed.pdf 
18/11/2014 
11:27 
12-333 2b Minutes/notes of team meetings, or briefing materials used in 
awareness sessions. 
VACS - IG Staff Declaration Form- 
signed.pdf 
18/11/2014 
11:27 
12-335 2a A staff briefing and/or induction materials, IGP, SLSP or other 
equivalent policies and procedures available on desktop or 
local intranet, or hard copy materials handed to staff and/or 
placed prominently in communal areas 
VACS - Improvement Plan.pdf 14/11/2014 
14:22 
12-120 1c Documented IG Improvement plan. 
VACS - Improvement Plan.pdf 14/11/2014 
14:22 
12-120 2a Sign off should be documented on the IG improvement plan, 
for example the date that it was signed-off and by whom 
VACS - Incident Management 
Plan.docx 
11/11/2014 
16:55 
12-333 1a UEA- Incident Reporting and Handling 
VACS - Incident Management 
Plan.docx 
11/11/2014 
16:55 
12-333 2a Documented procedures and a template incident reporting form 
for staff. 
VACS - Incident Management 
Plan.docx 
11/11/2014 
16:55 
12-333 2b Project Incident Management Plan 
VACS - Incident Management 
Plan.docx 
11/11/2014 
16:55 
12-333 2c Completed incident reporting forms and reports made to senior 
management and where necessary to the commissioning or 
hosting organisation, the Information Commissioner, insurers, 
or the police. 
VACS - Incident Management Plan.pdf 14/11/2014 
16:11 
12-221 2b Project's Incident Management Plan 
VACS - Incident Management Plan.pdf 14/11/2014 
16:11 
12-332 1b Documented staff guidance. 
VACS - Incident Management Plan.pdf 14/11/2014 
16:11 
12-333 1a A named individual's job description, or a signed note or e-mail 
assigning responsibility. 
VACS - Incident Management Plan.pdf 14/11/2014 
16:11 
12-333 2a Project's Incident Management Plan 
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VACS - Information Asset Register.pdf 14/11/2014 
17:04 
12-331 2a Documented Information Asset register. 
VACS - System Level Security Policy 
Final.pdf 
14/11/2014 
12:27 
12-223 1b System Level Security Policy 
VACS - System Level Security Policy 
Final.pdf 
14/11/2014 
12:27 
12-223 1c Minutes of meetings, in a document or email or a personal 
endorsement in writing from an appropriately senior manager. 
VACS - System Level Security Policy 
Final.pdf 
14/11/2014 
12:27 
12-335 1a Documentation of the organisation's assigned responsibilities 
and processes for the scoping, development and approval of an 
IGP, SLSP or equivalent policy. 
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Annex F - HSCIC Level Two Information 
Governance Approval HSCIC Level Two 
Information Governance Approval 
 
From: Nwolie Ifeoma (HEALTH AND SOCIAL CARE INFORMATION CENTRE)  
<magi.nwolie@hscic.gov.uk> 
Sent: 27 November 2014 09:54 
To: Peninah Murage (MED) 
Subject: HPOV 952160: IG Toolkit version 12 assessment - University of 
East  
Anglia 
Attachments: IGT Exemption Request Form (Vers 4 Template) - OrgName 
(OrgCode)  
DDMMYYYY.dotx 
 
Dear Penny,  
This is to inform you that your version 12 IG Toolkit assessment has been 
reviewed and is satisfactory. 
 
IG Toolkit assessments are required on an annual basis and you should 
ensure that version 13 is completed on or before 31 March 2016.  
 
Just one thing to note: When you complete your version 13 assessment, you 
should apply for an exemption from the mobile computing requirement via 
the Exeter Helpdesk(exeter.helpdesk@hscic.gov.uk) rather than scoring the 
requirement at level 2. 
 
Best wishes 
 
Magi 
(Ifeoma) Magi Nwolie RGN LLB(Hons) 
Information Governance Delivery Manager - IG Assurance 
External Information Governance Delivery 
Operations and Assurance Directorate 
Health and Social Care Information Centre 
 
E: magi.nwolie@hscic.gov.uk 
W: http://systems.hscic.gov.uk/infogov 
 
Please send new IG queries to: exeter.helpdesk@hscic.gov.uk  
 
From: DONOTREPLY@hscic.gov.uk [mailto:DONOTREPLY@hscic.gov.uk]  
Sent: 18 November 2014 16:32 
To: Exeter Helpdesk (HEALTH AND SOCIAL CARE INFORMATION CENTRE) 
Subject: Information Governance Toolkit Assessment Publication 
 
This e-mail has been automatically generated by the IG Toolkit because an 
organisation has published an IGT Assessment. The details of the IGT 
Assessment are as follows: 
Organisation National Code:  EE133853  
Organisation Name:    University of East Anglia 
Organisation Type:      Hosted Secondary Use Team/Project 
Requirements Version:            12 
Key Requirements Met:          Yes 
Purpose of Assessment:          Other 
(As part of requirement to obtain secondary data for a research project. 
No patient identifiable data has been requested, however, some fields, 
when used in combination pose a slight risk to identifying patients.) 
Instructions to 1st Line Support: please raise a new Service Call as 
follows: 
Call Description:         <this e-mail> 
Service:           IGTK (3rd Line, not 2nd Line) 
Call Type:        IGTK Submissions 
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Annex G - University’s Ethics Approval 
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Annex H -  Data Sharing Agreements, Public Health 
England and University of East Anglia 
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Annex I - Honorary contract with Public Health 
England 
 


